SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2016
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2016)
S8710_other
Validating a local failure risk stratification for use in a
n/a
prospective study of adjuvant radiation in bladder cancer.
BC Baumann, J He, W Hwang, KN Tucker, JE Bekelman, HW
Herr, SP Lerner, TJ Guzzo, S Malkowicz, JP Christodouleas.
International Journal of Radiation Oncology, Biology, and Physics,
Jun 1;95(2):703-706. 2016 Jan 23 [Epub ahead of print].
PMID27020106; PMC pending.
http://www.ncbi.nlm.nih.gov/pubmed/27020106
n/a
S9346
Evaluating intermittent androgen deprivation therapy phase
5/15/95
III clinical trials: “The devil is in the details.” M Hussain, C
Tangen, C Higano, N Vogelzang, I Thompson. Journal of
Clinical Oncology, Jan 20;34(3):280-285, 2016. PMID26552421;
PMC Journal – In Process
http://www.ncbi.nlm.nih.gov/pubmed/26552421
9/1/08
S9916_S4021
Multiple
A meta-analysis evaluating the impact of site of metastasis
n/a
on overall survival in men with castration-resistant prostate
cancer . S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon,
K Fizazi, CM Tangen, M Rosenthal, DP Petrylak, M Hussain,
NJ Vogelzang, IM Thompson, KN Chi, J de Bono, AJ Armstrong,
MA Eisenberger, A Fandi, S Li, JC Araujo, CJ Logothetis, DI Quinn,
MJ Morris, CS Higano, IF Tannock, EJ Small. Journal of Clinical
Oncology, 2016 May 10;34(14):1652-1659; 2016 Mar 7 [Epub
ahead of print]. PMID26951312; PMC Journal - pending
http://www.ncbi.nlm.nih.gov/pubmed/26951312
n/a
E2805
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic
5/15/06
renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind,
placebo-controlled, randomised, phase 3 trial. NB Haas, J
Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett,
JP Dutcher, MB Atkins, M Pins, G Wilding, D Cella, L Wagner,
S Matin, TM Kuzel, WJ Sexton, Y-Ni Wong,TK Choueiri, R Pili,
I Puzanov, M Kohli, W Stadler, M Carducci, R Coomes, RS
DiPaola. Lancet May 14;387(10032):2008-2016, 2016.
2016 Mar 8 [Epub ahead of print]. PMID26969090; PMC4878938
http://www.ncbi.nlm.nih.gov/pubmed/26969090
9/1/10
Multiple*
Summary and recommendations from the National Cancer
n/a
Institute's Clinical Trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. SP Lerner,
DF Bajorin, CPDinney, JA Efstathiou , S Groshen , NM Hahn,
D Hansel, D Kwiatkowski, M O'Donnell, J Rosenberg, R Svatek,
JS Abrams, H Al-Ahmadie, AB Apolo, J Bellmunt , M Callahan,
EK Cha, C Drake, J Jarow, A Kamat, W Kim, M Knowles, B Mann,
L Marchionni, D McConkey, L McShane, N Ramirez, A Sharabi , AH
Sharpe, D Solit, CM Tangen, AT Amiri , E Van Allen, PJ West,
JA Witjes, D Quale. Bladder Cancer Apr 27;2(2):165-202, 2016.
PMID27376138; PMC4927845
http://www.ncbi.nlm.nih.gov/pubmed/27376138
*incudes SWOG studies S0337,S0353, S1314, S1602, S8507
n/a
GU MANUSCRIPTS SUBMITTED (2016)
S0421
Validation of the association of RECIST changes with survival 8/21/06
in men with metastatic castration resistant prostate cancer
treated on SWOG study S0421. G Sonpavde, GR Pond, M
Plets, CM Tangen, MHA Hussain, PN Lara, Jr, A Goldkorn,
MG Garzotto, PC Mack, CS Higano, NJ Vogelzang, IM
Thompson, Jr, PW Twardowski, PJ Van Veldhuizen, Jr,
N Agarwal, MA Carducci, J Monk, DI Quinn. Journal of
Urology, under review.
5/1/10
S1014
Phase II Trial of Abiraterone Acetate for metastatic prostate
cancer with suboptimal biochemical response to hormone
induction (SWOG S1014). TW Flaig, M Plets, M Hussain,
N Agarwal, N Mitsiades, HA Deshpande, U Vaishampayan,
IM Thompson. JAMA Oncology, pending resubmission.
8/1/13
8/9/11
GU ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2016)
S0421
Validation of the association of RECIST 1.0 changes with
8/21/06
survival in men with metastatic castration resistant prostate
cancer (mCRPC) treated on SWOG study S0421.GR Pond,
G Sonpavde, M Plets, CM Tangen, MH Hussain, PN Lara ,
A Goldkorn, M Garzotto, P Mack, C Higano N Vogelzang, IM
Thompson, P Twardowski , P Van Veldhuizen , N Agarwal,
M Carducci, JP Monk, Quinn DI. American Society of Clinical
Oncology Annual Meeting (June 3-7, 2016, Chicago, IL),
poster session. J Clin Oncol 34, 2016 (suppl; abstr 5079).
http://abstract.asco.org/176/AbstView_176_166577.html
5/1/10
S0421
Bone biomarkers and overall survival (OS) in men with
8/21/06
castration resistant prostate cancer (CRPC) and skeletal
metastases: updated results from SWOG 0421, a phase III
trial of docetaxel +/- atrasentan. PN Lara, Jr., M Plets, C
Tangen, E Gertz, NJ Vogelzang, DI Quinn, I Thompson, M Van
Loan. European Society for Medical Oncology (October
7-11, 2016, Copenhagen, Denmark), accepted, poster
presentation.
5/1/10
S1216
Circulating tumor cells (CTCs) in SWOG S1216: a phase 3
3/1/13
multicenter trial in metastatic hormone sensitive prostate
cancer (mHSPC). A Goldkorn, M Plets, N Agarwal, M Hussain,
P Lara, D Vaena, GR MacVicar, T Crispino, A Harzstark, P
Twardowski, C Tangen, C Hugen, T Xu, Y Xu, J Pinski, S
Ingles, C Higano, N Vogelzang, I Thompson, D Quinn.
American Society of Clinical Oncology Annual Meeting
(June 3-7, 2016, Chicago, IL),poster discussion. J Clin
Oncol 34, 2016 (suppl; abstr 11516)
http://abstract.asco.org/176/AbstView_176_164681.html
n/a
E3805
Genome-wide association study (GWAS) of response to
androgen deprivation therapy (ADT) and survival in
metastatic prostate cancer (PCa. M Pomerantz, V Wang,
P Kantoff, W Xie, M Kohli, G-S M Lee, E Wang, Y-H Chen,
N Hahn, D Jarrard, G Liu, J Garcia, M Carducci, RS DiPaola,
M Freedman, CJ Sweeney. American Society of Clinical
Oncology Annual Meeting (June 3-7, 2016, Chicago, IL),
poster session. J Clin Oncol
34, 2016 (suppl; abstr 1540).
http://abstract.asco.org/176/AbstView_176_170312.html
11/21/12
9/1/08
E3805
Long term efficacy and QOL data of chemohormonal
therapy (C-HT) in low and high volume hormone naïve
metastatic prostate cancer (PrCa): E3805 CHAARTED trial.
C Sweeney, Y-H Chen, G Liu, M Carducci, D Jarrard, M
Eisenberger, Y-N Wong, L Patrick-Miller, N Hahn, M Kohli,
M Conney, R Dreicer, NJ Vogelzang, J Picus, D Shevrin, M
Hussain, J Garcia, R Dipaola. European Society for Medical
Oncology (October 7-11, 2016, Copenhagen, Denmark),
accepted, poster presentation.
9/1/08
11/21/12
SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2015
____________________________________________________________________________________________
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
____________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED (2015)
4B951
Variability in surgical quality in a phase III prospective
clinical trial of radical cystectomy in patients with organconfined, node-negative urothelial carcinoma of the bladder.
DA Mata, S Groshen, F-C von Rundstedt, DG Skinner, WM
Stadler, RJ Cote, JP Stein, SP Lerner. Journal of Surgical
Oncology Jun;111(7):923-928, 2015. PMID 25873574;
PMC4602027
http://www.ncbi.nlm.nih.gov/pubmed/25873574
10/15/01
3/28/06
4B951
Significance of lymphovascular invasion in organ-confined,
node-negative urothelial cancer of the bladder: data from the
prospective p53-MVAC trial. F von Rundstedt, DA Mata, S
Groshen, JP Stein, DG Skinner, WM Stadler, RJ Cote, ON
Kryvenko, G Godoy, SP Lerner. British Journal of Urology
International 116(1):44-49, 2015. PMID25413313;
PMC4524781
http://www.ncbi.nlm.nih.gov/pubmed/25413313
10/15/01
3/28/06
S0421
Circulating tumor cell telomerase activity as a prognostic
marker for overall survival in metastatic castration resistant
prostate cancer: results from SWOG S0421. A Goldkorn,
B Ely, C Tangen, Y-C Tai, T Xu, H Li, P Twardowski, P Van
Veldhuizen, N Agarwal, M Carducci, J Monk, M Garzotto,
P Mack, P Lara, C Higano, M Hussain, N Vogelzang, IM
Thompson, R Cote, D Quinn. International Journal of
Cancer . Apr 15;136(8):1856-62, 2015. [Epub 2014 Oct 8.].
PMID25219358; PMC4323674
http://www.ncbi.nlm.nih.gov/pubmed/25219358
8/21/06
5/1/10
S0925
SWOG S0925: A randomized phase 2 study of androgen
12/15/10
deprivation combined with cixutumumab versus androgen
deprivation alone in patients with new metastatic hormonesensitive prostate cancer. EY Yu, H Li, CS Higano, N Agarwal,
SK Pal, A Alva, EI Heath, ET Lam, S Gupta, MB Lilly, Y Inoue,
KN Chi, NJ Vogelzang, DI Quinn, HH Cheng, SR Plymate, M
Hussain, CM Tangen, IM Thompson, Jr. Journal of Clinical
Oncology May 10;33(14):1601-8,2015. PMID25847934;
PMC4417730
http://www.ncbi.nlm.nih.gov/pubmed/25847934
12/1/12
E2804
BEST: A randomized phase II study of vascular endo4/1/08
thelial growth factor, RAF kinase, and mammalian target
of rapamycin combination targeted therapy with bevacizumab,
sorafenib, and temsirolimus in advanced renal cell carcinomaa trial of the ECOG-ACRIN Cancer Research Group (E2804).
K Flaherty, J Manola, M Pins, DF McDermott, MB Atkins, JJ
Dutcher, DJ George, KA Margolin, RS DiPaola. Journal of
Clinical Oncology Jul 20;33(21):2384-2391, 2015.
PMID26077237; PMC4500832
http://www.ncbi.nlm.nih.gov/pubmed/26077237
12/10/10
E2805
Effects of adjuvant sorafenib and sunitinib on cardiac
function in renal cell carcinoma patients without overt
metastases: results from ASSURE, ECOG 2805. NB Haas,
J Manola, B Ky, KT Flaherty, RG Uzzo, CJ Kane, M Jewett,
L Wood, CG Wood, MB Atkins, JJ Dutcher, G Wilding, RS
DiPaola. Clinical Cancer Research 21(18):4048-4054, 2015.
PMID25967143; PMC4573791
http://www.ncbi.nlm.nih.gov/pubmed/25967143
5/15/06
9/1/10
E3805
Chemohormonal therapy in metastatic hormone-sensitive
prostate cancer. C Sweeney, Y-H Chen, M Carducci, G Liu,
D Jarrard, Y-N Wong, M Eisenberger, N Hahn, M Kohli, M
Cooney, R Dreicer, N Vogelzang, J Picus, D Shevrin, M
Hussain, J Garcia, R DiPaola. New England Journal of
Medicine Aug 20;373(8):737-746, 2015; 2015 Aug 5
[Epub ahead of print]. PMID26244877; PMC4562797
http://www.ncbi.nlm.nih.gov/pubmed/26244877
9/1/08
11/21/12
GU ABSTRACTS PUBLISHED/PRESENTED (2015)
S0421
SWOG 0421: Impact of circulating markers of bone metabolism on
overall survival in men with metastatic castration resistant prostate
cancer (CRPC). PN Lara, Jr., M Plets, C Tangen, E Gertz, DI Quinn,
I Thompson, M Van Loan. European Multidisciplinary Meeting on
Urological Cancers (EMUC) (November 12 -15, 2015, Barcelona,
Spain), submitted 7/1/15; accepted, oral presentation.
8/21/06
5/1/10
S1011
A phase III surgical trial to evaluate the benefit of a standard
versus an extended pelvic lymphadenectomy performed at time
of radical cystectomy for muscle invasive urothelial cancer:
SWOG S1011 (NCT #01224665). SP Lerner, C Tangen, RS Svatek,
TM Koppie, A Alva, FG LaRosa, SK Pal, S Daneshmand, CPN
Dinney, AS Kibel, K Pohar, DJ Canter, W Kassouf, R Bangs,
IM Thompson. American Urological Association (May 15-19, 2015,
New Orleans), moderated poster presentation; Journal of Urology,
Vol. 193, Issue 4, e807 [abst MP65-02].
http://www.jurology.com/article/S0022-5347(15)02603-8/pdf
8/1/11
n/a
S1014
Phase II trial of abiraterone acetate (AA) treatment for metastatic
prostate cancer (PC) patients with a PSA of more than four following
initial androgen deprivation therapy: SWOG S1014. TW Flaig, CM
Tangen, MHA Hussain, N Agarwal, N Mitsiades, H Deshpande, U
Vaishampayan, IM Thompson. ASCO GU Cancers Symposium
(February 26-28, 2015, Orlando, FL), poster presentation;
Journal of Clinical Oncology 33(suppl 7; abstr 152), 2015.
http://meetinglibrary.asco.org/content/141041-159
8/9/11
8/1/13
S1107
SWOG 1107: Parallel randomized phase II evaluation of tivantinib
(ARQ-197) and tivantinib in combination with erlotinib in patients
(pts) with advanced papillary renal cell carcinoma (pRCC).
PW Twardowski, M Plets, ER Plimack, N Aggarwal, CM Tangen,
NJ Vogelzang, IM Thompson, Jr, PN Lara, Jr.. American Society
of Clinical Oncology Annual Meeting (May 29-June 2, 2015,
Chicago, IL), poster discussion. J Clin Oncol 33:5s
(suppl; abstr 4523), 2015.
http://abstracts.asco.org/156/AbstView_156_143218.html
8/20/12
5/29/14
E2805
Results from ASSURE (E2805): adjuvant sorafenib or sunitinib for
unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3
trial. NS Balzer-Haas, J Manola, RG Uzzo, MB Atkins, G Wilding,
M Pins, MA Jewett, CJ Kane, D Cella, LI Wagner, R Coomes,
CG Wood, JJ Dutcher, KT Flaherty, RS DiPaola. ASCO GU
Cancers Symposium (February 26-28, 2015, Orlando, FL),
general poster session. Journal of Clinical Oncology
33 (suppl 7; abstr 403), 2015.
http://meetinglibrary.asco.org/content/141765-159
5/15/06
9/1/10
SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2014
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2014)
S0421
Circulating tumor cell (CTC) counts are prognostic of
overall survival in SWOG S0421: docetaxel with or
without atrasentan for metastatic castration resistant
prostate cancer. A Goldkorn, B Ely, DI Quinn, CM
Tangen, LM Fink, Tong Xu, P Twardowski, PJ Van
Veldhuizen, N Agarwal, M Carducci, JP Monk, RH Datar,
M Garzotto, PC Mack, Lara P, Higano CS, M Hussain,
IM Thompson, RJ Cote, NJ Vogelzang. Journal of
Clinical Oncology, 32(11):1136-1142, 2014.
PMID24616308; PMC3970171
http://www.ncbi.nlm.nih.gov/pubmed/24616308
8/21/06
5/1/10
S0421
Serum biomarkers of bone metabolism in castration
resistant prostate cancer patients with skeletal metastases.
PN Lara, B Ely, DI Quinn, PC Mack, CM Tangen, E Gertz,
PW Twardowski, A Goldkorn, M Hussain, NJ Vogelzang,
IM Thompson, MD Van Loan. Journal of the National
Cancer Institute, 106(4):dju013, 2014. doi: 10.1093/jnci/
dju013. PMID24565955; PMC3982883
http://www.ncbi.nlm.nih.gov/pubmed/24565955
8/21/06
5/1/10
S1107
Papillary renal cell carcinoma: current progress and future
directions. PW Twardowski, PC Mack, PN Lara, Jr. Clinical
Genitourinary Cancer 12(2):74-79, 2014. PMID24629521
(reviews not within scope of Public Access Policy)
http://www.ncbi.nlm.nih.gov/pubmed/24629521
8/20/12
n/a
S1314
Novel neoadjuvant therapy paradigms for bladder cancer:
7/9/14
results from the National Cancer Center Institute Forum. C
Dinney, D Hansel, D McConkey, W Shipley, M Hagan, R
Dreicer, S Lerner,B Czerniak, F Waldman, S Groshen, LD
True, E Petricoin, D Theodorescu, A Hruszkewycz, D Bajorin.
Urologic Oncology 32(8):1108-15, 2014.
http://www.ncbi.nlm.nih.gov/pubmed/25443274
n/a
30904-EORTC
Renal function after nephron-sparing surgery versus radical
nephrectomy: results from EORTC randomized trial 30904.
E Scosyrev, EM Messing, R Sylvester, S Campbell, H van
Poppe. European Urology 65(2):372-377, 2014.
PMID23850254; NIHMS628822
http://www.ncbi.nlm.nih.gov/pubmed/23850254
5/15/00
1/13/03
C90202
Randomized controlled trial of early zoledronic acid in men
with castration-sensitive prostate cancer and bone
metastases: results of CALGB 90202 (Alliance). MR Smith,
S Halabi, CJ Ryan, A Hussain, N Vogelzang, W Stadler,
RJ Hauke, JP Monk, P Saylor, N Bhoopalam, F Saad, B
Sanford, WK Kelly, M Morris, EJ Small. Journal of Clinical
Oncology 32(11):1143-1150, 2014. PMID24590644
PMC3970172.
http://www.ncbi.nlm.nih.gov/pubmed/24590644
8/1/04
4/4/12
GU ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2014)
S0925
SWOG S0925: A randomized phase 2 study of androgen
12/15/10
deprivation combined with cixutumumab (IMC-A12) versus
androgen deprivation alone for patients with new metastatic
castration-sensitive prostate cancer. EY Yu, CM Tangen, CS
Higano, N Agarwal, SK Pal, A Alva, EI Heath, ET Lam, S Gupta,
MB Lilly, Y Inoue, KN Chi, NJ Vogelzang, DI Quinn, H Li, H Cheng,
SR Plymate, MHA Hussain, IM Thompson, Jr. American Society of
Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago,
IL), oral session. Journal of Clinical Oncology 32:5s (suppl; abstr
5006), 2014.
http://abstracts.asco.org/144/AbstView_144_126259.html
12/1/12
S0925
Comparison of plasma microRNAs with CTCs and PSA in
12/15/10
patients treated on SWOG S0925, a randomized phase II
study of androgen deprivation combined with cixutumumab
versus androgen deprivation alone for patients with new metastatic
hormone-sensitive prostate cancer. HH Cheng, H Li, CS Higano,
CM Tangen, N Agarwal, J Yan, NJ Vogelzang, M Hussain, IM
Thompson, Jr., M Tewari, EY Yu. American Society of Clinical
Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL),
poster highlights session. Journal of Clinical Oncology 32:5s
(suppl; abstr 5017), 2014.
http://abstracts.asco.org/144/AbstView_144_130085.html
12/1/12
S1011
Pre-randomization factors and utilization of neoadjuvant
chemotherapy in a clinical trial of extended vs. standard
pelvic lymphadenectomy at the time of radical cystectomy
for bladder cancer. SP Lerner, H Li, R Svatek, T Koppie,
A Alva, F La Rosa, R Bangs, S Pal, S Daneshmand, AS
Kibel, DJ Canter, CM Tangen, IM Thompson. ASCO GenitoUrinary Cancers Symposium (January 30-February 1, 2014,
San Francisco, CA), submitted 10/1/13, poster presentation;
Journal of Clinical Oncology 32(suppl 4; abstr 297), 2014.
http://meetinglibrary.asco.org/content/124396-142
open
S1216
SWOG S1216: A phase III randomized trial comparing
3/1/13
androgen deprivation therapy (ADT) + TAK-700 with ADT +
bicalutamide in patients with newly diagnosed metastatic
hormone sensitive prostate cancer (HSPC) (NCT01809691).
N Agarwal, C Tangen, M Hussain, P Lara, C Higano, D Vaena,
GR MacVicar, H Li, T Crispino, D Quinn, N Vogelzang, I Thompson.
American Society of Clinical Oncology Annual Meeting (May 30June 3, 2014, Chicago, IL), trials in progress, general
poster session. Journal of Clinical Oncology 32:5s (suppl; abstr
TPS5102), 2014.
http://abstracts.asco.org/144/AbstView_144_130445.html
n/a
S8710
Optimizing a risk stratification for local-regional failure after
8/1/87
radical cystectomy using the SWOG 8710 cohort. B Baumann,
J He, W-T Hwang, K Tucker, SP Lerner, CM Tangen, H Herr, TJ
Guzzo, SB Malkowicz, JP Christodouleas. ASCO Genitourinary
Cancers Symposium (January 30-February 1, 2014, San Francisco,
CA), poster presentation; Journal of Clinical Oncology 32(suppl 4;
abstr 297), 2014.
http://meetinglibrary.asco.org/content/124396-142
7/1/98
8/1/11
E2805
Lymphadenectomy at the time of surgery for high risk
localized RCC: results from the ASSURE adjuvant trial
(ECOG 2805). R Uzzo, J Manola, N Haas, C Kane,
C Wood, M Jewett, R DiPaola. American Urological
Association 2014 Annual Meeting (May 16 -21, 2014,
Orlando, FL), poster discussion; Journal of Urology
Vol. 191, No. 4S, Supplement, p. e283 (PD10-04), 2014.
http://www.jurology.com/article/S0022-5347(14)00738-1/pdf
5/15/06
9/1/10
E3805
Impact on overall survival (OS) with chemohormonal therapy 9/1/08
versus hormonal therapy for hormone-sensitive newly metastatic
prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
C Sweeney, Y-H Chen, MA Carducci, G Liu, DF Jarrard, MA
Eisenberger, Y-N Wong, NM Hahn, M Kohli, NJ Vozelgang, MM
Cooney, R Dreicer, J Picus, DH Shevrin, M Hussain, JA Garcia,
RS DiPaola. American Society of Clinical Oncology Annual Meeting
(May 30-June 3, 2014, Chicago, IL), accepted, scientific program
plenary session (oral). Journal of Clinical Oncology 32:5s (suppl;
abstr LBA2), 2014
http://abstracts.asco.org/144/AbstView_144_127755.html
11/21/12
R0524
The initial report of RTOG 0524: Phase I/II trial of a
12/15/06
combination of paclitaxel and trastuzumab with daily
irradiation or paclitaxel alone with daily irradiation following
transurethral surgery for noncystectomy candidates with
muscle-invasive bladder cancer. MD Michaelson, C Hu, HT
Pham, DM Dahl, C-L Wu, RM Whittington, GP Swanson, J
Vuky, RJ Lee, L Souhami, BK Chang, A George, HM Sandler,
WU Shipley. American Society of Clinical Oncology Genitourinary Cancers Symposium (January 30 – February 1, 2014,
San Francisco CA), oral; Journal of Clinical Oncology 32
(suppl 4; abstr LBA287), 2014.
http://meetinglibrary.asco.org/content/123707-142
2/22/13
Multiple Groups* The site of visceral metastases (mets) to predict
n/a
overall survival (OS) in castration-resistant prostate
cancer (CRPC) patients (pts): A meta-analysis of five
phase III trials. S Halabi, WK Kelly, H Zhou, AJ
Armstrong, D Quinn, K Fizazi, NC Solomon, I Tannock,
DP Petrylak, MJ Morris, E Small. American Society of
Clinical Oncology Annual Meeting (May 30-June 3, 2014,
Chicago, IL), oral session. Journal of Clinical Oncology
32:5s (suppl; abstr 5002), 2014. *includes SWOG S0421
http://abstracts.asco.org/144/AbstView_144_129874.html
n/a
NONE
n/a
Association of higher institutional volume with
n/a
improved overall survival in clinical stage III testicular
cancer- results from the National Cancer Data Base
(1998-2011). C Jeldres, K Pham, S Daneshmand, C
Kollmannsberger, B Hayes-Lattin, E Wolffe, K Odem-Davis,
CR Porter, CR Nichols. Journal of Clinical Oncology 32:5s
(suppl; abstr 4519); ASCO Annual Meeting (May 30-June 3,
2014, Chicago, IL), poster highlight session.
SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2013
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2013)
S0353
SWOG S0353: Phase II trial of intravesical gemcitabine in
patients with non-muscle invasive bladder cancer who
recurred following at least two prior courses of BCG.
E Skinner, B Goldman, W Sakr, D Petrylak, H Lenz,
CT Lee, S Wilson, M Benson, SP Lerner, CM Tangen,
IM Thompson. Journal of Urology 190(4):1200-1204, 2013.
PMID23597452; NIHMSID #573393
http://www.ncbi.nlm.nih.gov/pubmed/23597452
11/15/06
10/15/09
S0421
Docetaxel and atrasentan compared docetaxel and placebo
for men with advanced castration resistant prostate cancer:
SWOG S0421. D Quinn, C Tangen, M Hussain, P Lara,
A Goldkorn, M Garzotto, P Mack, M Carducci, JP Monk,
P Twardowski, P Van Veldhuizen, N Agarwal, C Higano,
N Vogelzang, IM Thompson. Lancet Oncology 14(9):893900, 2013. PMID23871417
8/21/06
5/1/10
S9346
Intermittent versus continuous androgen deprivation in
5/15/95
prostate cancer. M Hussain, C Tangen, D Berry, C Higano,
E Crawford, G Liu, G Wilding, S Prescott, S Kanaga-Sundaram,
EJ Small, NA Dawson, B Donnelly, P Venner, U Vaishampayan,
PL Schellhammer, DI Quinn, D Raghavan, B Ely, C Moinpour,
N Vogelzang, IM Thompson. New England Journal of Medicine,
368(14):1314-1325, 2013. PMID23550669; PMC3682658
http://www.ncbi.nlm.nih.gov/pubmed/23550669
9/1/08
Multiple*
Time from prior chemotherapy enhances prognostic risk
n/a
grouping in the second-line setting of an advanced urothelial
carcinoma: a retrospective analysis of pooled, prospective
phase 2 trials. G Sonpavde, GR Pond, R Fougeray, T Choueiri,
A Qu, D Vaughn, G Niegisch, P Albers, N James, Y-N Wong, Y-J
Ko, S Sridhar, P Galsky, D Petrylak, U Vaishampayan, A Khan,
Nicholas Vogelzang, T Beer, W Stadler, P O’Donnell, CN Sternberg,
J Rosenberg, J Bellmunt. European Urology, 63(4):717-723, 2013.
[Review and analysis of retrospective pooled data). PMID23206856;
(Reviews are not within the scope of the Public Access Policy).
*Studies: S0031, S0306 & other (pooled analysis).
http://www.ncbi.nlm.nih.gov/pubmed/23206856
n/a
http://www.ncbi.nlm.nih.gov/pubmed/23871417
ABSTRACTS PUBLISHED/PRESENTED (2013)
S8710
Robust risk stratification model predicts local-regional re8/1/87
currence after radical cystectomy in different patient cohorts.
B Baumann, J He, W-T Hwang, K Tucker, S Lerner, C Tangen,
H Herr, T Guzzo, SB Malkowicz, J Christodouleas. American
Society for Radiation Oncology Annual Meeting (September 22-25,
2013, Atlanta, GA), oral presentation. International Journal of
Radiation Oncology * Biology * Physics 87(2):Supplement, p. S82.
(selected as one of the abstracts to be presented at the "Best of ASTRO"
meeting in San Diego.
http://www.redjournal.org/article/S0360-3016(13)00882-1/fulltext
7/1/98
S8710/other
(pooled
analysis)
Risk stratification for local-regional failure after cystectomy
8/1/87
BC Bauman, J He, H Hwang, K Tucker, SP Lerner, CM
Tangen, HW Herr, T Guzzo, SB Malkowicz, J Christodouleas.
American Urological Association 2013 Annual Meeting (May 4-8,
2013, San Diego, CA), moderated poster discussion, abstr. #1628.
http://www.aua2013.org/abstracts/archive/abstracts_Baumann_Brian.cfm
7/1/98
SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2012
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED (2012)
S8494/S8894/
S9346
Improved overall survival trends of men with newly
diagnosed M1 prostate cancer: A SWOG phase III trial
experience (SS8494, S8894 & S9346). CM Tangen, MHA
Hussain, CS Higano, MA Eisenberger, EJ Small, G Wilding,
BJ Donnelly, DG McLeod, PF Schellhammer, ED Crawford,
NJ Vogelzang, IJ Powell, IM Thompson. Journal of Urology,
188(4):1164-1169, 2012. PMID22921015; PMC3481164
http://www.ncbi.nlm.nih.gov/pubmed/22921015
12/15/89
9/15/94
S9109
Ten-year follow-up of neoadjuvant therapy with goserelin
12/1/93
acetate and flutamide prior to radical prostatectomy for
clinical T3/T4 prostate cancer: update on Southwest Oncology
Group Study 9109. RK Berglund, C Tangen, IJ Powell, BA
Lowe, G Haas, P Carroll, ED Canby-Hagino, R deVere White,
GP Hemstreet, ED Crawford, IM Thompson, E Klein.
Urology 79(3):633-637, 2012. PMID22386416;
PMC3839235
http://www.ncbi.nlm.nih.gov/pubmed/22386416
10/15/96
S9450
Prostate cancer – uncertainty and a way forward. IM
Thompson, CM Tangen. New England Journal of
Medicine 367(3):270-271, 2012. PMID22808963.
(Commentary - not within scope of Public
Access Policy).
http://www.ncbi.nlm.nih.gov/pubmed/22808963
5/1/95
11/30/01
E8802
A phase II trial of doxorubicin and gemcitabine in renal
cell carcinoma with sarcomatoid features: ECOG 8802.
NB Haas, X Lin, J Manola, M Pins, G Liu, D Mcdermott,
D Nanus, E Heath, G Wilding, J Dutcher. Medical Oncology
29(2):761-767, 2012. PMID21298497; PMC3566570
http://www.ncbi.nlm.nih.gov/pubmed/21298497
5/15/06
4/19/07
EORTC30987
Randomized phase III study comparing paclitaxel/cisplatin/
6/15/02
gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients
with locally advanced or metastatic urothelial cancer without
prior systemic therapy: EORTC intergroup study 30987. J
Bellmunt, H von der Maase, GM Mead, N Skonecza, M
DeSantis, G Daugaard, J Heyer, L Paz-Ares, L Laufman, E
Winquist, D Raghavan, S Marreaud, S Collette, R Sylvester,
R de Wit. Journal of Clinical Oncology, 30(10):1107-1113,
2012. PMID22370319; PMC3341152.
http://www.ncbi.nlm.nih.gov/pubmed/22370319
6/1/04
NCIC PR7
Intermittent androgen suppression for rising PSA level after
radiotherapy. J Crook, CJ O’Callaghan, G Duncan, DP
Dearnaley, CS Higano, EM Horwitz, E Frymire, S Malone,
J Chin, A Nabid, P Warde, T Corbett, S Angyalfi, SL
Goldenberg, Gospodarowicz, F Saad, JP Logue, E Hall,
PF Schellhammer, K Ding, L Klotz. New England Journal
of Medicine, 367(10):895-903, 2012. PMID22931259;
PMC3521033
http://www.ncbi.nlm.nih.gov/pub med/22931259
7/1/99
11/30/05
ABSTRACTS PUBLISHED/PRESENTED (2012)
S0353
SWOG S0353: Phase II trial of intravesical gemcitabine in
11/15/06
10/15/09
patients with superficial bladder cancer with recurrence
following 2 prior courses of BCG. E Skinner, B Goldman, W
Sakr, P Petrylak, H Lenz, CT Lee, SS Wilson, SP Lerner, CM
Tangen, IM Thompson. American Urological Association Annual
Meeting (May 19-23, 2012, Atlanta, GA), oral presentation;
Journal of Urology 187, No. 4S, Supplement, e673, #1666, 2012.
http://download.journals.elsevierhealth.com/pdfs/journals/0022-5347/PIIS0022534712018861.pdf
S0421
SWOG S0421: phase III study of docetaxel and placebo (P) 8/21/06
for men with advanced castrate resistant prostate cancer. D
Quinn, C Tangen, M Hussain, P Lara, A Goldkorn, M Garzotto,
PC Mack, M Carducci, JP Monk, PW Twardowski, PJ Van
Veldhuizen, N Agarwal, CS Higano, NJ Vogelzang, IM
Thompson. American Society of Clinical Oncology 2012
Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
J Clin Oncol 30, 2012 (suppl; abstr 4511).
http://abstract.asco.org/AbstView_114_99398.html
5/1/10
S0421
SWOG 0421: Prognostic and predictive value of bone
8/21/06
metabolism biomarkers (BMB) in castration resistant prostate
cancer (CRPC) patients (pts) with skeletal metastases treated
with docetaxel +/- atrasentan (ATR). PN Lara, B Ely, DI Quinn,
C Tangen, E Gertz, M Hussain, NJ Vogelzang, I Thompson, M van
Loan. American Society of Clinical Oncology 2012 Annual Meeting
(June 1-5, 2012, Chicago, Il), poster discussion; J Clin Oncol 30,
2012 (suppl; abstr 4547).
http://abstract.asco.org/AbstView_114_91416.html
5/1/10
S0421
Results of telomerase activity measurements from live
8/21/06
circulating tumor cells captured on a slot microfilter in a
phase III SWOG-coordinated prostate cancer trial (S0421).
A Goldkorn, B Ely, DI Quinn, C Tangen, Y-C Tai, PW
Twardowski, PJ Van Veldhuizen, N Agarwal, M Carducci, JP
Monk, MG Garzotto, PC Mack, PN Lara, CS Higano, M Hussain,
N Vogelzang, RJ Cote, IM Thompson. American Society of
Clinical Oncology 2012 Annual Meeting (June 1-5, 2012,
Chicago, IL), poster presentation; J Clin Oncol 30, 2012
(suppl; abstr 4663).
http://abstract.asco.org/AbstView_114_99398.html
5/1/10
S0421
Results of circulating tumor cell counts using the CellSearch
platform in a prospective randomized phase III SWOGsponsored prostate cancer trial (S0421). N Vogelzang,
B Ely, LM Fink, A Goldkorn, CM Tangen, PW Twardowski,
PJ Van Velhuizen, N Agarwal, M Carducci, JP Monk, MG
Garzotto, PC Mack, PN Lara, CS Higano, M Hussain,
DI Quinn, RJ Cote, IM Thompson. American Society of
Clinical Oncology 2012 Annual Meeting (June 1-5, 2012,
Chicago, IL), oral presentation; J Clin Oncol 30, 2012
(suppl; abstr 10503).
http://abstract.asco.org/AbstView_114_99469.html
8/21/06
S0421
Circulating tumor cell (CTC) counts and CTC telomerase
8/21/06
5/1/10
activity (TA) are prognostic of overall survival (OS) in SWOG
S0421 – docetaxel with or without atrasentan for metastatic
castration resistant prostate cancer (mCRPC). A Goldkorn,
NJ Vogelzang, B Ely, LM Fink, DI Quinn, CM Tangen, Y-C
Tai, P Twardowski, PJ Van Veldhuizen, N Agarwal, MA Carducci,
JP Monk, M Garzotto, PC Mack, P Lara, CS Higano, M Hussain,
RJ Cote, IM Thompson. ASCO Markers in Cancer Annual Meeting
(October 11-13, 2012, Hollywood, FL), oral presentation;
J Clin Oncol 30: 2012 (suppl 30; abstr 1).
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=127&abstractID=103697
S9346
Intermittent (IAD) vs continuous androgen deprivation
5/15/95
(CAD) in hormone sensitive metastatic prostate cancer
(HSM1PC) patients (pts): results of S9346 (INT-0162) an
international phase III trial. M Hussain, C Tangen, C Higano, E
Crawford, G Liu, G Wilding, S Prescott, A Akdas, E Small, N
Dawson, B Donnelly, P Venner, U Vaishampayan, P Schellhammer,
D Quinn, D Raghavan, N Vogelzang, IM Thompson. American
Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012,
Chicago, IL), oral presentation (plenary session); J Clin Oncol 30,
2012 (suppl; abstr 4).
http://abstract.asco.org/AbstView_114_92516.html
9/1/08
S9346
Preliminary quality of life outcomes for SWOG-9346:
5/15/95
intermittent androgen deprivation in patients with hormone
sensitive metastatic prostate cancer (HSM1PC), phase III.
C Moinpour, DL Berry, B Ely, C Tangen, C Higano, J Picus,
P Schellhammer, C Skinner, M Cher, I Thompson, M Hussain.
American Society of Clinical Oncology 2012 Annual Meeting
(June 1-5, 2012, Chicago, IL), poster discussion;
Journal of Clinical Oncology 30, 2012 (suppl; abstr 4571).
http://abstract.asco.org/AbstView_114_101068.html
9/1/08
E2805
Cardiac safety analysis for a phase III trial of sunitinib (SU)
or sorafenib (SO) or placebo (PLC) in patients (pts) with
resected renal cell carcinoma (RCC). NB Haas, J Manola,
B Ky, KT Flaherty, RG Uzzo, CG Wood, CJ Kane, MAS
Jewett, MB Atkins, JP Dutcher, RS DiPaola. American
Society of Clinical Oncology 2012 Annual Meeting
(June 1-5, 2012, Chicago, IL), oral presentation; Journal
of Clinical Oncology 30(suppl; abstr 4500), 2012.
http://meetinglibrary.asco.org/content/94335-114
9/1/10
5/15/06
5/1/10
SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2011
(PCPT and SELECT listed with CC&P Committees)
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED (2011)
S0032
Phase II evaluation of early oral estramustine, oral etoposide 12/1/01
and intravenous paclitaxel in combination with hormone
therapy in patients with high risk metastatic adenocarcinoma
of the prostate: Southwest Oncology Group (SWOG)
S0032. DC Smith, DM Tangen,, PJ Van Veldhuizen, GW
Harrer, A Golshayan, GM Mills, NJ Vogelzang, IM Thompson,
MHA Hussain. Urology 77(5):1172-1176, 2011;
PMID21334731; PMC3528346
http://www.ncbi.nlm.nih.gov/pubmed/21334731
6/1/05
S8710
Do mixed histologic features affect survival benefit from
neoadjuvant platinum-based combination chemotherapy
in patients with locally advanced bladder cancer treated
with radical cystectomy? A secondary analysis of
Southwest Oncology Group-directed intergroup
Study (S8710). E Scosyrev, BW Ely, EM Messing,
VO Speights, HB Grossman, DP Wood, RW
de Vere White, NJ Vogelzang, DL Trump, R Natale,
C Tangen, ED Crawford, IM Thompson. British Journal
8/1/87
7/1/98
2/1/00
11/1/06
of Urology International 108(5):693-699, 2011;
PMID21105991; PMC3117124
http://www.ncbi.nlm.nih.gov/pubmed/21105991
S9917
Selenium supplementation and prostate cancer among
men with high grade prostatic intraepithelial neoplasia:
SWOG-directed intergroup trial S9917. JR Marshall, CM
Tangen, WA Sakr, DP Wood, DL Berry, EA Klein, SM
Lippman, HL Parnes, DS Alberts, DF Jarrard, WR Lee,
JM Gaziano, ED Crawford, B Ely, M Ray, W Davis, L
Minasian, IM Thompson. Cancer Prevention Research,
4(11):1761-1769, 2011. PMID21896650; PMC3208719
http://www.ncbi.nlm.nih.gov/pubmed/21896650
S9921
Adjuvant androgen deprivation for high-risk prostate cancer
10/15/99
after radical prostatectomy: SWOG S9921 study. T Dorff, T
Flaig, C Tangen, M Hussain, G Swanson, DP Wood, W Sakr,
N Dawson, N Haas, ED Crawford, NJ Vogelzang, IM Thompson,
LM Glode. Journal of Clinical Oncology, 29(15):2040-2045, 2011.
PMID21502546; PMC3107759
http://www.ncbi.nlm.nih.gov/pubmed?term=dorff%20t%20S9921
1/12/07
4B951
A phase III study of molecularly targeted adjuvant therapy
10/15/01
in locally advanced urothelial cancer of the bladder based
on p53 status. W Stadler, SP Lerner, S Groshen, JP Stein, E
Tuazon, D Skinner, D Raghavan, D Esrig, G Steinberg, D
Wood, L Klotz, C Hall, R Cote. Journal of Clinical Oncology,
29(25):3443-9, 2011. PMID21810677; PMC3164246
http://www.ncbi.nlm.nih.gov/pubmed/21810677
3/28/06
JPR3
(NCIC-CTG)
Combined androgen deprivation therapy
and radiation therapy for locally advanced prostate
cancer: a randomized, phase 3 trial. P Warde,
M Mason, K Ding, P Kirkbride, M Brundage,
R Cowan, M Gospodarowicz, E Kostashuk,
G Swanson, J Barber, A Hiltz, MK Parmer, J
Sathya, J Anderson, J Hetherington, MR Sydes,
W Parulekar. Lancet 378(9809):2104-2111,
2011. PMID 22056152; PMC3243932
http://www.ncbi.nlm.nih.gov/pubmed/22056152
8/31/05
11/106
GU ABSTRACTS PUBLISHED/PRESENTED (2011)
S0931
SWOG 0931 – Everest: EVErolimus for renal
cancer ensuing surgical therapy, a phase II
study. CW Ryan, CM Tangen, EI Heath,
PN Lara, GS Palapattu, PC Mack, MN Stein,
th
BW Ely, IM Thompson. 10 International
Kidney Cancer Symposium (Oct 14-15, 2011,
Chicago, IL), poster presentation.
4/1/11
n/a
JPR.7
(NCIC-CTG)
A phase III randomized trial of intermittent versus
7/1/99
11/30/05
continuous androgen suppression for PSA progression
after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU J
PR.7/UK intercontinental trial CRUKE/01/013. JM Crook,
CJ O’Callaghan, K Ding, G Duncan, D Dearnaley, C Higano,
E Horwitz, E Frymire, S Malone, J Chin, A Nabid, P Warde,
T Corbett, S Angyalfi, SL Goldenberg, MK Gospodarowicz,
J Loque, P Schellhammer, F Saad, L Klotz. ASCO 2011 annual
meeting (June 4-8, 2011, Chicago, IL), oral presentation;
Journal of Clinical Oncology 29: (suppl; abstr 4514), 2011.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=777
75
JPR.7
(NCIC-CTG)
A phase III randomized trial comparing intermittent versus
7/1/99
11/30/05
continuous androgen suppression for patients with PSA
progression after radical therapy: NCIC CTG PR.7/SWOG
JPR.7/CTSU JPR.7/UK intercontinental trial CRUKE/01/013.
L Klotz, CJ O’Callaghan, K Ding, D Dearnaley, CS Higano,
EM Horwitz, S Malone, SL Goldenberg, MK Gospodarowicz,
JM Crook. ASCO GU Symposium (poster presentation.
Journal of Clinical Oncology 29:2011 (suppl 7; abstr 3).
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=104&abstractID=725
03
SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2010
(PCPT and SELECT publication listed CCP Committees)
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED (2010)
S0031
Results of Southwest Oncology Group phase II
evaluation (study S0031) of ZD 1839 for Advanced
transitional cell carcinoma of the urothelium.
DP Petrylak, C Tangen, PJ VanVeldhuizen,
W Goodwin, PW Twardlowski, JN Atkins,
SR Dakhil, ML Lange, ED Crawford.
British Journal of Urology, 105(3):317-321,
2010. PMID: 19888985
http://www.ncbi.nlm.nih.gov/pubmed/19888985
2/15/01
S0354
Clinical and correlative results of SWOG S0354: a
4/1/07
Phase II trial of CNTO328, a monoclonal antibody
against interleukin-6 (IL-6), in chemotherapy pretreated patients with castration-resistant Prostate
cancer (CRPC). T Dorff, B Goldman, J Pinksi,
P Mack, P Lara, P Van Veldhuizen, DI Quinn,
N Vogelzang, IM Thompson, M Hussain.
Clinical Cancer Research, 16(11):3028-3034,
2010. PMC2898710; PMID20484019
http://www.ncbi.nlm.nih.gov/pubmed?term=dorff%20t%20monoclonal
10/15/02
5/15/08
GU ABSTRACTS PUBLISHED/PRESENTED (2010)
S0028
Paclitaxel-gemcitabine (P-G) for patients (pts) with
7/1/01
12/15/06
advanced (adv) urothelial cancer (UC), aged > 70
years (yrs): SWOG 0028. D Raghavan, C Tangen,
C Moinpour, C Gotay, K Albain, S Louie, H-J Lenz, D Quinn,
M Hussain, I Thompson. Poster presentation,
American Society for Clinical Oncology, 2010
Annual Meeting; Journal of Clinical Oncology
28:7s (suppl; abstr 4569), 2010
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51619
S0421
Circulating tumor cell capture and analysis in a multi8/21/06
n/a
center SWOG-coordinated prostate cancer trial.
A Goldkorn, T Xu, B Lu, A Williams, LM Fink, CM Tangen,
Y-C Tai, DI Quinn, P Twardowski, RJ Cote. “Trials in
Progress” poster presentation, American Society for
Clinical Oncology, 2010 Annual Meeting; Journal
of Clinical Oncology 28:7s (suppl;abstr TPS342),
2010
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=53487
S8710
Do Mixed Histologic Features Affect Survival Benefit
8/1/87
from Neo-Adjuvant Platinum-Based Combination
Chemotherapy In Patients With Locally Advanced
Bladder Cancer? E Scosyrev, BW Ely, EM Messing,
VO Speights, HB Grossman, DP Wood, RW deVereWhite,
NJ Vogelzang, DL Trump, RB Natale, C Tangen, ED
Crawford, IM Thompson. Poster presentation, 2010 Annual
Meeting of the American Urological Association; Journal
of Urology 183(4):suppl. E659 (abstr #1708), 2010.
http://www.jurology.com/article/S0022-5347(10)01811-2/fulltext
*S8710
Do mixed histologic features affect survival benefit from
8/1/87
7/1/98
neoadjuvant platinum-based combination chemotherapy
in patients with locally advanced bladder cancer? Messing
EM, Scosyrev E, Grossman HB, deVereWhite R, Trump DL,
Natale RB, Tangen C, Crawford ED, Thompson IM. Oral
Presentation, 2010 American Society for Clinical Oncology
Genitourinary Cancers Symposium (March 5-7, 2010, San
Francisco, CA),abstr. # 274.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30750
S9346/S8894
Improved overall survival (OS) of patients (pts) with new
n/a
n/a
metastatic prostate cancer (PCa): better efficacy or stage
migration? Data from SWOG:S9346 and 8894. M Hussain,
CM Tangen, CS Higano, MA Eisenberger, EJ Small, G Wilding,
BJ Donnelly, D McLeod, ED Crawford, IM Thompson. Poster
presentation, 2010 American Society for Clinical Oncology
Genitourinary Cancers Symposium, abstr. 30, 2010.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=3044
9
S9917
Southwest Oncology Group (SWOG) trial S9917:
Randomized phase 3 trial of selenium supplementation
to prevent prostate cancer among men with high grade
prostatic intraepithelial neoplasia (HGPIN). JR Marshall,
CM Tangen, WA Sakr, DP Wood, SM Lippman, D Jarrad,
DS Alberts, DL Berry, ED Crawford, IM Thompson.
American Urological Association 2010 Annual Meeting,
“late breaking” oral presentation.
S9921
Southwest Oncology Group study 9921: prolonged event
10/15/99
free survival in high risk prostate cancer (PC) patients
receiving adjuvant androgen deprivation. IM Thompson,
CM Tangen, MHA Hussain, DP Wood, GP Swanson,
DI Quinn, TB Dorff, NA Dawson, NB Haas, ED Crawford,
LM Glode. Oral presentation, American Urological Association
Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA),
“late breaking” abstract .
*JPR3
Intergroup randomized phase III study of androgen
11/1/96
8/31/05
deprivation therapy (ADT) plus radiation therapy (RT) in
locally advanced prostate cancer (CAP) (NCIC-CTG,
SWOG, MRC-UK, INT: T94-0110; NCT00002633).
PR Warde, MD Mason, MR Sydes, MK Gospodarowicz,
GP Swanson, P Kirkbride, E Kostashuk, J Hetherington,
K Ding, W Parulekar, NCIC CTG PR.3/MRC PRO7/
SWOG JPR3 investigators. Oral presentation, American
Society for Clinical Oncology, 2010 Annual Meeting
(June 4-8, 2010, Chicago, IL); Journal of Clinical Oncology
28:7s, (suppl; abstr CRA4504), 2010.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=49170
2/1/00
7/1/98
11/1/06
01/12/08
4B951
*Presented
Cell cycle regulatory protein alterations in a randomized
10/15/01
clinical trial of adjuvant chemotherapy following radical
cystectomy and pelvic lymphadenectomy. S Lerner, W Stadler,
S Groshen, J Cai, A Mitra, E Tuazon, D Skinner, D Raghavan,
D Esrig, G Steinberg, C Hall, R Cote. Poster presentation,
American Urological Association Annual Meeting 2010
(May 29-June 3, 2010, San Francisco, CA); Journal of
Urology 183(4);suppl.E662 (abstr 1715), 2010.
http://www.jurology.com/article/S0022-5347(10)01818-5/fulltext
3/28/06
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2009
(PCPT and SELECT publications are listed separately)
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED (2009)
S8507
(2379)
Failure to achieve a complete response to induction BCG
therapy is associated with increased risk of progression
and death in patients with high risk non-muscle invasive
bladder cancer. SP Lerner, CM Tangen, H Sucharew,
D Wood, ED Crawford. Urologic Oncology 27(2):155159, 2009. PMID: 18367117
12/20/85
12/15/88
S8710
(2624)
Quality of pathologic response and surgery correlate
with survival for completely resected bladder cancer
following neoadjuvant mVAC. G Sonpavde, BH Goldman,
VO Speights, SP Lerner, DP Wood, NJ Vogelzang, DL
Trump, RB Natale, HB Grossman, ED Crawford
Not accepted by JNCI 11/08; Cancer, 12115(18):4104-4109,
2009. PMID: 19517476
8/1/87
7/1/98
S8794
(2613)
Adjuvant radiotherapy for pathological T3N0M0 prostate
8/15/88
Cancer significantly reduces risk of metastases and improves
survival: long-term followup of a randomized clinical trial.
IM Thompson, CM Tangen, J Paradelo, MS Lucia, G Miller,
D Troyer, E Messing, J Forman, J Chin, G Swanson, E
Canby-Hagino and ED Crawford. Journal of Urology,
181(3):956-962, 2009. PMID: 19167731
1/1/97
S8949
(2561)
Predictors of survival in advanced renal cell carcinoma:
long-term results from Southwest Oncology Group trial
S8949. PN Lara, CM Tangen, S Conlon, RC Flanigan,
ED Crawford. Submitted to JU 2008; Journal of Urology,
181(2) 512-516, 2009. PMID: 19100570
3/1/94
8/1/00
S9346/9916
(2584)
Prostate-specific antigen progression (PSA-P) predicts
overall survival (OS) in patients with metastatic prostate
cancer: data from Southwest Oncology Group (SWOG)
Trials 9346 (INT 0162) and 9916. M Hussain, B
Goldman, C Tangen, C Higano, DP Petrylak, G Wilding,
A Akdas, EJ Small, BJ Donnelly, L Collette, PA Burch,
RS DiPaola, ED Crawford. Journal of Clinical
Oncology 27(15):2450-2456, 2009. PMID: 19380444
5/15/95
10/15/99
9/1/08
1/15/03
S9916
(2559)
Chemotherapeutic impact on pain and global healthrelated quality of life in hormone-refractory prostate
cancer: dynamically modified outcomes analysis of
a randomized controlled trial. CM Moinpour, GW
Donaldson, Y Nakamura. Quality of Life Research
18:147-155, 2009. PMID: 19130298
10/15/99
1/15/03
S9921
Biased hormonal therapy analysis makes results uninterpretable. CM Tangen, B Goldman, G Swanson, IM
Thompson. In press, Journal of Clinical Oncology, 27(33):
e203, 2009. PMID: 19786655
10/15/99
01/12/08
S0031
(2580)
Results of Southwest Oncology Group phase II
evaluation (study S0031) of ZD 1839 for Advanced
transitional cell carcinoma of the urothelium.
DP Petrylak, C Tangen, PJ VanVeldhuizen,
W Goodwin, PW Twardlowski, JN Atkins,
SR Dakhil, ML Lange, ED Crawford.
British Journal of Urology, 2009
Nov 2 [Epub ahead of print]. PMID: 19888985
2/15/01
10/15/02
S0219
(2591)
A sequential treatment approach to myoinvasive
urothelial cancer: a phase II Southwest Oncology
Group Trial (S0219). RW de Vere White, PN Lara,
B Goldman, MC Tangen, DC Smith, DP Wood, MHA
Hussain, ED Crawford. Journal of Urology 181(6):
2476-2480, 2009. PMID:1937909
1/1/03
12/15/06
S0312
(2560)
A phase II study of gemcitabine and capecitabine
in patients with advanced renal cell cancer (RCC):
Southwest Oncology Group study S0312. PJ
Van Veldhuizen, M Hussey, PN Lara, PC Mack,
R Gandour-Edwards, JI Clark, MK Lange, ED
Crawford. American Journal of Clinical
Oncology, 2009 May 29 [Epub ahead of print]
PMID: 19487915
12/1/04
8/15/05
S0317
(2563)
A phase II study of erlotinib (OSI-774) in
patients with locally advanced or metastatic papillary
histology renal cell cancer SWOG S0317. MS Gordon,
M Hussey, R Nagle, PN Lara, Jr, PC Mack, J Dutcher,
W Samlowski, JI Clark, DI Quinn, CX Pan, DE Crawford.
Journal of Clinical Oncology 27(34):5788-5793, 2009.
PMID: 19884559
5/1/03
12/15/05
Multiple
(2686)
Cooperative group trials – Southwest Oncology Group
(SWOG) innovations in advanced prostate cancer. TB Dorff,
CM Tangen, ED Crawford, DP Petrylak, CS Higano,
D Raghavan, DI Quinn, NJ Vogelzang, IM Thompson, MHA
Hussain. Therapeutic Advances in Medical
Oncology, 1(2):69-77, 2009.
n/a
n/a
GU MANUSCRIPTS SUBMITTED/ACCEPTED (2009)
S8710
Do mixed histologic features affect survival benefit from
neoadjuvant platinum-based combination chemotherapy
in patients with locally advanced bladder cancer treated
with radical cystectomy? A secondary analysis of
Southwest Oncology Group-directed intergroup
Study (S8710). E. Scosyrev, B.W. Ely, E.M. Messing,
V.O. Speights, H. B. Grossman, D.P. Wood, R.W.
de Vere White, N.J. Vogelzang, D.L.Trump, R.B. Natale,
.
C. Tangen, E.D. Crawford, I.M.Thompson . Submitted
to Journal of Clinical Oncology, 9/09.
8/1/87
7/1/98
S9109
Long-term follow-up of neoadjuvant therapy prior to
radical prostatectomy for clinical T3/T4 prostate cancer:
a Southwest Oncology Group Study 9109. IM
Thompson, IJ Powell, BA Lowe, G Haas, P Carroll, ED
Canby-Hagino, R deVere White, GP Hemstreet, ED
Crawford. Resubmitted to Journal of Urology, 10/13/09.
12/1/93
10/15/96
S9142
(1697)
Phase II study of continuous infusion gallium
nitrate in platinum-refractory urothelial tract tumors:
a Southwest Oncology Group Study. DP Petrylak,
E Fisher, PA Seligman, HM Gross, D Raghavan,
AJ Bueschen, PF Schellhammer, SS Buys, ED Crawford.
Not accepted by Cancer, 10/31/02; submitted to Urology,
2/10/09; revisions submitted, pending acceptance 12/09
9/15/93
2/1/96
GU ABSTRACTS PUBLISHED/PRESENTED (2009)
S8710
(2601)
Quality of pathologic response and surgery correlate
with survival for completely resected bladder cancer
following neoadjuvant MVAC. G Sonpavde, BH
Goldman, VO Speights, SP Lerner, DP Wood, NJ
Vogelzang, DL Trump, RB Natale, HB Grossman,
ED Crawford. American Society of Clinical Oncology
2009 Genitourinary Cancers Symposium, abst.#249.
8/1/87
7/1/98
*S8794
Lack of low-risk pathologic findings in SWOG 8794.
G Swanson, B Goldman, C Tangen, IM Thompson,
J Chin, E Mesing, E Canby-Higano, JD Forman,
E Crawford. International Journal of Radiation
Oncology, Biology & Physics 75(S):abst. #20,
S10, 2009 (ASTRO,oral presentation).
8/15/88
1/1/97
S9217
Cancer prevention clinical trials: assessing for
disparities in recruitment in Hawaii. E. Bantum, I
Cheng, K Cassel, L Ka’opua, J Berenberg. Poster
Presentation, American Association of Cancer
Research 2009; Proceedings of Frontiers in
Cancer Prevention Research, abst. #B26, p. 116,
2009.
10/13/93
12/6/96
*S9921
(2639)
Southwest Oncology Group S9921: prolonged
event free survival in high risk prostate cancer
(PC) patients receiving adjuvant androgen
deprivation. LM Glode, CM Tangen, MHA Hussain,
DP Wood, GP Swanson, N Dawson, N Balzer-Haas,
DI Quinn, E David Crawford, IM Thompson.
Journal of Clinical Oncology 27:15s, abst. #5009,
2009.
10/15/99
open
S0354
(2632)
SWOG S0354: a phase II trial of CNT0328, a
monoclonal antibody against interleukin-6 (IL-6), in
chemotherapy pre-treated patients (pts) with castration
resistant prostate cancer (CRPC). J Pinski, B Goldman,
T Dorff, P Mack, P Lara, P vanVeldhuizen, D Quinn,
MHA Hussain, IM Thompson. Journal of Clinical
Oncology 27:15s, abst. #5143, 2009.
4/1/07
5/15/08
4B951
(2610)
Variability in surgical quality in a randomized clinical
trial of adjuvant chemotherapy following radical
cystectomy and pelvic lymphadenectomy. SP Lerner,
JP Stein, WM Stadler, S Groshen, E Tuazon, DG
Skinner, D Raghavan, D Esrig, G Steinberg, L
Klotz, C Hall, R Cote. Poster presentation,
American Urological Association Annual Meeting,
2009, abstract #1747.
10/15/01
3/28/06
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GU COMMITTEE
2008
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
GU MANUSCRIPTS PUBLISHED/PRESENTED
8733
(2408)
Treatment options for muscle invasive urothelial cancer
for patients who were not eligible for cystectomy or
neoadjuvant chemotherapy with methotrexate,
vinblastine, adriamycin, and cisplatin: report of
Southwest Oncology Group trial 8733. CS Higano,
CM Tangen, WA Sakr, KJ Russell, J Faulkner,
SE Rivkin, FJ Meyers, M Hussain, LH Baker,
EJ Russell, D Raghavan, ED Crawford. Cancer,
112(10):2181-2187, 2008. PMID 18404692
GU
4/1/88
2/15/97
8794
(2481)
The prognostic impact of seminal vesicle involvement
found at prostatectomy and the effects of adjuvant
radiation in those patients: data from SWOG 8794.
GP Swanson, B Goldman, CM Tangen, JL Chin,
EM Messing, ED Canby-Higino, JD Forman, IM
Thompson, ED Crawford. Accepted by the Journal of
Urology, 180:2453-2457, 2008. PMID: 18930488
GU
8/15/88
1/1/97
8994
(2301)
Health-related quality of life results in pathologic stage C
prostate cancer from a Southwest Oncology Group trial
comparing radical prostatectomy alone with radical
prostatectomy plus radiation therapy. CM Moinpour,
KA Hayden, JM Unger, IM Thompson Jr, MW Redman,
ED Canby-Hagino, BA Higgins, JW Sullivan, D Lemmon,
S Breslin, ED Crawford. Journal of Clinical Oncology
26(1):112-120, 2008. PMID: 18165645
CC
GU
2/15/90
1/1/97
9217
(2471)
Insulin-like growth factor-I, insulin-like growth factor
GU
binding protein-3 and risk of benign prostate hyperplasia.
CC
ML Neuhouser, J Schenk, Y Song, CM Tangen, P Goodman,
M Pollak, DF Penson, IM Thompson, AR Kristal. Prostate
68(13):1477-1486, 2008. PMID: 18618736
10/13/93
9217
(2456)
Finasteride, prostate cancer, and weight gain: evidence
for genetic or environmental factors that affect cancer
outcomes during finasteride treatment. Y Song, C Tangen
P Goodman, HL Parnes, MS Lucia, IM Thompson,
AR Kristal. The Prostate 68:281-286, 2008.
PMID: 18163420
GU
CC
10/13/93
12/6/96
9217
(2467)
The performance of PSA for predicting prostate cancer is
maintained after a prior negative prostate biopsy. IM
Thompson, CM Tangen, DP Ankerst, C Chi, MS Lucia,
P Goodman, HL Parnes, CA Coltman. Journal of Urology
180(2):544-547, 2008. PMID: 18550097
GU
CC
10/13/93
12/6/96
9217
(2457)
Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate
Cancer Prevention Trial. A Hoque, P. Goodman, CB
Ambrosone, WD Figg, DK Price, W Kopp, X Wu,
J Conroy, TA Lehman, RM Santella.
Urology 71(5):967-970, 2008. PMID: 18267333.
GU
CC
10/13/93
12/6/96
12/6/96
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9217
(2396)
Dietary patterns, supplement use and the risk of
symptomatic benign prostatic hyperplasia (BPH):
results from the Prostate Cancer Prevention Trial.
AR Kristal, KB Arnold, JM Schenk, ML Neuhouser,
P Goodman, DF Penson, IM Thompson. American
Journal of Epidemiology 167(8):925-934, 2008.
PMID: 1823602
GU
CC
10/13/93
12/6/96
9217
2473
Integrating the predictiveness of a marker with its
performance as a classifier. MS Pepe, Z Feng,
Y Huang, G Longton, R Prentice, IM Thompson,
Y Zheng. American Journal of Epidemiology,
167(3)362-368, 2008. PMID: 179821157
GU
CC
10/13/93
12/6/96
9217
(2492)
Pathologic characteristics of cancers detected in the
Prostate Cancer Prevention Trial: implications for
prostate cancer detection and chemprevention.
MS Lucia, A Darke, PJ Goodman, FG LaRosa,
HL Parnes, LG Ford, CA Coltman, Jr., IM Thompson.
Cancer Prevention Research 1(3):167-173, 2008.
PMID: 19138952
GU
CC
10/13/93
12/6/96
9217
(2433)
Does the level of prostate cancer risk affect cancer
prevention with finasteride? IM Thompson, CM Tangen,
HL Parnes, SM Lippman, CA Coltman Jr.
Urology 71(5); 854-857, 2008. PMID: 18455628
GU
CC
10/13/93
12/6/96
9217
(2467)
The performance of PSA for predicting prostate cancer is
maintained after a prior negative prostate biopsy. IM
Thompson, CM Tangen, DP Ankerst, C Chen, MS Lucia,
P Goodman, HL Parnes, CA Coltman. Journal of Urology,
180(2):544-547, 2008. PMID: 18550097
GU
CC
10/13/93
12/6/96
9217
(2470)
Serum steroid and sex hormone binding globulin
concentrations and the risk of incident benign prostatic
hyperplasia (BPH): Results from the Prostate Cancer
Prevention Trial. AR Kristal, Y Song , JM Schenk ,
KB Arnold, ML Neuhouser, P Goodman, CM Tangen,
DW Lin, FZ Stanczyk, and IM Thompson. American
Journal of Epidemiology 168(12):1416-1424, 2008.
PMID: 18945688
GU
CC
10/13/93
9217
(2493)
Finasteride does not increase the risk of high-grade prostate
cancer: a bias-adjusted modeling approach. MW Redman,
CM Tangen, PJ Goodman, MS Lucia, CA Coltman, IM
Thompson. Cancer Prevention Research 1(3):174-181,
2008. PMID: 19138953
GU
CC
10/13/93
12/6/96
9217
(2433)
Does the level of prostate cancer risk affect cancer
prevention with finasteride? IM Thompson, CM Tangen,
HL Parnes, SM Lippman, CA Coltman Jr. Urology,
71(5):854-857, 2008. PMID: 18455628
GU
CC
10/13/93
12/6/96
9217
(2480)
Does finasteride affect the severity of prostate cancer? A
causal sensitivity analysis. BE Shepherd, MW Redman,
DP Ankerst. Accepted by Journal of the American
Statistical Association, 103(484):1392-1404, 2008.
(PMID number not available).
GU
CC
10/13/93
12/6/96
12/6/96
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9426
(2336)
Antiandrogen withdrawal in hormone refractory prostate
cancer: a Southwest Oncology Group trial (SWOG 9426).
AO Sartor, CM Tangen, MHA Hussain, MA Eisenberger,
M Parab, JA Fontana, RA Chapman, GM Mills, D Raghavan,
ED Crawford. Cancer 112(11):2392-2400, 2008.
PMID 1838357
GU
3/15/95
06/01/01
9460
(2428)
Phase III prevention trial of fenretinide in patients with
resected non-muscle-invasive bladder cancer.
AL Sabichi, SP Lerner, EN Atkinson, HB Grossman,
NP Caraway, CP Dinney, DF Penson, S Matin, A Kamat,
LL Pisters, DW Lin, RL Katz, DE Brenner, GP Hemstreet III,
M Wargo, A Bleyer, WH Sanders, JL Clifford, HL Parnes,
SM Lippman. Clinical Cancer Research 14(1):224-229,
2008. PMID: 18172274
GU
CC
6/1/96
10/15/99
S9921
(2392)
Randomization reveals unexpected acute leukemias in
SWOG prostate cancer trial. TW Flaig, CM Tangen,
MHA Hussain, WM Stadler, D Raghavan, ED Crawford,
LM Glode. Journal of Clinical Oncology 26(9):1532-1536,
2008. PMID: 18349405
GU
10/15/99
01/12/08
S0306
(2431)
Southwest Oncology Group phase II study of irinotecan
in patients with advanced transitional cell carcinoma of
the urothelium. TM Beer, B Goldman, CR Nichols,
DP Petrylak, M Agarwal, CW Ryan, ED Crawford.
Clinical Genitourinary Cancer 6(1):36-39, 2008.
PMID:18501081
GU
7/15/03
2/1/07
S0418
(2587)
Southwest Oncology Group phase II study of
Ispinesib in androgen-independent prostate cancer
(AIPC) previously treated with taxanes. TM Beer,
B Goldman, TW Synold, CW Ryan, LS Vasist,
PJ Van Veldhuizen, Jr, SP Dakhil, JP Lara,
A Drelichman, MHA Hussain, ED Crawford.
Clinical Genitourinary Cancer 6(2):103-109,
2008. PMID18824433
4/1/05
5/1/06
GU ABSTRACTS PUBLISHED/PRESENTED
*S8794
(2528)
Adjuvant radiotherapy for pT3 for prostate cancer:
results of a randomized, prospective clinical trial,
2008 update. GP Swanson, IM Thompson, C
Tangen, J Paradelo, E Cany-Hagino, ED Crawford,
F Miller, MS Lucia, J Forman, J Chin E Messing.
Presented (“late breaking”) at American Urological
Association Annual Meeting, 2008.
8/15/88
1/1/97
*S8794
(2614)
Updated results of SWOG 8794: adjuvant radiation for
8/15/88
1/1/97
high risk prostate cancer . G Swanson, I Thompson,
C Tangen, J Pardelo, E Canby-Hagino, E Crawford,
G Miller, M Lucia, J Forman, J Chin, E Messing.
ESTRO 27, Goteborg, Sweden, September, 2008;
Radiotherapy and Oncology 88(S2):S148(449), 2008.
http://www.estro27.org/programme/Documents/ESTRO27%20AbstractBook.pdf
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
S8794
(2615)
Prognostic significance of pathologic SV Involvement
8/15/88
1/1/97
and the effect of adjuvant radiation therapy on outcome.
I Thompson, B Goldman, C Tangen, J G Swanson,
Chin, E Messing, E Canby-Hagino, J Forman, E Crawford.
ESTRO 27, Goteborg, Sweden, September, 2008;
Radiotherapy and Oncology 88(S2):S337(1057), 2008.
http://www.estro27.org/programme/Documents/ESTRO27%20AbstractBook.pdf
*S8794
(2616)
Update of SWOG 8794: Adjuvant radiotherapy for pT3
Prostate cancer improves metastasis free survival.
G Swanson, IM Thompson, C Tangen, J Paradelo,
E Canby-Hagino, E Crawford, G Miller, MS Lucia,
J Forman, J Chin. ASTRO, Boston, MA, September,
2008; International Journal of Radiation Oncology
Biology Physics, 72(1) suppl. 1:S31, 2008
8/15/88
1/1/97
http://www.sciencedirect.com.libproxy.uthscsa.edu/science?_ob=ArticleUR
L&_udi=B6T7X-4T85W5M-2R&_user=108488&_coverDate=09%2F01%2F2008&_alid=785
532217&_rdoc=1&_fmt=high&_orig=search&_cdi=5070&_sort=d&_docanchor=&view
=c&_ct=29&_acct=C000059724&_version=1&_urlVersion=0&_userid=108488&md5=5
cae9b1302e5a1e06e12146c78d74ea0
**S8949
(2509)
Predictors of survival in advanced renal cell carcinoma
3/1/94
8/1/00
(RCC): long-term results from Southwest Oncology
Group trial S8949. S Conlon, CM Tangen, RC Flanigan,
ED Crawford, PN Lara. Journal of Clinical Oncology
26(15S):260s, #5042, 2008.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&c
onfID=55&abstractID=32157
*S8949
(2661)
Predictors of survival in advanced renal cell carcinoma
3/1/91
10/1/98
(RCC): long-term results froom Southwest Oncology
Group trial S8949. S Conlon, CM Tangen, RC Flanigan,
ED Crawford, PN Lara. American Society of Clinical
Oncology 2008 Genitourinary Cancers Symposium,
abstract #347.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&co
nfID=54&abstractID=20243
*S9346/S9916
(2511)
Use of prostate-specific antigen progression (PSA-P)
n/a
n/a
to predict overall survival (OS) in patients (pts) with
metastatic prostate cancer (PC): data from S9346
and S9916. M Hussain, B Goldman, C Tangen, C
Higano, DP Petrylak, ED Crawford. Journal of Clinical
Oncology 26(15S):253s, #5015, 2008.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view
&confID=55&abstractID=32059
***9346/S9916
(2524)
Prostate-specific antigen progression (PSA-P) as a
n/a
n/a
predictor of overall survival (OS) in patients (pts) with
metastatic prostate cancer (PC): data from S9346 and
S9916. B Goldman, M Hussain, C Tangen, C Higano,
DP Petrylak, NJ Vogelzang, ED Crawford. American
Society of Clinical Oncology 2008 Genitourinary Cancers
Symposium, abstract #165.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&conf
ID=54&abstractID=20310
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
*S0219
(2514)
A sequential treatment approach to muscle-invasive
1/1/03
12/15/06
urothelial cancer – a phase II Southwest Oncology Group
trial (S0219) of neoadjuvant paclitaxel, carboplatin, and
gemcitabine (PCG). PN Lara Jr, B Goldman, R deVere
White, C Tangen, DC Smith, D Wood, M Hussain, ED
Crawford. Journal of Clinical Oncology, 26(15S):255s,
#5022, 2008.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&conf
ID=55&abstractID=32346
**S0317
(2440)
Encouraging survival with erlotinib in advanced papillary
5/1/03
12/15/05
renal cell carcinoma (pRCC): final results from Southwest
Oncology Group study 0317. C Pan, M Hussey, P Lara,
P Mack, R Nagle, J Dutcher, W Samlowski, J Clark,
M Gordon, E Crawford. Journal of Clinical Oncology,
26(15S):262s, #5051, 2008.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&conf
ID=55&abstractID=31466
*4B951
(2609)
*Presented
Results of the p53 targeted therapy trial for patients
with organ confined node negative bladder cancer
treated with radical cystectomy. SP Lerner, JP Stein,
WM Stadler, S Groshen, E Tuazon, DG Skinner, D
Raghavan, D Esrig, G Steinberg, C Hall, R Cote.
Oral presentation at 2008 Annual Meeting
of the Society of Urological Oncology (December).
10/15/01
3/28/06
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8507
(2370)
Patterns of recurrence and outcomes following induction
bacillus calmette-guerin for high risk Ta, T1 bladder
cancer. SP Lerner, CM Tangen, H Sucharew, D Wood,
ED Crawford. Journal of Urology 177:1727-1731, 2007.
GU
12/20/85
12/15/88
8794
(2364)
Predominant treatment failure in postprostatectomy
patients is local: analysis of patterns of treatment failure
in SWOG 8794. GP Swanson, MA Hussey, CM Tangen,
J Chin, E Messing, E Canby-Hagino, JD Foreman,
IM Thompson, ED Crawford. Journal of Clinical Oncology
25(16):2225-2229, 2007.
GU
8/15/88
1/1/97
8894/9916
(2366)
Association of body mass index with response and survival
GU
in men with metastatic prostate cancer: Southwest Oncology
Group trials 8894 and 9916. RB Montgomery, B Goldman,
CM Tangen, M Hussain, DP Petrylak, S Page, EA Klein, ED
Crawford. Journal of Clinical Oncology, 178(5):1946-1951,
2007. PMID: 17868721
9217
(2371)
Finasteride improves the sensitivity of digital rectal
examination for prostate cancer detection. IM Thompson,
CM Tangen, PJ Goodman, MS Lucia, HL Parnes,
SM Lippman, CA Coltman, Jr. Journal of Urology
177:1749-1752, 2007.
GU
CC
10/13/93
12/6/96
9217
(2302)
Longitudinal analysis of sexual function reported by men
GU
in the prostate cancer prevention trial. CM Moinpour,
CC
AK Darke, GW Donaldson, IM Thompson, Jr, C Langley,
DP Ankerst, DL Patrick, JE Ware, Jr, PA Ganz, SA Shumaker,
SM Lippman, CA Coltman, Jr. Journal of the National
Cancer Institute 99:1025-1035, 2007.
10/13/93
12/6/96
9217
(2393)
Race/ethnicity, obesity, health related behaviors and the
risk of symptomatic benign prostatic hyperplasia: results
from the Prostate Cancer Prevention Trial. AR Kristal,
KB Arnold, JM Schenk, ML Neuhouser, N Weiss,
P Goodman, CM Antvelink, DF Penson, IM Thompson.
Journal of Urology 177:1395-1400, 2007.
GU
CC
10/13/93
12/6/96
9217
(2376)
Finasteride decreases the risk of prostatic intraepithelial
neoplasia. IM Thompson, SM Lucia, MW Redman,
A Darke, FG La Rosa, HL Parnes, SM Lippman,
CA Coltman. Journal of Urology 178:107-110, 2007.
GU
CC
10/13/93
12/6/96
9217
(2395)
Prediction of prostate cancer for patients receiving
finasteride: results from the Prostate Cancer Prevention
Trial. IM Thompson, DP Ankerst, C Chi, PJ Goodman,
CM Tangen, SM Lippman, MS Lucia, HL Parnes,
CA Coltman, Jr. Journal of Clinical Oncology 25(21):
3076-3081, 2007.
GU
CC
10/13/93
12/6/96
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9217
(2369)
Finasteride and high-grade prostate cancer in the
GU
Prostate Cancer Prevention Trial. MS Lucia, JI Epstein,
CC
PJ Goodman, AK Darke, VE Reuter, F Civantos, CM Tangen,
HL Parnes, SM Lippman, F La Rosa, MW Kattan, ED Crawford,
LG Ford, CA Coltman Jr, IM Thompson. Journal of the National
Cancer Institute 99(18):1375-1383, 2007. PMID: 17848673
10/13/93
9217
(2472)
Is prostate-specific antigen velocity useful in early detection
of prostate cancer? A critical appraisal of the evidence.
Etzioni RD. Ankerst DP. Weiss NS. Inoue LY. Thompson IM.
Journal of the National Cancer Institute 99(20):1510-5, 2007.
PMID: 17925534
GU
CC
10/13/93
S9809
(2340)
Aneusomy for detection of bladder cancer recurrence: a
Southwest Oncology Group study. SR Wolman, B Goldman,
ML Slovak, C Tangen, DL Persons, D Wood. Cancer
Genetics and Cytogenetics 176:22-27, 2007.
GU
4/15/99
7/1/01
S9916
2389
Do general dimensions of quality of life add clinical value to
GU
symptom data? CM Moinpour, GW Donaldson, Redman MW.
Journal of the National Cancer Institute 37:31-38, 2007.
PMID: 17951229
10/15/99
1/15/03
S0412
(2373)
Sorafenib with interferon alpha-2b as first-line treatment
of advanced renal carcinoma: a phase II study of the
Southwest Oncology Group. CW Ryan, BH Goldman,
PN Lara Jr, PC Mack, TM Beer, CM Tangen, D Lemmon,
CX Pan, HA Drabkin, ED Crawford. Journal of Clinical
Oncology 25(22):3296-3301, 2007.
9/1/04
5/15/05
GU
12/6/96
12/6/96
ABSTRACTS PUBLISHED/PRESENTED
S0312
(2347)
A phase II study of IV gemcitabine (G) and oral capecitabine
(C) in patients (pts) with advanced renal cell cancer (RCC):
results of Southwest Oncology Group study 0312. PJ Van
Veldhuizen Jr, M Hussey, PN Lara, PH Gumerlock, J Clark,
MK Lange, ED Crawford. Proc of the American Society of
Clinical Oncology, Journal of Clinical Oncology 25(18S):
#15562, 2007.
GU
12/1/04
8/15/05
S0317
(2348)
Phase II trial of the epidermal growth factor receptor (EGFR)
inhibitor erlotinib (E) in patients (pts) with advanced papillary
renal cell carcinoma (pRCC)--SWOG S0317. C Pan, M
Hussey, P Lara, PC Mack, RB Nagle, J Dutcher, W
Samlowski, J Clark, ED Crawford, MS Gordon. Proc of the
American Society of Clinical Oncology, Journal of Clinical
Oncology 25(18S):#15516, 2007.
GU
5/01/03
12/15/05
S0412
(2351)
Clinical and molecular factors predictive of outcome with
first-line sorafenib-based therapy in advanced renal
carcinoma (RCC): an analysis of SWOG 0412. BH
Goldman, PN Lara, Jr, TM Beer, PC Mack, HA Drabkin,
WS Holland,ED Crawford, CW Ryan. Proc of the American
Society of Clinical Oncology, Journal of Clinical Oncology
25(18S):#5108, 2007.
GU
9/01/04
5/15/05
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8794
(2268)
Adjuvant radiotherapy for pathologically advanced prostate
GU
cancer: a randomized clinical trial. IM Thompson Jr., CM
Tangen, J Paradelo, MS Lucia, G Miller, D Troyer, E Messing,
J Forman, J Chin, G Swanson, E Canby-Hagino, ED Crawford.
Journal of the American Medical Association 296(19):23292335, 2006.
8/15/88
1/1/97
8894
(2262)
The prognostic value of hemoglobin change after initiating
GU
androgen-deprivation therapy for newly diagnosed
metastatic prostate cancer: a multivariate analysis of
Southwest Oncology Group study 8894. TM Beer, CM Tangen,
LB Bland, M Hussain, BH Goldman, TG DeLoughery, ED
Crawford. Cancer 107(3):489-496, 2006.
12/15/89
9/15/94
9024
(2218)
Locally advanced prostate cancer treated with concomitant
radiation and 5-fluorouracil: Southwest Oncology Group
study 9024. GP Swanson, J Faulkner, SR Smalley, MJ
Noble, RL Stephens, TJ O’Rourke, GR Weiss, DP Quick,
IM Thompson Jr, ED Crawford. Journal of Urology 176:548553, 2006.
GU
8/1/91
3/15/95
9217
(2258)
Assessing prostate cancer risk: results from the
prostate cancer prevention trial. IM Thompson,
DP Ankerst, C Chi, PJ Goodman, CM Tangen,
MS Lucia, Z Feng, HL Parnes, CA Coltman Jr.
Journal of the National Cancer Institute 98(8):529-534,
2006
GU
10/13/93
12/6/96
9217
(2272)
Associations of demographic and lifestyle characteristics
with prostate-specific antigen (PSA) concentration and
rate of PSA increase. AR Kristal, C Chi, CM Tangen,
PJ Goodman, R Etzioni, IM Thompson. Cancer 106(2):
320-328, 2006.
GU
CC
10/13/93
12/6/96
9217
(2297)
Comparison of the operating characteristics of PSA for
prostate cancer detection for finasteride and placebo in
the Prostate Cancer Prevention Trial. IM Thompson,
C Chi, P Goodman, C Tangen, D Pauler Ankerst, MS Lucia,
CA Coltman, Jr. Proc of the AUA, Journal of Urology 175(4)
Suppl:152, (#470), 2006.
GU
10/13/93
12/6/96
9217
(2367)
Effect of finasteride on the sensitivity of PSA for detecting
prostate cancer. IM Thompson, C Chi, DP Ankerst, PJ
Goodman, CM Tangen, SM Lippman, MS Lucia, HL
Parnes, CA Coltman, Jr. Journal of the National Cancer
Institute 98(16):1128-1133, 2006.
GU
CC
10/13/93
12/6/96
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9217
(2374)
Modeling the effect of a preventive intervention on the
natural history of cancer: application to the prostate
cancer prevention trial. P Pinsky, R Etzioni, N Howlader,
P Goodman, IM Thompson. International Journal of
Biostatistics 2(1): article 12, 2006. Available at:
http://www.bepress.com/ijb/vol2/iss1/12.
GU
CC
10/13/93
12/6/96
9217
(2337)
Obesity, diabetes, and risk of prostate cancer: results
from the prostate cancer prevention trial. Z Gong, ML
Neuhouser, PJ Goodman, D Albanes, C Chi, AW Hsing,
SM Lippman, EA Platz, MN Pollak, IM Thompson, AR
Kristal. Cancer Epidemiol Biomarkers Prev 15(10):
1977-1983.
GU
CC
10/13/93
12/6/96
9217
(2193)
The prostate cancer prevention trial: design, biases, and
GU
interpretation of study results. PJ Goodman, IM Thompson Jr, CC
CM Tangen, JJ Crowley, LG Ford, CA Coltman Jr.
Journal of Urology 175:2234-2242, 2006.
10/13/93
12/6/96
9346
(2275)
Absolute prostate specific antigen value after androgen
deprivation is a strong independent predictor of
survival in new metastatic prostate cancer: data from
Southwest Oncology Group trial 9346 (INT-0162).
M Hussain, CM Tangen, C Higano, PF Schellhammer,
J Faulkner, ED Crawford, G Wilding, A Akdas, EJ Small,
B Donnelly, G MacVicar, D Raghavan.
Journal of Clinical Oncology 24(24):3984-3990, 2006.
GU
5/15/95
Open
9458
(2265)
Evaluation of Ki67, p53 and angiogenesis in patients enrolled
in a randomized study of neoadjuvant chemotherapy with or
without cystectomy: a Southwest Oncology Group study.
HB Grossman, CM Tangen, C Cordon-Cardo, R Cote, FM
Waldman, RW De Vere White, AB Karnad, M Glode, ED
Crawford. Oncology Reports 16:807-810, 2006.
GU
11/15/95
11/1/98
S9812
(2162)
Selenium accumulation in prostate tissue during a
GU
randomized controlled short-term trial of I-selenomethionine.
A Southwest Oncology Group study. AL Sabichi, JJ Lee,
RJ Taylor, IM Thompson, BJ Miles, CM Tangen, LM Minasian,
LL Pisters, JR Caton, JW Basler, SP Lerner, DG Menter, JR
Marshall, ED Crawford, SM Lippman. Clinical Cancer Research
12(7):2178-2184, 2006.
6/15/99
6/1/01
S9916
(2189)
Evaluation of prostate-specific antigen declines for
surrogacy in patients treated on SWOG 99-16.
D Petrylak, D Pauler Ankerst, CS Jiang, CM Tangen,
MHA Hussain, PN Lara Jr, JA Jones, ME Taplin, PA
Burch, M Kohli, MC Benson, EJ Small, D Raghavan,
ED Crawford. Journal of the National Cancer Institute
98(8):516-521, 2006.
GU
10/15/99
1/15/03
S9916
(2260)
Quality of life and pain in advanced stage prostate cancer:
GU
results of a Southwest Oncology Group randomized trial
comparing docetaxel and estramustine to mitoxantrone and
prednisone. DL Berry, CM Moinpour, CS Jiang, DP Ankerst,
DP Petrylak, LV Vinson, PN Lara, S Jones, ME Taplin, PA Burch,
MHA Hussain, ED Crawford. Journal of Clinical Oncology
24(18):2828-2835, 2006.
10/15/99
1/15/03
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
S9917
(2310)
Design and progress of a trial of selenium to prevent
CCRC
prostate cancer among men with high-grade prostatic
GU
intraepithelial neoplasia. JR Marshall, W Sakr, D Wood,
D Berry, C Tangen, F Parker, I Thompson, SM Lippman,
R Lieberman, D Alberts, D Jarrard, C Coltman, P Greenwald,
L Minasian, ED Crawford. Cancer Epidemiol Biomarkers Prev
15(8):1479-1484, 2006.
2/1/00
OPEN
S0000A
(2378)
Studying the effects of vitamin E and selenium for
alzheimer’s disease prevention: the PREADVISE model.
AM Caban-Holt, FA Schmitt, CR Runyons, RJ Kryscio,
MS Mendiondo, MS Healey, WR Markesbery, CA Coltman,
JJ Crowley, PJ Goodman, JL Hartline. In: Research and
Practice In Alzheimer’s Disease Volume 11, 2006, B Vellas,
LJ Fitten, B Winblad, H Feldman, M Grundman, E Giacobini
eds, Serdi Publishers 124-130, 2006.
CC
GU
7/25/01
6/24/04
S0207
(2261)
Southwest Oncology Group phase II study of arsenic
trioxide in patients with refractory germ cell malignancies.
TM Beer, CM Tangen, CR Nichols, KA Margolin, R Dreicer,
WT Stephenson, DI Quinn, D Raghavan, ED Crawford.
Cancer 106(12):2624-2629, 2006.
GU
4/1/02
3/1/05
ABSTRACTS PUBLISHED/PRESENTED
8794
(296)
Pre radiation PSA predicts for outcome of adjuvant radiation
in SWOG 8794. GP Swanson, MA Hussey, IM Thompson,
ED Crawford. Proc of the AUA, Journal of Urology 175(4)
Suppl:216, (#668), 2006.
GU
8/15/88
1/1/97
8894
(2250)
Prognostic value of hemoglobin change after initiation of
androgen deprivations therapy for newly diagnosed
metastatic prostate cancer: a multivariate analysis of
SWOG 8894. TM Beer, BH Goldman, CM Tangen,
LB Bland, M Hussain, TG DeLoughery, ED Crawford.
Proc of the AUA, Journal of Urology 175(4) Suppl:385-386,
(#1197), 2006.
GU
12/15/89
9/15/94
9217
(2249)
Association of erectile dysfunction and subsequent
cardiovascular disease. IM Thompson Jr, J Probstfield,
C Tangen, P Goodman, C Moinpour, CA Coltman Jr.
Proc of the AUA, Journal of Urology 175(4) Suppl:429
(#1333), 2006.
GU
10/13/93
12/6/96
9346
(2248)
Absolute PSA value after androgen deprivation (AD) is a
strong independent predictor of survival in new metastatic
(D2) prostate cancer (PCa): data from Southwest Oncology
Group trial 9346 (INT-0162). M Hussain, C Tangen, P
Schellhammer, ED Crawford, C Higano, G Wilding, A Akdas,
EJ Small, B Donnelly, D Raghavan. Proc of the American
Society of Clinical Oncology, Journal of Clinical Oncology
24(18S):#4517, 2006.
GU
5/15/95
Open
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
S0412
(2235)
*Presented
Sorafenib plus interferon-a2b (IFN) as first line therapy for
advanced renal cell carcinoma (RCC): SWOG 0412. CW
Ryan, BH Goldman, PN Lara Jr, TM Beer, HA Drabkin,
ED Crawford. Proc of the American Society of Clinical
Oncology, Journal of Clinical Oncology 24(18S):#4525,
2006.
GU
9/1/04
5/15/05
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
9140
(1831)
A phase II clinical trial of oral bropirimine in combination
GU
with intravesical bacillus calmette-guerin for carcinoma
in situ of the bladder; a Southwest Oncology Group
study. MF Sarosdy, CM Tangen, GR Weiss, BR Nestok,
MC Benson, PF Schellhammer, AI Sagalowsky, DP
Wood Jr, ED Crawford. Urologic Oncology 23:386-389, 2005.
12/1/92
12/1/97
9217
(2255)
Assessing benefit and risk in the prevention of prostate
cancer: the prostate cancer prevention trial revisited.
EA Klein, CM Tangen, PJ Goodman, SM Lippman,
IM Thompson. Journal of Clinical Oncology 23(30):
7460-7466, 2005.
GU
10/13/93
12/6/96
9217
(2264)
Erectile dysfunction and subsequent cardiovascular disease. GU
IM Thompson, CM Tangen, PJ Goodman, JL Probstfield,
CM Moinpour, CA Coltman. JAMA 294(23):2996-3002, 2005.
10/13/93
12/6/96
9217
(2069)
Estimated impact of the prostate cancer prevention trial
on population mortality. JM Unger, IM Thompson Jr, M
LeBlanc, JJ Crowley, PJ Goodman, LG Ford, CA Coltman Jr.
Cancer 103(7):1375-1380, 2005.
GU
10/13/93
12/6/96
9217
(2298)
Long-term effects of finasteride on prostate specific antigen
GU
levels: results from the prostate cancer prevention trial.
RD Etzioni, N Howlader, PA Shaw, DP Ankerst, DF Penson,
PJ Goodman, IM Thompson. Journal of Urology 174:877-881,
2005.
10/13/93
12/6/96
9217
(2211)
Operating characteristics of prostate-specific antigen in
men with an initial PSA level of 3.0 ng/mL or lower. IM
Thompson, DP Ankerst, C Chi, MS Lucia, PJ Goodman,
JJ Crowley, HL Parnes, CA Coltman. The Journal of the
American Medical Association 294(1):66-70, 2005.
GU
10/13/93
12/6/96
9217
(2365)
Phase III prostate cancer prevention trials: are the costs
CC
justified? IM Thompson, CM Tangen, EA Klein, SM Lippman. GU
Journal of Clinical Oncology 23(32):8161-8164, 2005.
10/13/93
12/6/96
9457
(2166)
Phase II trial of carboplatin and paclitaxel in cisplatinpretreated advanced transitional cell carcinoma: a
Southwest Oncology Group study. UN Vaishampayan,
JR Faulkner, EJ Small, BG Redman, WL Keiser, DP
Petrylak, ED Crawford. Cancer 104(8):1627-1632, 2005.
7/15/96
4/15/00
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
S0000
(2093)
Centralized blood processing for the selenium and
vitamin E Cancer prevention trial: effects of delayed
processing on carotenoids, tocopherols, insulin-like
growth factor-I, insulin-like growth factor binding protein 3,
steroid hormones and lymphocyte viability. AR Kristal,
IB King, D Albanes, MN Pollak, FZ Stanzyk, RM Santella,
A Hoque. Cancer Epidemiology, Biomarkers & Prevention
14(3):727-730, 2005.
GU
7/25/01
6/24/04
S0000
(2088)
Designing the selenium and vitamin E cancer prevention
trial (SELECT). SM Lippman, PJ Goodman, EA Klein,
HL Parnes, IM Thompson Jr, AR Kristal, RM Santella,
JL Probstfield, CM Moinpour, D Albanes, PR Taylor,
LM Minasian, A Hoque, SM Thomas, JJ Crowley,
JM Gaziano, JL Stanford, ED Cook, NE Fleshner, MM
Lieber, PJ Walther, FR Khuri, DD Karp, GG Schwartz,
LG Ford, CA Coltman Jr. Journal of the National Cancer
Institute 97(2):94-102, 2005.
GU
7/25/01
6/24/04
S0000
(2173)
Minority recruitment to the selenium and vitamin E cancer
prevention trial (SELECT). ED Cook, SM Thomas, KB
Anderson, R Campbell, SJ Hamilton, JM Harrington,
SM Lippman, LM Minasian, ED Paskett, S Craine,
KB Arnold, JL Probstfield. Clinical Trials 2:436-442,
2005.
GU
7/25/01
6/24/04
S0109
(2075)
A phase II study of flavopiridol in patients with advanced
renal cell carcinoma: results of Southwest Oncology Group
trial 0109. PJ Van Veldhuizen, JR Faulkner, PN Lara Jr,
PH Gumerlock, JW Goodwin, SR Dakhil, HM Gross,
RC Flanigan, ED Crawford. Cancer Chemotherapy and
Pharmacology 56:39-45, 2005.
GU
5/1/01
2/1/02
S0111
(2252)
Ixabepilone (epothilone B analogue BMS-247550) is active
in chemotherapy-naïve patients with hormone-refractory
prostate cancer: a Southwest Oncology Group trial S0111.
M Hussain, CM Tangen, PN Lara Jr, UN Vaishampayan,
DP Petrylak, AD Colevas, WA Sakr, ED Crawford.
Journal of Clinical Oncology 23(34):8724-8729, 2005.
GU
6/15/01
11/15/03
8/1/87
7/1/98
8/15/88
1/1/97
ABSTRACTS PUBLISHED/PRESENTED
*8710
(2206)
Optimal combined modality treatment improves outcome of
locally advanced bladder cancer: analysis of SWOG 8710.
ZA Dotan, DF Bajorin, BH Grossman, HW Herr. Proc of
the American Society of Clinical Oncology, Journal of
Clinical Oncology 23(16s):385s (#4531), 2005.
GU
*8794
(2145)
Adjuvant radiotherapy for pathologic T3 prostate cancer:
GU
results of a randomzied, prospective clinical trial with
metastasis-free survival endpoint. IM Thompson, C Tangen,
G Miller, MS Lucia, D Troyer, J Paradelo, J Chin, E Messing,
E Canby-Hagino, J Forman, ED Crawford. Journal of Urology
173(4):451 (#1665), 2005.
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
*8794
(2267)
Phase III randomized study of adjuvant radiation therapy
versus observation in patients with pathologic T3 prostate
Cancer (SOWG 8794). G Swanson, I Thompson, C Tangen,
G Miller, MS Lucia, D Troyer, J Paradelo, J Chin, E Messing,
E Canby-Hagino, J Forman, Ed Crawford. Proc ASTRO,
Int J Radiat Oncol Biol Phy 63(Suppl1):S1 (#1), 2005.
GU
8/15/88
1/1/97
*8994
(2151)
Short-and long-term genitourinary symptom status
GU
and global quality of life (QOL) from a Southwest
Oncology Group (SWOG) trial. KA Hayden, CM Moinpour,
J Faulkner, CM Tangen, ED Canby-Hagino, D Lemmon,
S Breslin, IM Thompson, ED Crawford. Proc of the American
Society of Clinical Oncology, Journal of Clinical Oncology
23(16S):391s (#4556), 2005.
2/15/90
1/1/97
S9129
(2321)
Phase III trial of all-trans retinoic acid (ATRA) vs daunorubicin Leuk
(D) and cytosine arabinoside (A) as induction therapy and
ATRA vs observation as maintenance therapy for children
with newly diagnosed acute promyelocytic leukemia (APL).
J Gregory, H Kim, T Alonzo, R Gerbing, A Ogden, W Woods,
H Weinstein, L Shepherd, C Schiffer, F Appelbaum, C Willman,
P Wiernik, J Rowe, M Tallman, J Feusner. Blood (ASH Annual
Meeting Abstracts) 106(11): #894, 2005.
6/15/92
2/1/95
9217
(2291)
Individual prediction of prostate cancer based on prostate
specific antigen. C Chi, D Pauler Ankerst, P Goodman.
Clinical Trials 2 (Suppl 1):P40, 2005.
GU
10/13/93
12/6/96
*9217
(2146)
Pathological assessment of high grade tumors in the Prostate GU
Cancer Prevention Trial (PCPT). MS Lucia, A Darke, P Goodman,
C Tangen, CA Coltman, IM Thompson. Journal of Urology
173(4):451 (#1664), 2005.
10/13/93
12/6/96
*9217
(2147)
Prostate specific antigen (PSA) as a predictor of adverse
pathological features at prostatectomy in the Prostate
Cancer Prevention Trial (PCPT). MS Lucia, P Goodman,
C Tangen, CA Coltman, IM Thompson. Journal of Urology
173(4):143 (#525), 2005.
GU
10/13/93
12/6/96
*9217
(2180)
The performance characteristics of prostate-specific antigen
GU
IM Thompson Jr, DP Ankerst, C Chi, P Goodman, C Tangen,
CA Coltman Jr. Journal of Urology 173(4):143 (#526), 2005.
10/13/93
12/6/96
S0000
(2196)
Minority participant accrual workshops-innovative strategy
to increase African American accrual. RD Campbell.
Clinical Trials 2(Suppl 1):S81 (#P80), 2005.
GU
7/25/01
6/24/04
S0000
(2197)
Minority recruitment to the selenium and vitamin e cancer
prevention trial (SELECT). ED Cook, SM Thomas, KB
Anderson, R Campbell, SJ Hamilton, JM Harrington,
SM Lippman, LM Minasian, ED Paskett, S Craine, J
Probstfield. Clinical Trials 2(Suppl 1):S82 (#P81), 2005.
GU
7/25/01
6/24/04
S0000
(2195)
Study-provided resources for quality pill counts. KB Gower.
Clinical Trials 2(Suppl 1):S58 (#P29), 2005.
GU
7/25/01
6/24/04
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
S0000
(2194)
Supplemental financial support for minority recruitment:
GU
SELECT-selenium and vitamin E cancer prevention trial.
KB Anderson, R Campbell, GB Gower, S Hamilton,
W McCaskill-Stevens, L Minasian, SM Thomas, S Moon,
F Stallings, J Probstfield. Clinical Trials 2(Suppl 1):S57 (#P25),
2005.
7/25/01
6/24/04
S0000
(2198)
The black church: an invaluable ally for enhancing minority
recruitment. JM Harrington, S Hamilton, R Campbell,
S Moon, E Cook. Clinical Trials 2(Suppl 1):S24 (#05),
2005.
7/25/01
6/24/04
*Presented
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8710
(2081)
Pathologic evaluation of radical cystectomy specimens.
A Cooperative Group report. HW Herr, JR Faulkner,
HB Grossman, ED Crawford. Cancer 100(11):24702475, 2004.
GU
8/1/87
7/1/98
8710
(2080)
Surgical factors influence bladder cancer outcomes: a
Cooperative Group report. HW Herr, JR Faulkner,
HB Grossman, RB Natale, R de Vere White, MF
Sarosdy, ED Crawford. Journal Of Clinical Oncology
22(14):2781-2789, 2004.
GU
8/1/87
7/1/98
8894
(2175)
Prognostic value of anemia in newly diagnosed metastatic
prostate cancer: a multivariate analysis of Southwest
Oncology Group study 8894. TM Beer, CM Tangen,
LB Bland, IM Thompson, ED Crawford. Journal of
Urology 172(6, part 1 of 2):2213-2217, 2004.
GU
12/15/89
9/15/94
8949
(2112)
Cytoreductive nephrectomy in patients with metastatic
renal cancer: a combined analysis. RC Flanigan,
G Mickisch, R Sylvester, C Tangen, H Van Poppel,
ED Crawford. Journal of Urology 171:1071-1076, 2004.
GU
3/1/91
10/1/98
9217
(1494)
Implementation of the prostate cancer prevention trial (PCPT). GU
PJ Goodman, CM Tangen, JJ Crowley, SM Carlin, A Ryan,
CA Coltman Jr, LG Ford, IM Thompson. Controlled Clinical
Trials 25:203-222, 2004.
10/13/93
12/6/96
9217
(2074)
Prevalence of prostate cancer among men with a
prostate-specific antigen level of <4.0 ng per milliliter.
IM Thompson, DK Pauler, PJ Goodman, CM Tangen,
MS Lucia, HL Parnes, LM Minasian, LG Ford, SM
Lippman, ED Crawford, JJ Crowley, CA Coltman Jr.
New England Journal of Medicine 350(22):2239-2246,
2004.
GU
10/13/93
12/6/96
9217
(2111)
The person-years saved model and other methodologies
for assessing the population impact of cancer-prevention
strategies. JM Unger, M LeBlanc, IM Thompson, CA
Coltman, Jr. Urologic Oncology: Seminars and Original
Investigations 22:362-368, 2004.
GU
10/13/93
12/6/96
9217/S0000
(2174)
Prostate cancer chemoprevention: an overview of United
States trials. A Barqawi, IM Thompson, ED Crawford.
Journal of Urology 171:S5-S9, 2004.
GU
S9916
(2068)
Docetaxel and estramustine compared with mitoxantrone
and prednisone for advanced refractory prostate cancer.
DP Petrylak, CM Tangen, MHA Hussain, PN Lara Jr,
JA Jones, ME Taplin, PA Burch, D Berry, C Moinpour,
M Kohli, MC Benson, EJ Small, D Raghavan, ED Crawford.
New England Journal of Medicine 351(15):1513-1520, 2004.
GU
10/15/99
1/15/03
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
S9917
(2121)
Low rate of confirming prostate cancer on repeat biopsies
GU
following diagnosis of high grade prostatic intraepithelial
neoplasia. Preliminary analysis of Southwest Oncology
Group study S9917. WA Sakr, JR Faulkner, D Wood,
I Thompson, D Crawford, S Lippman, C Coltman, J Marshall.
Proc of the American Association for Cancer Research 45:305
(#1333), 2004.
None
(2177)
First international conference on chemoprevention of
prostate cancer. IM Thompson, D Albanes, JW Basler,
ED Crawford, LJ Denis, B Djavan N Fleshner, TL JohnsonPais, EA Klein, AR Kristal, MS Lucia, HL Parnes, GA Piazza,
EA Platz, BH Pollock, DK Price, JK Reichardt, CM Tangen,
AW Tolcher, MC McMann. Journal of Urology 171:S3-S4,
2004.
GU
Statistical
Paper
(2082)
Statistical design issues and other practical considerations
for conducting phase III prostate cancer prevention trials.
CM Tangen, PJ Goodman, JJ Crowley, IM Thompson.
Journal of Urology 171:S64-S67, 2004.
CC
GU
2/1/00
OPEN
ABSTRACTS PUBLISHED/PRESENTED
8507
(2064)
Timing of recurrence and outcomes following induction BCG
for high risk Ta, T1 Bladder Cancer. a Southwest Oncology
Group trial. SP Lerner, C Tangen, H Sucharew, DP Wood,
ED Crawford. Journal of Urology 171(Suppl 4):72(#273),
2004.
GU
12/20/85
12/15/88
8894
(2179)
Prognostic value of anemia in untreated metastatic prostate
cancer: a multivariate analysis of SWOG 8894. LB
Bland, CM Tangen, IM Thompson, ED Crawford,
TM Beer. Proc of the American Society of Clinical
Oncology 23:399 (#4574), 2004.
GU
12/15/89
9/15/94
9217
(2290)
The prostate cancer prevention trial: the association of study GU
site and participant adherence interventions to the study site
end-of-study biopsy rates. S Carlin, P Goodman, C Moinpour,
C Tangen. Clinical Trials 1 (Suppl 1):P45, 2004.
10/13/93
12/6/96
*S9916
(2050)
SWOG 99-16: randomized phase III trial of docetaxel (D)/
estramustine (E) versus mitoxantrone (M)/prednisone (P) in
men with androgen-independent prostate cancer (AIPCA).
DP Petrylak, C Tangen, M Hussain, PN Lara, J Jones, ME
Talpin, P Burch, G Greene, E Small, ED Crawford.
Proc of the American Society of Clinical Oncology 23:2 (#3),
2004.
GU
10/15/99
1/15/03
*S9916
(2048)
Quality of life (QOL) and pain in advanced stage prostate
cancer: Impact of missing data on evaluating palliation in
SWOG 9916. DL Berry, CM Moinpour, C Jiang, LV Vinson,
PN Lara, S Lanier, ME Taplin, PA Burch, DP Petrylak, ED
Crawford. Proc of the American Society of Clinical
Oncology 23:400 (#4579), 2004.
GU
10/15/99
1/15/03
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
*S9916
(2049)
Three-month change in PSA as a surrogate endpoint for
GU
mortality in advanced hormone-refractory prostate cancer
(HRPC): data from Southwest Oncology Group study S9916.
ED Crawford, DK Pauler, CM Tangen, MHA Hussain, EJ Small,
ME Taplin, PA Burch, GF Greene, P Lara Jr, DP Petrylak.
Proc of the American Society of Clinical Oncology 23:382
(#4505), 2004.
10/15/99
1/15/03
*S0000
(2134)
Introducing HIPAA: triple the cost and triple the time for
GU
patient recruitment to the SELECT study. NS Gorby,
MS Wolf, CL Bennett. Proc of the American Society of Clinical
Oncology 23:519 (#6009), 2004.
7/25/01
OPEN
S0000
(2094)
Participant’s perception of recruitment and retention in the
selenium and vitamin E cancer prevention trial. D Banerjee,
JM Choe, D Ward, AM Hoque, K Basen-Engquist, J Song,
D Ramsey, SM Lippman, ED Cook. Proc of AACR Frontiers
in Cancer Prevention Research, Oct 16-20:131, 2004.
GU
7/25/01
6/24/04
*S0111
(2061)
Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) GU
administered every 21 days in patients (pts) with hormone
refractory prostate cancer (HRPC). a Southwest Oncology
Group study (S0111). M Hussain, J Faulkner, U Vaishampayan,
P Lara, D Petrylak, D Colevas, W Sakr, ED Crawford.
Proc of the American Society of Clinical Oncology 23:383
(#4510), 2004.
6/15/01
11/15/03
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8710
(1844)
Neoadjuvant chemotherapy plus cystectomy compared
with cystectomy alone for locally advanced bladder
cancer. HB Grossman, RB Natale, CM Tangen,
VO Speights, NJ Vogelzang, DL Trump, RW deVere White,
MF Sarosdy, DP Wood Jr, D Raghavan, ED Crawford.
New England Journal of Medicine 349(9):859-866, 2003.
GU
8/1/87
7/1/98
8792
(2422)
Phase III study of interferon alfa-NL as adjuvant treatment
for resectable renal cell carcinoma: an Eastern Cooperative
Oncology Group/Intergroup trial. EM Messing, J Manola,
G Wilding, K Propert, J Fleischmann, ED Crawford,
JE Pontes, R Hahn, D Trump. Journal of Clinical Oncology
21(7):1214-1222, 2003.
GU
6/15/87
4/8/92
8894
(1997)
Metastatic carcinoma of the prostate: identifying prognostic
GU
groups using recursive partitioning. TR Glass, CM Tangen, ED
Crawford, I Thompson. Journal of Urology 169:164-169, 2003.
12/15/89
9/15/94
8894
(1984)
Ten-year survival in patients with metastatic prostate
cancer. CM Tangen, JR Faulkner, ED Crawford, IM
Thompson, D Hirano, M Eisenberger, M Hussain.
Clinical Prostate Cancer 2(1):41-45, 2003.
GU
12/15/89
9/15/94
9217
(2020)
The influence of finasteride on the development of prostate
GU
cancer. IM Thompson, PJ Goodman, CM Tangen, MS Lucia,
GJ Miller, LG Ford, MM Lieber, RD Cespedes, JN Atkins,
SM Lippman, SM Carlin, A Ryan, CM Szczepanek, JJ
Crowley, CA Coltman Jr. New England Journal of Medicine
349:215-224, 2003.
10/13/93
12/6/96
9217
(1983)
The prostate cancer prevention trial: design, status, and
promise. IM Thompson C Tangen, P Goodman.
World Journal of Urology 21:28-30, 2003.
10/13/93
12/6/96
9403
(1685)
A phase II study of 13-cis retinoic acid plus interferon a-2a in GU
advanced stage penile carcinoma: an Eastern Cooperative
Oncology Group study (E3893). RT Skeel, J Huang, J Manola,
G Wilding, R Dreicer, P Walker, F Muggia, ED Crawford, JP
Dutcher, PJ Loehrer. Cancer Investigation 21(1):41-46, 2003.
3/1/96
6/17/98
S0000
(2485)
SELECT: the selenium and vitamin E cancer prevention
trial. EA Klein, IM Thompson, SM Lippman, PJ Goodman,
D Albanes, PR Taylor, C Coltman. Urologic Oncology
21(1):59-65, 2003. PMID: 12684129
CC
GU
7/25/01
6/24/04
S0000
(2486)
The selenium and vitamin E cancer prevention trial.
World Journal of Urology 21(1):21-27, 2003.
PMID: 12756490
CC
GU
7/25/01
6/24/04
Multiple
Studies
(2003)
Southwest Oncology Group studies in bladder cancer.
GU
ED Crawford, DP Wood, DP Petrylak, J Scott, CA Coltman Jr,
D Raghavan. Cancer Supplement 97(8):2099-2108, 2003.
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*8710
(1879)
Surgical variables impact bladder cancer outcomes: a
cooperative group report. H Herr, JR Faulkner,
HB Grossman, ED Crawford. Proc of the American
Society of Clinical Oncology 22:383 (#1540), 2003.
GU
8/1/87
7/1/98
9217
(2289)
The prostate cancer prevention trial: Did the adherence
interventions for the end of study biopsy really work? S
Carlin, P Goodman, C Moinpour, S Hill. Controlled Clinical
Trials 24(3S):P22, 2003.
GU
10/13/93
12/6/96
*9346
(1872)
Determinants of prostate specific antigen (PSA) normalization GU
in prostate cancer (PCa) patients (pts) treated with androgen
deprivation (AD) on Southwest Oncology Group (SWOG) study
9346 (INT-0162). CM Tangen, M Hussain, G Wilding, EJ Small,
L Goldenberg, A Akdas, ED Crawford. Proc of the American Society
of Clinical Oncology 22:396 (#1591), 2003.
5/15/95
Open
S0000
(2038)
Challenges of implementing ancillary studies within
multi-site clinical trials. T Chay, P Goodman, J Hartline.
Controlled Clinical Trials 24(3S) Suppl:182S (#P173), 2003.
GU
7/25/01
OPEN
S0000
(2040)
Drug distribution challenges in a multi-site clinical trial.
A Darke, J Vertrees, P Goodman. Controlled Clinical
Trials 24(3S) Suppl:203S (#P217), 2003.
GU
7/25/01
OPEN
S0000
(2031)
Effectiveness of a media based launch to recruit to a
prostate cancer prevention trial. L Minasian,
K Smigel-Croker, A Ryan, A Voss, L Cave, E Klein,
L Ford. Controlled Clinical Trials 24(3S) Suppl:50S
(#14), 2003.
GU
7/25/01
OPEN
S0000
(2039)
Form and function: PDF+ versus HTML form design.
KB Gower, B Kleinman. Controlled Clinical Trials
24(3S) Suppl:188S (#P186), 2003.
GU
7/25/01
OPEN
S0000
(2036)
Optimizing data collection in a large web-based trial.
KB Gower, A Darke. Controlled Clinical Trials 24(3S)
Suppl:47S (#10), 2003.
GU
7/25/01
OPEN
S0000
(2037)
Planning for successful recruitment for cancer trials.
K Anderson, J Probstfield, SM Thomas.
Controlled Clinical Trials 24(3S) Suppl:102S (#P18),
2003.
GU
7/25/01
OPEN
S0031
(1884)
Evaluation of ZD1839 for advanced transitional cell
carcinoma (TCC) of the urothelium: a Southwest
Oncology Group trial. D Petrylak, JR Faulkner,
PJ Van Veldhuizen, M Mansukhani, ED Crawford.
Proc of the American Society of Clinical Oncology
22:403 (#1619), 2003.
GU
2/15/01
10/15/02
*S0109
(1875)
A phase II study of flavopiridol (Flavo) in patients (pts)
with advanced renal cell cancer: results of Southwest
Oncology Group trial S0109. PJ Van Veldhuizen, JR
Faulkner, PN Lara, RC Flanigan, PH Gumerlock, ED
Crawford. Proc of the American Society of Clinical
Oncology 22:387 (#1553), 2003.
GU
5/1/01
2/1/02
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8894
(1838)
Impact of previous local treatment for prostate cancer
on subsequent metastatic disease. IM Thompson, C
Tangen, J Basler, and ED Crawford. Journal of Urology
168:1008-1012, 2002.
GU
12/15/89
9/15/94
8949
(1847)
The possible role of postoperative azotemia in enhanced
survival of patients with metastatic renal cancer after
cytoreductive nephrectomy. RA Gatenby, ET Gawlinski,
CM Tangen, RC Flanigan, ED Crawford.
Cancer Research 62:5218-5222, 2002.
GU
3/1/91
10/1/98
9109
(1818)
Neoadjuvant therapy before radical prostatectomy for clinical GU
T3/T4 carcinoma of the prostate: 5 year follow-up, phase II
Southwest Oncology Group study 9109. IJ Powell, CM Tangen,
GJ Miller, BA Lowe, G Haas, PR Carroll, MB Osswald,
R deVere-White, IM Thompson Jr, ED Crawford.
Journal of Urology 168:2016-2019, 2002.
12/1/931
10/15/96
9217
(1857)
Biomarker-based methods for determining noncompliance
in a prevention trial. DK Pauler, KB Gower, PJ Goodman,
JJ Crowley, IM Thompson. Controlled Clinical Trials 23:
675-685, 2002.
GU
10/13/93
12/6/96
9217
(1765)
Energy from fat is associated with obesity in US men: results GU
from the Prostate Cancer Prevention Trial. J Satia-Abouta, RE
Patterson, RN Schiller, AR Kristal. Preventive Medicine
34:493-501, 2002.
10/13/93
12/6/96
9230
(1782)
Phase II trial of recombinant human interleukin-4 in patients
GU
with advanced renal cell carcinoma: a Southwest Oncology
Group study. RP Whitehead, D Lew, RC Flanigan, GR Weiss,
V Roy, ML Glode, SR Dakhil, ED Crawford. Journal of
Immunotherapy 25(4):352-358, 2000.
6/1/93
5/1/95
9452
(1982)
Randomized study of three different doses of suramin
administered with a fixed dosing schedule in patients with
advanced prostate cancer: results of Intergroup 0159,
Cancer and Leukemia Group B 9480. EJ Small,
S Halabi, MJ Ratain, G Rosner, W Stadler, D Palchak,
E Marshall, R Rago, V Hars, G Wilding, D Petrylak,
NJ Vogelzang. Journal of Clinical Oncology 20(16):
3369-3375, 2002.
GU
10/1/96
7/15/98
9510
(1770)
SWOG-9510: Evaluation of topotecan in hormone refractory
prostate cancer: a Southwest Oncology Group study. CE
Klein, CM Tangen, TJ Braun, MHA Hussain, DM Peereboom,
CR Nichols, SE Rivkin, SR Dakhil, ED Crawford.
GU
11/1/96
8/15/99
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
The Prostate 52:264-268, 2002.
S0000
(1993)
The Das/Kaplan article reviewed: The role of PC-SPES,
selenium, and vitamin E in prostate cancer. EA Klein.
Oncology 16(3):296-300, 2002.
GU
7/25/01
Open
S0000
(1992)
The Das/Kaplan article reviewed: The role of PC-SPES,
selenium, and vitamin E in prostate cancer. EJ Small.
Oncology 16(3):291-296, 2002.
GU
7/25/01
Open
ABSTRACTS PUBLISHED/PRESENTED
8894
(1801)
Ten-year survival in patients with metastatic (M+) prostate
cancer (CAP): analysis of Southwest Oncology Group
(SWOG) 8894. D Crawford, J Faulkner, IM Thompson,
MA Eisenberger, CM Tangen, MH Hussain.
Journal of Urology 167(4) Suppl:304 (#1202), 2002.
GU
12/15/89
9/15/94
8894
(1870)
Ten-year survival in patients with metastatic (M+) prostate
cancer (CaP): analysis of Southwest Oncology Group
(SWOG) 8894. C Tangen, ED Crawford, J Faulkner,
I Thompson, M Eisenberger, M Hussain.
Proc of the American Society of Clinical Oncology 21:188a
(#749), 2002.
GU
12/15/89
9/15/94
8894
(1901)
The relationship of gleason sum and survival in patients
with metastatic (M+) prostate cancer (CaP): analysis of
SWOG 8894. ED Crawford, G Miller, J Faulkner, C Tangen,
IM Thompson, E Eisenberger, M Hussain. South Central
Section of the AUA, 81st Annual Meeting:170 (#31), 2002.
GU
12/15/89
9/15/94
9023
(1784)
Cytogenetic and flow cytometric results in advanced
renal cell carcinoma: a Southwest Oncology Group
study. RP Whitehead, C Tangen, SR Wolman, RC
Flanigan, TV Shankey, ML Slovak, ED Crawford.
Proc of the American Society of Clinical Oncology 21:147b
(#2400), 2002.
GU
7/1/93
11/1/98
9217
(1855)
Biomarker-based methods for determining non-compliance
in a prevention trial. KB Gower, DK Pauler, PJ Goodman.
Controlled Clinical Trials 23(2S):49S-50S (#26), 2002.
GU
10/13/93
12/6/96
9426
(1791)
Anti-Androgen withdrawal in prostate cancer: results from
GU
SWOG 9426. AO Sartor, C Tangen, M Hussain, M Eisenberger,
ED Crawford. Proc of the American Society of Clinical Oncology
21:197a (#785), 2002.
3/15/95
6/1/01
9458
(1832)
SWOG 9458: evaluation of Ki-67, p53 and angiogenesis in
GU
patients registered to SWOG 8710. HB Grossman, C CordonCardo, R Cote, FM Waldman, C Tangen, ED Crawford.
International Journal of Cancer Suppl 13:114 (#O 140), 2002.
11/15/95
11/1/98
9812
Selenium accumulates in prostate tissue of prostate cancer
6/15/99
6/1/01
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
(1828)
patients after short-term administration of I –selenomethlonine.
AL Sabichi, JJ lee, RJ Taylor, IM Thompson Jr, BJ Miles, JW
Basler, LL Platera, M Wargo, D Menter, CM Tangen, ED Crawford,
SM Lippman. Proc of the American Association for Cancer
Research 43:1007 (#4993), 2002.
S0000
(1856)
The challenges and benefits of a web-based trial.
B Kleinman, A Darke, JA Hartline. Controlled Clinical
Trials 23(2S):91S-92S (#P 62), 2002.
*Presented
GU/CCR
7/25/01
OPEN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8894
(1630)
Association of African-American ethnic background
with survival in men with metastatic prostate cancer.
IM Thompson, CM Tangen, A Tolcher, ED Crawford,
M Eisenberger, CM Moinpour. Journal of the National
Cancer Institute 93(3):219-225, 2001.
GU
12/15/89
9/15/94
8894
(1915)
Response to Letter to the Editor: RE: Association of
African-American ethnic background with survival in men
with metastatic prostate cancer. A Tolcher, ED Crawford,
M Eisenberger, CM Moinpour. Journal of the National
Cancer Institute 93(15):1175, 2001.
GU
12/15/89
9/15/94
8949
(1740)
Nephrectomy followed by interferon Alfa-2b compared with
interferon alfa-2b alone for metastatic renal-cell cancer.
RC Flanigan, SE Salmon, BA Blumenstein, SI Bearman,
V Roy, PC McGrath, JR Caton, Jr, N Munshi, ED Crawford.
New England Journal of Medicine 345(23):1655-1659, 2001.
GU
3/1/91
10/1/98
9217
(1809)
Dietary supplement use in the prostate cancer prevention
trial: implications for prevention trials. ML Neuhouser,
AR Kristal, RE Patterson, PJ Goodman, IM Thompson.
Nutrition and Cancer 39(1):12-18, 2001.
GU
10/13/93
12/6/96
9217
(1745)
The prostate cancer prevention trial: current status
and lessons learned. IM Thompson Jr, J Kouril, EA
Klein, CA Coltman, A Ryan, P Goodman. Urology
57(Suppl 4A):230-234, 2001.
GU
10/13/93
12/6/96
9235
(1559)
Phase II trial of bicalutamide in patients with advanced
prostate cancer in whom conventional hormonal therapy
failed: a Southwest Oncology Group study (SWOG 9235).
O Kucuk, E Fisher, CM Moinpour, D Coleman, MHA
Hussain, AO Sartor, GS Chatta, BA Lowe, MA Eisenberger,
ED Crawford. Urology 58(1):53-58, 2001.
GU
12/15/93
6/1/94
9312
(1635)
Combination cisplatin, 5-fluorouracil and radiation therapy
for locally advanced unresectable or medically unfit bladder
cancer cases: a Southwest Oncology Group study.
MHA Hussain, TR Glass, J Forman, W Sakr, DC Smith,
M Al-Sarraf, J Jones, SP Balcerzak, ED Crawford, HB
Grossman. Journal of Urology 165:56-61, 2001.
GU
10/1/93
4/1/98
9407
(1595)
A phase II trial of estramustine and etoposide in hormone
refractory prostate cancer: a Southwest Oncology Group
trial (SWOG-9407). KJ Pienta, EI Fisher, MA Eisenberger,
GM Mills, JW Goodwin, JA Jones, SR Dakhil, ED Crawford,
GU
3/1/96
7/1/96
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MHA Hussain. The Prostate 46:257-261, 2001.
9461
(1675)
Phase II evaluation of suramin in advanced renal cell
carcinoma: a Southwest Oncology Group study. LE
Schroder, D Lew, RC Flanigan, MA Eisenberger, TE
Seay, N Hammond, BM Needles, ED Crawford.
Urologic Oncology 6:145-148, 2001.
GU
S0000
(1741)
Molecular epidemiologic studies within the selenium and
GU/CCR
vitamin E cancer prevention trial (SELECT). A Hoque,
D Albanes, SM Lippman, MR Spitz, PR Taylor, EA Klein,
IM Thompson, P Goodman, JL Stanford, JJ Crowley, CA
Coltman, RM Santella. Cancer Causes and Control 12:627-633,
2001.
S0000
(1764)
SELECT: The next prostate cancer prevention trial.
EA Klein, IM Thompson, SM Lippman, PJ Goodman,
D Albanes, PR Taylor, C Coltman. Journal of Urology
166:1311-1315, 2001.
2/1/97
6/15/99
GU
ABSTRACTS PUBLISHED/PRESENTED
*8710
(1730)
SWOG 8710 (INT-0080): randomized phase III trial of
GU
neoadjuvant MVAC + cystectomy versus cystectomy alone
in patients with locally advanced bladder cancer. D Crawford,
B Grossman, B Blumenstein, N Vogelzang, D Trump, VO
Speights, RW DeVere White, R Natale. Journal of Urology
165(5) Suppl:260 (#1069), 2001.
8/1/87
7/1/98
*8710
(1737)
SWOG 8710 (INT-0080): randomized phase III trial of
GU
neoadjuvant MVAC + cystectomy versus cystectomy alone
in patients with locally advanced bladder cancer. RB Natale,
HB Grossman, B Blumenstein, N Vogelzang, DL Trump, VO
Speights, R de Vere White, ED Crawford. Proc of the American
Society of Clinical Oncology 20:2a (#3), 2001.
8/1/87
7/1/98
*8894
(1739)
Does a prior radical prostatectomy (RP) alter outcome of
hormonal therapy for metastatic (M+) prostate cancer (CAP).
IM Thompson, J Basler, C Tangen, ED Crawford. Journal of
Urology 165(5) Suppl:168 (#689), 2001.
GU
12/15/89
9/15/94
9109
(1715)
Neoadjuvant zoladex and flutamide in bulky and non-bulky
clinical stage C carcinoma of the prostate. IJ Powell, CM
Tangen, GP Haas, D Crawford, GJ Miller, BA Lowe, IM
Thompson. Journal of Urology 165(5) Suppl:330 (#1355),
2001.
GU
12/1/93
10/15/96
9217
(1767)
Promoting adherence to the prostate cancer prevention trial
end of study biopsy requirement. AM Ryan, P Goodman,
S Hill, C Moinpour. Controlled Clinical Trials 22(2S):88S
(#P71), 2001.
GU
10/13/93
12/6/96
9427
Phase II evaluation of suramin in advanced adrenal carcinoma GU
3/1/97
6/1/00
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
(1725)
Southwest Oncology Group (SWOG) trial 9427. LE Schroder,
T Glass, M Eisenberger, D Culkin, R Bukowski, E Crawford.
Proc of the American Society of Clinical Oncology 20:153b
(#2361), 2001.
S0000
(1766)
The web-based management of the selenium and vitamin E
cancer prevention trial. PA Shaw, PJ Goodman, J Brace.
Controlled Clinical Trials 22(2S):57S (#P06), 2001.
*Presented
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8507
(1544)
Maintenance Bacillus Calmette-Guerin immunotherapy for
recurrent Ta, T1 and carcinoma in situ transitional cell
carcinoma of the bladder: a randomized Southwest
Oncology Group study. DL Lamm, BA Blumenstein,
JD Crissman, JE Montie JE Gottesman, BA Lowe,
MF Sarosdy, RD Bohl, HB Grossman, TM Beck, JT
Leimert, ED Crawford. Journal of Urology 163:1124-1129,
2000.
8795
(1477)
GU
12/20/85
12/15/88
The prognostic significance of s-phase analysis in stage
GU
Ta/T1 bladder cancer: A Southwest Oncology Group study.
RW deVere White, AD Deitch, S Daneshmand, B Blumenstein,
BA Lowe, AI Sagalowsky, JA Smith, Jr, PF Schellhammer, TH
Stanisic, HB Grossman, E Messing, JD Crissman, ED Crawford.
European Urology 37:595-600, 2000.
12/1/88
5/15/92
8925
(1547)
Phase II evaluation of cisplatin and etoposide followed
by mitotane at disease progression in patients with locally
advanced or metastatic adrenocortical carcinoma:
a Southwest Oncology Group study. SK Williamson, D Lew,
GJ Miller, SP Balcerzak, LH Baker, ED Crawford.
Cancer 88(5):1159-1165, 2000.
GU
6/15/89
12/1/95
9217
(1667)
Letters to the editor: RE: RE: Chemoprevention of
Urological Cancer. IM Thompson, CA Coltman.
Journal of Urology 164(4):1321-1322, 2000.
GU
10/13/93
12/6/96
9217
(1669)
Minority recruitment in the prostate cancer prevention
trial. CM Moinpour, JO Atkinson, SM Thomas, S Millon
Underwood, C Harvey, J Parzuchowski, LC Lovato,
AM Ryan, MS Hill, E DeAntoni, ER Gritz, IM Thompson Jr,
CA Coltman Jr. Annals of Epidemiology 10(S8):S85-S91,
2000.
GU
10/13/93
12/6/96
9217
(1517)
Profile of men randomized to the prostate cancer
prevention trial: Baseline health-related quality of life,
urinary and sexual functioning, and health behaviors.
CM Moinpour, LC Lovato, IM Thompson Jr,
JE Ware Jr, PA Ganz, DL Patrick, SA Shumaker,
GW Donaldson, A Ryan, CA Coltman Jr. Journal of
Clinical Oncology 18(9):1942-1953, 2000.
GU
10/13/93
12/6/96
9217
(1398)
Television and news print media are effective in recruiting
potential participants in a prostate cancer chemoprevention
trial. TDK Chung, II Park, L Ignacio, R Catchatourian,
M Kopnick, E Davison, G Conrad, AM Awan, D Crawford,
S. Vijayakumar. International Journal of Cancer 90:302-304,
GU
10/13/93
12/6/96
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
2000.
9338
(1520)
Infusional interleukin-2 and 5-fluorouracil with subcutaneous GU
interferon- α for the treatment of patients with advanced renal
cell carcinoma: A Southwest Oncology Group phase II study.
L Elias, D Lew, RA Figlin, RC Flanigan, ME Thompson, PL
Triozzi, RJ Belt, DP Wood Jr, SE Rivkin, ED Crawford.
Cancer 89(3):597-603, 2000.
12/15/94
9/1/97
9343
(1543)
Androgen deprivation and four-courses of fixed-schedule
GU
suramin treatment in patients with newly diagnosed metastatic
prostate cancer: a Southwest Oncology Group study.
M Hussain, EI Fisher, DP Petrylak, J O’Connor, DP Wood,
EJ Small, MA Eisenberger, ED Crawford. Journal of Clinical
Oncology 18(5):1043-1049, 2000.
8/15/94
1/15/97
9457
(1557)
Southwest Oncology Group study of paclitaxel and
carboplatin for advanced transitional-cell carcinoma: the
importance of survival as a clinical trial end point. EJ Small
D Lew, BG Redman, DP Petrylak, N Hammond, HM Gross,
JA Eastham, ED Crawford. Journal of Clinical Oncology
18(13):2537-2544, 2000.
GU
7/15/96
9/15/98
S0000
(1656)
SELECT: the selenium and vitamin E cancer prevention trial
rationale and design. EA Klein, IM Thompson, SM Lippman,
PJ Goodman, D Albanes, PR Taylor, C Coltman. Prostate
Cancer and Prostatic Diseases 3:145-151, 2000.
GU
NONE
(1742)
Selenium effects on prostate cell growth. DG Menter,
AL Sabichi, SM Lippman. Cancer Epidemiology &
Prevention 9:1171-1182, 2000.
GU/CCR
ABSTRACTS PUBLISHED/PRESENTED
8894
(1612)
African American ethnic background is an independent and
GU
negative predictor of survival in metastatic prostate cancer.
I Thompson, A Tolcher, ED Crawford, M Eisenberger, C
Tangen, E Fisher. Journal of Urology 163(4):56 Suppl (#242),
2000.
12/15/89
9/15/94
8894
(1623)
Prognostic value of serum PSA in patients with newly
diagnosed metastatic prostate cancer. D Crawford,
I Thompson, A Tolcher. Journal of Urology 163(4):259
Suppl (#1149), 2000.
12/15/89
6/15/94
*8949
(1678)
Cytoreduction nephrectomy in metastatic renal cancer: the
GU
results of Southwest Oncology Group trial 8949. RC
Flanigan, BA Blumenstein, S Salmon, E Crawford. Proc of the
American Society of Clinical Oncology 19:2a (#3), 2000.
3/1/91
10/1/98
8949
(1613)
Cytoreduction nephrectomy in metastatic renal cancer: the
results of Southwest Oncology Group trial 8949. RC
3/1/91
10/1/98
GU
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
Flanigan, BA Blumenstein, S Salmon, SI Bearman, V Roy,
SP Balcerzak, PC McGrath, JR Caton, B Barlogie, ED
Crawford. Journal of Urology 163(4) Suppl:154, (#685), 2000.
*9217
(1644)
Dietary supplement use in the prostate cancer prevention
trial: implications for study findings. ML Neuhouser, AR
Kristal, RE Patterson, IM Thompson. American Society of
Prevention Oncology #76, 2000.
*9452
(1615)
Results of CALGB 9480, a phase III trial of 3 different doses GU
of suramin for the treatment of hormone refractory prostate
cancer (HRPC). S Halabi, EJ Small, RH Ansari, G Wilding,
DP Petrylak, DI Palchak, E Marshall, RP Rago, V Hars, NJ
Vogelzang. Proc of the American Society of Clinical Oncology
19:328a (#1291), 2000.
0000
(1617)
Design of the selenium and vitamin E chemoprevention trial
(SELECT). PJ Goodman, S Lippman, E Klein, A Ryan, J
Crowley, M LeBlanc, CA Coltman Jr. Proc of the Society for
Clinical Trials #11, 2000.
*Presented
GU
GU
10/13/93
12/6/96
10/1/96
7/15/98
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
8507
(1497)
Maintenance BCG Immunotherapy: Evidence of additional
protection against cancer: A Southwest Oncology Group
study. DL Lamm, JD Crissman, JE Montie, JB Gottesman,
BA Lowe, MF Sarosdy, RD Bohl, HB Grossman, TM Beck,
JT Leimert, ED Crawford, U Kosecka, RC Wittes. Proc of
the American Urological Association #1464, 1999.
GU
12/20/85
12/15/88
8793
(1523)
Immediate hormonal therapy vs observation for node
positive prostate cancer following radical prostatectomy and
pelvic lymphadenectomy: A randomized phase III Eastern
Cooperative Oncology Group/Intergroup trial. E Messing,
G Wilding, M Sarosdy, D Crawford, J Manola. Proc of the
American Urological Association #45, 1999.
GU
3/15/88
4/15/93
*9312
(1498)
Phase II evaluation of cisplatin + 5-fluorouracil + radiation
GU
therapy in patients with locally advanced/inoperable bladder
cancer. A Southwest Oncology Group study 9312. M Hussain,
E Fisher, J Forman, W Sakr, A Drelichman, S Akhter, HB
Grossman, ED Crawford. Proc of the American Society
of Clinical Oncology 18:333a (#1281), 1999.
10/1/93
4/1/98
*9338
(1503)
Infusional interleukin-2 and 5-fluorouracil with subcutaneous GU
interferon- α for advanced renal cell carcinoma. A Southwest
Oncology Group study. L Elias, D Lew, RA Figlin, RC Flanigan,
ME Thompson, PL Triozzi, RJ Belt, DP Wood, SE Rivkin,
ED Crawford. Proc of the American Society of Clinical
Oncology 18:331a (#1275), 1999.
12/15/94
9/1/97
*9457
(1502)
Carboplatin and paclitaxel (CARBO/TAX) for advanced
transitional cell carcinoma (TCC) of the urothelium. EJ
Small, D Lew, DP Petrylak, ED Crawford. Proc of the
American Society of Clinical Oncology 18:333a (#1280),
1999.
7/15/96
OPEN
*Presented
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
8507
(1497)
Maintenance BCG Immunotherapy: Evidence of additional
protection against cancer: A Southwest Oncology Group
study. DL Lamm, JD Crissman, JE Montie, JB Gottesman,
BA Lowe, MF Sarosdy, RD Bohl, HB Grossman, TM Beck,
JT Leimert, ED Crawford, U Kosecka, RC Wittes. Proc of
the American Urological Association #1464, 1999.
GU
12/20/85
12/15/88
8793
(1523)
Immediate hormonal therapy vs observation for node
positive prostate cancer following radical prostatectomy and
pelvic lymphadenectomy: A randomized phase III Eastern
Cooperative Oncology Group/Intergroup trial. E Messing,
G Wilding, M Sarosdy, D Crawford, J Manola. Proc of the
American Urological Association #45, 1999.
GU
3/15/88
4/15/93
*9312
(1498)
Phase II evaluation of cisplatin + 5-fluorouracil + radiation
GU
therapy in patients with locally advanced/inoperable bladder
cancer. A Southwest Oncology Group study 9312. M Hussain,
E Fisher, J Forman, W Sakr, A Drelichman, S Akhter, HB
Grossman, ED Crawford. Proc of the American Society
of Clinical Oncology 18:333a (#1281), 1999.
10/1/93
4/1/98
*9338
(1503)
Infusional interleukin-2 and 5-fluorouracil with subcutaneous GU
interferon- α for advanced renal cell carcinoma. A Southwest
Oncology Group study. L Elias, D Lew, RA Figlin, RC Flanigan,
ME Thompson, PL Triozzi, RJ Belt, DP Wood, SE Rivkin,
ED Crawford. Proc of the American Society of Clinical
Oncology 18:331a (#1275), 1999.
12/15/94
9/1/97
*9457
(1502)
Carboplatin and paclitaxel (CARBO/TAX) for advanced
transitional cell carcinoma (TCC) of the urothelium. EJ
Small, D Lew, DP Petrylak, ED Crawford. Proc of the
American Society of Clinical Oncology 18:333a (#1280),
1999.
7/15/96
OPEN
*Presented
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8894
(1383)
Bilateral orchiectomy with or without flutamide for
metastatic prostate cancer. MA Eisenberger, BA
Blumenstein, ED Crawford, G Miller, DG McLeod,
PJ Loehrer, G Wilding, K Sears, DJ Culkin, IM
Thompson Jr, AJ Bueschen, BA Lowe. New England
Journal of Medicine 339:1036-1042, 1998.
GU
12/15/89
9/15/94
8997
(1413)
Randomized comparison of cisplatin and etoposide and
either bleomycin or ifosfamide in treatment of advanced
disseminated germ cell tumors: An Eastern Cooperative
Oncology Group, Southwest Oncology Group, and
Cancer and Leukemia Group B study. CR Nichols, PJ
Catalano, ED Crawford, NJ Vogelzang, LH Einhorn,
PJ Loehrer. Journal of Clinical Oncology
16(4):1287-1293, 1998.
GU
10/1/89
4/9/92
9039
(1388)
Quality of life in advanced prostate cancer: Results
of a randomized therapeutic trial. CM Moinpour, MJ
Savage, A Troxel, LC Lovato, M Eisenberger, RW Veith,
B Higgins, R Skeel, M Yee, BA Blumenstein, ED Crawford,
FL Meyskens Jr. Journal of the National Cancer Institute
90(20):1537-1544, 1998.
CCR
GU
10/1/90
9/15/94
9217
(1356)
Army and Air Force leadership in the prostate cancer
prevention trial. J Allerton, T Seay, S Optenberg, CA
Coltman Jr, B Higgins, I Thompson, L Lovato.
Urology 51 (Suppl 4A):64-66, 1998.
GU
10/13/93
12/6/96
None
(1367)
Hormone receptor immunoreactivity in hemangioblastomas
and clear cell renal cell carcinomas. DF Brown, MA Dababo,
CL Hladik, KP Eagan, CL White, EJ Rushing. Modern
Pathology 11(1):55-59, 1998.
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*8795
(1481)
Predictors of outcome in bladder transitional cell carcinoma
GU
(TCC) treated by intravesical chemotherapy. R deVere White,
AD Deitch, S Daneshmand, BA Blumenstein. The Journal of
Urology 159(5) Suppl:145 (#552), 1998.
12/1/88
5/15/92
9343
Analysis of suramin (S) levels obtained from D2 hormone
GU
8/15/94
1/15/97
(1378)
naive prostate cancer (HNPCA) patients (pts) treated with
fixed bolus suramin: A Southwest Oncology Group study.
DP Petrylak, JO Connor, E Fisher, M Eisenberger, ED
Crawford, M Hussain. Proc of the American Society of
Clinical Oncology 17:340a (#1310), 1998.
*9343
(1377)
Androgen deprivation (AD) + 4-courses of fixed-schedule
suramin in D2 prostate cancer (PCA) patients (pts): A
Southwest Oncology Group phase II study. M Hussain,
E Fisher, D Wood, E Small, M Eisenberger, ED Crawford.
Proc of the American Society of Clinical Oncology 17:314a
(#1211), 1998.
GU
8/15/94
1/15/97
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8221
(1138)
Treatment of advanced bladder cancer with combined
preoperative irradiation and radical cystectomy versus
radical cystectomy alone. A Phase III intergroup study.
JA Smith Jr, ED Crawford, JC Paradelo, B Blumenstein,
BR Herschman, HB Grossman, DW Christie.
Journal of Urology 157:805-808, 1997.
GU
10/29/82
11/15/89
8594
(1353)
Long-term follow-up of a phase III intergroup study of
cisplatin alone or in combination with methotrexate,
vinblastine, and doxorubicin in patients with metastatic
urothelial carcinoma: A cooperative group study.
SB Saxman, KJ Propert, LH Einhorn, ED Crawford,
I Tannock, D Raghavan, PJ Loehrer, D Trump.
Journal of Clinical Oncology 15(7):2564-2569, 1997.
GU
10/1/84
5/15/89
8711
(1189)
A study of reproductive function in patients with seminoma
CCR
treated with radiotherapy and orchidectomy: (SWOG-8711). GU
W Gordon Jr, K Siegmund, TH Stanisic, B McKnight,
IT Harris, PR Carroll, JC Paradelo, FJ Meyers, RA Chapman,
FL Meyskens Jr. International Journal of Radiation Oncology
Biology Physics 38(1):83-94, 1997.
4/1/88
6/1/94
8956
(1114)
Continuous-infusion 5-fluorouracil and cisplatin for
advanced/recurrent transitional cell cancer of the
bladder: A Southwest Oncology Group trial.
JA Kish, MK Wolf, PF Schellhammer, MHA Hussain,
AB Einstein, ED Crawford. American Journal
of Clinical Oncology (CCT) 20(4):327-330, 1997.
GU
10/1/90
6/15/93
9104
(1191)
Phase II evaluation of doxorubicin/vinblastine combined
with inhibitors trifluoperazine/verapamil of
p-glycoprotein in patients with advanced renal carcinoma.
LE Schroder, BA Blumenstein, RC Flanigan, JR Borst,
ED Crawford. Urologic Oncology 3:94--98, 1997.
GU
9/1/92
9/1/94
9217
(1334)
Chemoprevention of prostate cancer: The prostate
cancer prevention trial. IM Thompson, CA Coltman Jr,
J Crowley. The Prostate 33:217-221, 1997.
GU
10/13/93
12/6/96
9450
(1359)
The prostate cancer intervention versus observation trial
TJ Wilt, MK Brawer. Oncology 11(8):1133-1139, 1997.
GU
5/12/95
Multiple
Studies
(1309)
Prostate cancer clinical trials of the Southwest Oncology
Group. ED Crawford, EP DeAntoni, M Hussain, IM
Thompson, CA Coltman Jr. Oncology 11(8):1154-1170,
1997.
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
Multiple
Studies
(1322)
Towards the validation of aneusomy detection by
fluorescence in situ hybridization (FISH) in bladder cancer:
Comparative analysis with cytology, cytogenetics, and
clinical features predicts recurrence and defines clinical
testing limitations. FF Zhang, DA Arber, TG Wilson, MH
Kawachi, ML Slovak. Clinical Cancer Research 3:23172328, 1997.
GU
Cytogenetics
ABSTRACTS PUBLISHED/PRESENTED
8507
(1229)
Significant long-term patient benefit with BCG maintenance
therapy: A Southwest Oncology Group study. DL Lamm,
B Blumenstein, M Sarosdy, HB Grossman, ED Crawford.
Urology 157(4)(Suppl)(#831):213, 1997.
GU
12/20/85
12/15/88
*8894
(1268)
A comparison of bilateral orchiectomy (orch) with or without
flutamide in stage D2 prostate cancer (PC) (NCI INT-0105
SWOG/ECOG). M Eisenberger, ED Crawford, D McLeod,
P Loehrer, G Wilding, B Blumenstein. American Society
of Clinical Oncology 16:2a (#3), 1997.
GU
12/15/89
9/15/94
8894
(1230)
Comparison of bilateral orchiectomy with or without flutamide GU
for the treatment of patients (pts) with stage D2 adenocarcinoma
12/15/89
9/15/94
12/15/89
9/15/94
of the prostate (CaP): Results of NCI Intergroup study 0105
(SWOG and ECOG). ED Crawford, MA Eisenberger, DG
McLeod, G Wilding, BA Blumenstein. Urology 157(4)(Suppl)
(#1311):336, 1997.
*8894
(1341)
Comparison of bilateral orchiectomy with or without
flutamide for the treatment of patients (pts) with stage
D2 adenocarcinoma of the prostate (CaP): Results of
GU
the NCI intergroup study 0105 (SWOG and ECOG).
ED Crawford, M Eisenberger, DG McLeod, G Wilding,
BA Blumenstein. British Journal of Urology 80(Suppl 2):
278 (#1092), 1997.
8956
(1298)
High dose cisplatin (C) and continuous infusion 5
GU
fluorouracil (5FU CI) for the treatment of advanced/
recurrent transitional cell cancer of the bladder
(ARTCCB). Final report of a Southwest Oncology
Group (SWOG) trial. J Kish, M Wolf, P Schellhammer,
M Hussain, A Einstein, E Crawford. Proc Seventh
International Congress on Anti-Cancer Treatment #254, 1997.
10/1/90
6/15/93
9024
(1419)
Protracted venous infusion (PVI) 5-FU and radiation
as definitive therapy for stage C prostate cancer – a
Southwest Oncology Group phase II study. S Smalley,
D Lew, I Thompson, M Sarosdy, R Stephens, M Noble,
B Kimler. Proc of the American Society of Clinical
Oncology 16:343a (#1228), 1997.
8/1/91
3/15/95
GU
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9023
(1250)
Comparison of cytogenetic and flow cytometric results
of renal cell carcinoma (RCC) performed in the
Southwest Oncology Group (SWOG). SM Dobin, TS
McConnell, ML Slovak, R Whitehead, V Shankey, R
Flanigan. Proc Seventh International Workshop on
Chromosomes in Solid Tumors #21, 1997.
Cytogenetics
GU
7/1/93
Open
*9039
(1265)
Quality of life (QOL) endpoints in advanced stage prostate
cancer: a randomized, double blind study comparing
flutamide to placebo in orchiectomized stage D 2 prostate
GU
10/1/90
9/15/94
patients (pts). CM Moinpour, M Savage, L Lovato, A Troxel,
R Skeel, MA Eisenberger, ED Crawford, FL Meyskens Jr.
American Society of Clinical Oncology 16:53a (#183), 1997.
*9217
(1335)
Utility of the enrollment period in the Prostate Cancer
Prevention Trial (PCPT). PJ Goodman, L Lovato, A
Ryan, J Crowley, C Moinpour, I Thompson. Controlled
Clinical Trials 18(3S)(#19):52S, June 1997.
GU
10/13/93
12/6/96
*9217
(1336)
Data operations management with clinical datafax: The
prostate cancer prevention trial (PCPT) experience.
AM Ryan, L Emel, P Goodman. Controlled Clinical Trials
18(3S):156S (#P74), June 1997.
GU
10/13/93
12/6/96
None
(1290)
Aneusomy detection by fluorescence in situ hybridization
(FISH) using bladder washings: Correlation with cytology,
cytogenetics and clinical features predicts recurrence and
defines test limitations. ML Slovak, F Zhang, T Wilson, MH
Kawachi, DA Arber, TS McConnell, SM Dobin. Proc
Seventh International Workshop on Chromosomes in Solid
Tumors #20, 1997.
GU
None
(1269)
Comparison of fluorescence in-situ hybridization (FISH)
GU
and bladder tumor antigen test (BTA®) in bladder cancer:
A pilot study. TS McConnell, AY Smith, LA Haines Jr, T
Cushing, ED Crawford, M Slovak. Proc Seventh International
Workshop on Chromosomes in Solid Tumors #A22, 1997.
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8216
(1135)
Local toxicity patterns associated with intravesical
GU
bacillus calmette-guérin: A Southwest Oncology Group
study. DL Berry, BA Blumenstein, DL Magyary, DL Lamm,
ED Crawford. International Journal of Urology 3:98-100, 1996.
12/1/82
2/15/90
8704
(631)
Combination transurethral resection, systemic
chemotherapy, and pelvic radiotherapy for invasive
(T2-T4) bladder cancer unsuitable for cystectomy:
A phase I/II Southwestern Oncology Group study.
AB Einstein Jr, M Wolf, KR Halliday, GJ Miller,
M Hafermann, BA Lowe, FJ Meyers, JT Leimert,
ED Crawford. Urology 47(5):652-657, 1996.
GU
9/1/87
8/15/91
8719
(1094)
Phase II evaluation of ifosfamide/mesna in metastatic
prostate cancer. A Southwest Oncology Group study.
SK Williamson, MK Wolf, MA Eisenberger, MA O'Rourke,
W Brannan, ED Crawford. American Journal of Clinical
Oncology (CCT) 19(4):368-370, 1996.
GU
11/1/88
5/15/93
8795
(1139)
Prognostic significance of DNA ploidy in Ta/T1 bladder
cancer: A Southwest Oncology Group study.
RW deVere White, AD Deitch, H Tesluk, B Blumenstein,
BA Lowe, AI Sagalowsky, JA Smith Jr, PF Schellhammer,
TH Stanisic, HB Grossman, E Messing, JD Crissman,
ED Crawford. Urologic Oncology 2:27-34, 1996.
GU
12/1/88
5/15/92
GU
6/15/92
11/1/93
8955
Treatment of stage D2 hormone refractory carcinoma of the
(1158)
prostate with 5-fluorouracil and roferon-A ® : A Southwest
Oncology Group study. ME Marshall, M Wolf, M O'Rourke,
TC Barnett, ED Crawford. Cancer Biotherapy &
Radiopharmaceuticals 11(2):119-123, 1996.
9122
(1184)
A phase II trial of interferon- a and 5-fluorouracil in patients
with advanced renal cell carcinoma. A Southwest Oncology
Group study. L Elias, BA Blumenstein, J Kish, RC Flanigan,
JL Wade, BA Lowe, JW Goodwin, ED Crawford.
Cancer 78:1085-1088, 1996.
GU
6/1/92
10/15/93
9217
(1174)
Chemoprevention of prostate cancer with finasteride.
I Thompson, P Feigl, C Coltman. Principles & Practice
of Oncology 10(3):1-18, 1996.
GU
10/13/93
Open
9217
(1173)
Screening for prostate cancer: Opportunities for
prevention. IM Thompson, CA Coltman. Seminars
in Urologic Oncology 14(2) (Suppl 2):4-11, 1996.
GU
10/13/93
Open
None
(1201)
Southwest Oncology Group studies in hormone-refractory
GU
prostate cancer. MHA Hussain, B Blumenstein, M Eisenberger,
ED Crawford. Seminars in Oncology 23(6) (Suppl 14):24-27, 1996.
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*9217
(1172)
Prostate cancer prevention trial. BH Zoltick. Presented
at the AUAA Annual Assembly, Orlando, Florida,
May 3-7, 1996.
GU
10/13/93
Open
*9217
(1165)
The prostate cancer prevention trial: Efforts to increase
the recruitment of minority participants. CM Moinpour.
Poster presentation at the Conference on the Recruitment
and Retention of Minority Participants in Clinical Cancer
Research , Washington, DC, 1/26-27/1996.
GU
10/13/93
Open
9217
(1202)
The prostate cancer prevention trial. A Ryan. Prevention/
Early Detection SIG Newsletter 6(3):1, 1996.
GU
10/13/93
Open
9230
(1149)
Phase II trial of recombinant human interleukin-4
(rhuIL-4) in patients with disseminated renal cell
adenocarcinoma: A Southwest Oncology Group
(SWOG) study. RP Whitehead, B Blumenstein,
RC Flanigan, GR Weiss, DJ Culkin, SI Bearman,
S Dakhil, ED Crawford. American Society of Clinical
Oncology 15:259 (#672), 1996.
GU
6/1/93
5/1/95
*9235
(1150)
Phase II trial of casodex in advanced prostate cancer
(CaP) patients who failed conventional hormonal
manipulation: A Southwest Oncology Group (SWOG)
study (SWOG 9235). O Kucuk, B Blumenstein,
C Moinpour, D Lew, D Coleman, M Eisenberger,
D Crawford. American Society of Clinical Oncology
15:245 (#618), 1996.
GU
12/15/93
6/1/94
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8494/8894
(1157)
Overview analysis issues using combined androgen
deprivation overview analysis as an example.
B Blumenstein. Urologic Oncology 1:95-100, 1995.
GU
8708
(878)
Phase II trial of CHIP for the treatment of advanced,
hormonally refractory carcinoma of the prostate: A
Southwest Oncology Group study. ME Marshall, MK
Wolf, ED Crawford, GR Weiss, F Ahmann, FJ Meyers,
B Blumenstein, M Eisenberger, AB Einstein. American
Journal of Clinical Oncology 18(5):400-402, 1995.
GU
Dev Ther
4/1/89
9/1/90
8719
(1093)
Phase II evaluation of didemnin B in hormonally
refractory metastatic prostate cancer. A Southwest
Oncology Group study. SK Williamson, MK Wolf,
MA Eisenberger, M O'Rourke, W Brannon, ED Crawford.
Investigational New Drugs 13:167-170, 1995.
GU
11/1/88
5/15/93
8795
(1102)
Randomized Intergroup comparison of bacillus calmetteguérin immunotherapy and mitomycin C chemotherapy
prophylaxis in superficial transitional cell carcinoma of the
bladder. A Southwest Oncology Group study. DL Lamm,
BA Blumenstein, ED Crawford, JD Crissman, BA Lowe,
JA Smith Jr, MF Sarosdy, PF Schellhammer, AI Sagalowsky,
EM Messing, P Loehrer, HB Grossman.
Urologic Oncology 1:119-126, 1995.
GU
12/1/88
5/15/92
8824
(904)
A phase II trial of continuous-infusion recombinant
interleukin-2 in patients with advanced renal cell
carcinoma: A Southwest Oncology Group study.
RP Whitehead, MK Wolf, DL Solanki, GP Hemstreet III,
P Benedetto, SP Richman, RC Flanigan, ED Crawford.
Journal of Immunotherapy 18(2):104-114, 1995.
GU
5/1/89
8/15/91
9012
(438)
Evaluation of low dose alpha-interferon (Roferon-A® ) in
patients with advanced renal cell carcinoma: A Southwest
Oncology Group study. ME Marshall, M Wolf, ED Crawford,
IM Thompson, R Flanigan, SP Balcerzak, FJ Meyers.
Cancer Biotherapy 10(3):205-209, 1995.
GU
5/1/91
5/1/92
9217
(1117)
Chemoprevention of prostate cancer. IM Thompson,
CA Coltman, OW Brawley, A Ryan. Seminars in
Urology 13(2):122-129, 1995.
GU
10/13/93
Open
9217
(1110)
Chemoprevention of prostate cancer with finasteride.
I Thompson, P Feigl, C Coltman. In: Important Advances in
Oncology VT DeVita, S Hellman, SA Rosenberg, eds,
J.B. Lippincott Company pp. 57-76, 1995.
GU
10/13/93
Open
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9217
(1027)
Design of the prostate cancer prevention trial (PCPT).
P Feigl, B Blumenstein, I Thompson, J Crowley, M Wolf,
BS Kramer, CA Coltman Jr, OW Brawley, LG Ford.
Controlled Clinical Trials 16:150-163, 1995.
GU
Multiple
Studies
(1181)
Recent American multicenter trials for patients with
metastatic prostate cancer. E DeAntoni, ED Crawford.
Urologe (A) 34:382-388, 1995.
GU
Multiple
Studies
(1049)
Southwest Oncology Group strategies in prostatic
carcinoma. ED Crawford, M Hussain, EP DeAntoni,
IM Thompson, MA Eisenberger, B Blumenstein,
CA Coltman Jr. Seminars in Surgical Oncology
11:60-64, 1995.
GU
None
(1121)
Immunotherapy of superficial bladder carcinoma.
MF Sarosdy. AUA Update Series, Lesson 29,
14:234-240, 1995.
GU
10/13/93
Open
ABSTRACTS PUBLISHED/PRESENTED
*8894
(INT-0105)
(1088)
The prognostic significance of prostate specific antigen
(PSA) in stage D2 prostate cancer (PC) interim
evaluation of intergroup study 0105. M Eisenberger,
ED Crawford, D McLeod, M Hussain, P Loehrer, B
Blumenstein. ASCO 14:235 (#613), 1995.
GU
12/15/89
9/15/94
*9217
(1115)
Chemoprevention of prostate cancer with finasteride:
An Intergroup trial. CA Coltman Jr, J Unger, IM Thompson.
Cancer Investigation 13 (Suppl 1):43 (#36), 1995.
GU
10/13/93
Open
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8494
(INT-0036)
(1090)
Prognostic factors in stage D2 prostate cancer; important
GU
implications for future trials: Results of a cooperative
intergroup study (INT.0036). MA Eisenberger, ED Crawford,
M Wolf, B Blumenstein, DG McLeod, R Benson, FA Dorr,
M Benson, JT Spaulding. Seminars in Oncology 21(5):613-619,
1994.
3/18/85
7/1/87
8509
(442)
Phase II trial of menogaril in metastatic adenocarcinoma
GU
of the prostate: A Southwest Oncology Group study.
Dev Ther
SA Taylor, B Blumenstein, RL Stephens, ED Crawford,
B Pistone, JB Hill. Investigational New Drugs 12:67-70, 1994.
09/27/85
09/01/88
8509/8708
8719/8722
8955
(951)
Effects of continued androgen-deprivation therapy and
other prognostic factors on response and survival in
phase II chemotherapy trials for hormone-refractory
prostate cancer: A Southwest Oncology Group report.
M Hussain, M Wolf, E Marshall, ED Crawford,
M Eisenberger. Journal of Clinical Oncology
12(9):1868-1875, 1994.
GU
8722
(880)
Phase II trial of amonafide for the treatment of advanced,
hormonally refractory carcinoma of the prostate. A
Southwest Oncology Group study. ME Marshall,
B Blumenstein, ED Crawford, IM Thompson, JB Craig,
M Eisenberger, F Ahmann. American Journal of
Clinical Oncology 17(6):514-515, 1994.
GU
Dev Ther
11/1/87
4/1/89
8794
(INT-0086)
(1020)
An opportunity to determine optimal treatment
of pT3 prostate cancer: The window may be closing.
IM Thompson, JC Paradelo, ED Crawford, CA Coltman,
B Blumenstein. Urology 44(6):804-811, 1994.
GU
8/15/88
Open
8926
(906)
Evaluation of low dose continuous infusion 5-fluorouracil
in patients with advanced and recurrent renal cell carcinoma:
A Southwest Oncology Group study. JA Kish, M Wolf, ED
Crawford, JT Leimert, A Bueschen, JR Neefe, RC Flanigan.
Cancer 74(3):916-919, 1994.
GU
10/1/89
2/15/91
8929
(995)
Phase II evaluation of merbarone in renal cell carcinoma.
RC Flanigan, JH Saiers, M Wolf, EH Kraut, AY Smith, B
Blumenstein, ED Crawford. Investigational New Drugs
12(2):147-149, 1994.
GU
4/15/90
8/1/92
9217
(1068)
Prostate cancer prevention: Risk reduction through
life-style, diet, and chemoprevention. KE Greco, L
Kulawiak. Oncology Nursing Forum 21(9):1504-1511, 1994.
GU
10/13/93
Open
9217
(1070)
The prostate cancer prevention trial. A low-risk, highaccrual study. J O'Connor. Oncology Issues
9(5):20-24, 1994.
GU
10/13/93
Open
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*8894
(INT-0105)
(990)
Treatment of histologically confirmed D2 prostate
cancer - a comparison of bilateral orchiectomy with
or without flutamide. ED Crawford, MA Eisenberger,
B Blumenstein, DG McLeod, DJ Culkin, AJ Bueschen,
IM Thompson, BA Lowe. Urology 151(5):238A (#44),
1994.
GU
1215/89
Open
*9217
(1009)
Chemoprevention of prostate cancer with finasteride,
an Intergroup trial. CA Coltman Jr, J Unger, IM Thompson.
Annals of Oncology 5 (Suppl 8):65 (#P324), 1994.
GU
8/15/88
Open
Corrigendum, Annals of Oncology 6(6):621, 1995.
*Presented.
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8231
(511)
Alternating combination chemotherapy in patients with
extragonadal germ cell tumors: A Southwest Oncology
Group study. RM Bukowski, M Wolf, BG Kulander, J
Montie, ED Crawford, B Blumenstein. Cancer 71(8):
2631-2638, 1993.
GU
04/25/83
10/15/86
8302
(516)
Doxorubicin, mitomycin-C and 5-fluorouracil in the
treatment of hormone refractory adenocarcinoma
of the prostate. A Southwest Oncology Group study.
B Blumenstein, ED Crawford, JH Saiers, RL Stephens,
SE Rivkin, CA Coltman, Jr. Journal of Urology 150:411413, 1993.
GU
07/26/83
08/17/84
8325
(774)
Phase II trial of mitotane and cisplatin
in patients with adrenal carcinoma: A Southwest
Oncology Group study. RM Bukowski, M Wolf, HS
Levine, ED Crawford, RL Stephens, E Gaynor, WG
Harker. JCO 11:161-165, 1993.
GU
Dev Ther
01/19/84
07/01/89
8421
(870)
Cyclophosphamide, methotrexate and 5-fluorouracil in
the treatment of metastatic prostate cancer: A
Southwest Oncology Group study. AJ Wozniak,
BA Blumenstein, ED Crawford, M Boileau, SE Rivkin,
WS Fletcher. Cancer 71(12):3975-3978, 1993.
GU
01/11/85
09/27/85
8494
(INT-0036)
(970)
The use of flutamide in hormone-refractory metastatic
prostate cancer. DG McLeod, RC Benson, Jr,
MA Eisenberger, ED Crawford, BA Blumenstein,
D Spicer, JT Spaulding. Cancer Supplement 72(12):
3870-3873, 1993.
GU
03/18/85
07/01/87
8494/8894
(INT-0036)
(INT-0105)
(969)
Some statistical considerations for the interpretation
of trials of combined androgen therapy. BA Blumenstein.
Cancer Supplement 72(12):3834-3840, 1993.
GU
8789
(883)
Randomized trial of etoposide and cisplatin
versus etoposide and carboplatin in patients with
good risk germ cell tumors: A multi-institutional study.
DF Bajorin, MF Sarosdy, DG Pfister, M Mazumdar,
RJ Motzer, HI Scher, NL Geller, WR Fair, H Herr, P
Sogani, J Sheinfeld, P Russo, V Vlamis, R Carey, NJ
Vogelzang, ED Crawford, GJ Bosi. JCO 11(4):598606, 1993.
GU
08/15/88
12/15/90
8802
(884)
Phase II trial of echinomycin for the treatment of
advanced renal cell carcinoma: A Southwest Oncology
Group study. ME Marshall, MK Wolf, ED Crawford,
S Taylor, B Blumenstein, R Flanigan, FJ Meyers,
HE Hynes, B Barlogie, M Eisenberger. IND 11:207-209,
1993.
GU
Dev Ther
01/15/89
07/15/90
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
9217
(937)
Chemoprevention of prostate cancer with finasteride.
I Thompson, P Feigl, C Coltman. Cancer Prevention
Dec:1-15, 1993.
GU
None
(802)
How PSA testing has improved and complicated
therapeutic decision-making. ED Crawford, IM
Thompson, PT Scardino. Oncology 13:15-17, 1993.
GU
ABSTRACTS PUBLISHED/PRESENTED
8221
(671)
Pre-operative irradiation plus radical cystectomy
versus surgery alone for invasive bladder cancer:
Final results of a randomized, prospective Southwest Oncology Group study. JA Smith, Jr, ED
Crawford, BL Blumenstein, J Paradelo, BR
Herschman. American Urological Association,
Inc. 149:316A (#415), 1993.
GU
10/29/82
11/15/89
8795
(676)
A randomized comparison of bacillus calmetteguerin and mitomycin C prophylaxis in stage TA
and T1 transitional cell carcinoma of the bladder.
DL Lamm, ED Crawford, B Blumenstein, J Crissman,
R deVere White, M Wolf, B Lowe, M Sarosdy, P
Schellhammer, A Sagalowsky, J Smith, HB
Grossman, R Flanigan, T Moon, C Brendler, C Coltman,
Jr. American Urological Association, Inc 149:4 (#275),
1993.
GU
12/01/88
05/15/92
8824
(678)
A phase II trial of continuous infusion recombinant
interleukin-2 (rIL-2) in patients with advanced renal
cell carcinoma. A Southwest Oncology Group study.
RP Whitehead, MK Wolf, DL Solanki, P Benedetto, RC
Flanigan, ED Crawford. ASCO 12:253 (#799), 1993.
GU
05/01/89
08/15/91
8956
(681)
Evaluation of cisplatin + 5 fluorouracil infusion for
advanced/metastatic transitional cell carcinoma of the
bladder (AMTCCB). A Southwest Oncology Group
study. JA Kish, M Wolf, S Taylor, A Einstein, ED
Crawford. AACR 34:203 (#1214), 1993.
GU
10/01/90
05/15/92
8997
(INT)
(1038)
Phase III study of cisplatin (P) plus etoposide (VP16) with
either bleomycin (B) or ifosfamide (I) in advanced stage
germ cell tumors (GCT): An Intergroup trial. PJ Loehrer,
LH Einhorn, P Elson, SD Williams, K Havlin, NJ Vogelzang,
ED Crawford, DL Trump. ASCO 12:261 (#831), 1993.
GU
10/1/89
4/9/92
Multiple
Studies
(685)
Effects of prior hormone therapy on response and
survival in Southwest Oncology Group phase II
chemotherapy trials. M Hussain, M Wolf, E Marshall,
ED Crawford, M Eisenberger. ASCO 12:243 (#760),
1993.
GU
None
(898)
In the era of prostate specific antigen (PSA), is
prostate acid phosphatase (PAP) necessary for
staging prostate cancer? A Southwest Oncology
Group study. IM Thompson, EJ Zeidman, ED
Crawford, AI Sagalowski, PF Schellhammer, RW
deVere White, HB Grossman, E Klein, BA Lowe,
AJ Bueschen, PT Scardino, RC Flanigan. American
Urological Association, Inc. 149:308A (#360), 1993.
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8104
(430)
Treatment of stages B3 and C seminoma with
chemotherapy followed by irradiation therapy.
A Southwest Oncology Group study. ED Crawford,
P Goodman, WL Nabors, RL Stephens, K Khan,
LM Pass, AY Smith. Urology 39(5):457-460, 1992.
GU
12/21/81
08/01/86
8308
(436)
Combination cisplatin and dichloromethotrexate in
patients with advanced bladder cancer, phase II. A
Southwest Oncology Group study. FJ Meyers, B
Blumenstein, ED Crawford, HE Hynes, JE Montie, SA
Taylor, HB Grossman, RB Natale. Journal of Urology
148:52-54, 1992.
GU
Dev Ther
10/18/83
03/14/86
8517
(444)
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: A Southwest Oncology Group
study. CK Osborne, BA Blumenstein, ED Crawford,
GR Weiss, RM Bukowski, NR Larrimer. EJC 28:477478, 1992.
GU
12/10/86
08/01/87
8594
(525)
A randomized comparison of cisplatin alone or in
combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial
carcinoma: A Cooperative Group study. PJ Loehrer,
Sr, LH Einhorn, PJ Elson, ED Crawford, P Kuebler,
I Tannock, D Raghaven, R Stuart-Harris, MF Sarosdy,
BA Lowe, B Blumenstein, D Trump. JCO 10(7):10661073, 1992.
GU
10/84
05/15/89
8728
(458)
Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney: A Southwest Oncology Group
study. SA Taylor, P Goodman, ED Crawford, WJ Stuckey,
RL Stephens, ER Gaynor. IND 10:55-56, 1992.
GU
Dev Ther
01/01/88
02/01/89
8945
(547)
Phase II evaluation of piroxantrone in renal cell carcinoma:
A Southwest Oncology Group study. A Allen, M Wolf,
ED Crawford, MP Davis, RB Natale, ML Barnett.
IND 10:129-132, 1992.
GU
Dev Ther
09/01/90
05/01/91
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*8494
(822)
A comparison of leuprolide and flutamide vs
leuprolide alone in newly diagnosed stage D2
prostate cancer: Prognostic and therapeutic
importance of the minimal disease subset. M
Eisenberger, ED Crawford, D McLeod, R
Benson, A Dorr, B Blumenstein. ASCO 11:201
(#619), 1992.
GU
Dev Ther
03/18/85
07/01/87
8504/8617
8716/8802
8728/8707
(823)
Prognostic factors in patients with advanced renal
cell carcinoma (RCC): The Southwest Oncology Group
experience. ME Marshall, P Goodman, P Kuebler,
R Flanigan, ED Crawford. ASCO 11:206 (#638), 1992.
GU
*8507
(824)
Maintenance BCG immunotherapy of superficial
bladder cancer: A randomized prospective
Southwest Oncology Group study. DL Lamm, ED
Crawford, B Blumenstein, MF Sarosdy, HB
Grossman, RD Bohl, B Lowe, TD Moon, WL Weems,
TM Beck, J Montie, JA Smith, J Crissman, CA
Coltman, Jr. ASCO 11:203 (#627), 1992.
GU
12/20/85
12/15/88
8794
(INT-0086)
(837)
Adjuvant radiotherapy following radical prostatectomy
for pathologic stage C adenocarcinoma of the prostate:
Initial evaluation of toxicity. I Thompson, ED Crawford,
G Miller, J Paradelo, B Blumenstein, M Wolf, C Moinpour,
K Hayden. ASCO 11:212 (#663), 1992.
GU
08/15/88
Open
8802
(838)
Phase II trial of echinomycin in advanced renal cell
carcinoma: A Southwest Oncology Group study.
ME Marshall, S Taylor, M Wolf, R Flanigan, B
Blumenstein, ED Crawford. ASCO 11:206 (#637),
1992.
GU
Dev Ther
01/15/89
07/15/90
8956
(844)
Significant response rate to cisplatin + 5-fluorouracil
in advanced/recurrent bladder cancer. A preliminary
report. A Southwest Oncology Group study. JA Kish,
PF Schellhammer, M Wolf, AB Einstein, Jr. ASCO
11:219 (#692), 1992.
GU
10/01/90
Open
None
(849)
Comparison of flow cytometry in quantitative
florescence image analysis of superficial bladder
cancer. BA Blumenstein, RW deVere White, GP
Hemstreet. American Urological Association, Inc.
#848, 1992.
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7916
(427)
Gallium Nitrate in advanced bladder carcinoma.
A Southwest Oncology Group study. ED Crawford,
JH Saiers, LH Baker, JH Costanzi, R Bukowski.
Urology 38(4):355-357, 1991.
GU
07/20/79
01/19/84
7990
(484)
Staging relationships and outcome in early stage
testicular cancer: A report from the testicular
cancer intergroup study. DG McLeod, RB Weiss,
DM Stablein, FM Muggia, DF Paulson, JH Ellis,
JT Spaulding, JP Donohue. Journal of Urology
145:1178-1183, 1991.
GU
06/22/79
03/22/85
8110
(387)
A randomized trial of cisplatin, vinblastine,
and bleomycin vs vinblastine, cisplatin, and
etoposide in the treatment of advanced germ cell
tumors of the testis: A Southwest Oncology Group
study. AJ Wozniak, MK Samson, NT Shah, ED
Crawford, CD Ford, SJ Altman, RL Stephens, RB Natale,
BA Bouroncle, BA Blumenstein, GD Cummings.
JCO 9(1):70-76, 1991.
GU
04/26/82
08/01/86
8216/38
(433)
A randomized clinical trial of intravesical doxorubicin
immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. A Southwest
Oncology Group study. DL Lamm, BA Blumenstein,
ED Crawford, JE Montie, P Scardino, HB Grossman,
TH Stanisic, JA Smith, J Sullivan, MF Sarosdy, JD
Crissman, CA Coltman, Jr. NEJM 325:1205-1209, 1991.
GU
12/01/82
02/15/90
8716
(455)
Phase II evaluation of amonafide in renal cell
carcinoma: A Southwest Oncology Group study.
CS Higano, P Goodman, JB Craig, JA Kish, SE
Rivkin, B Blumenstein, ED Crawford. IND 9:361-363,
1991.
GU
11/01/87
11/15/88
8788
(493)
Randomized study of cisplatin dose intensity in poor-risk
germ cell tumors: A Southeastern Cancer Study Group
and Southwest Oncology Group protocol. CR Nichols,
SD Williams, PJ Loehrer, FA Greco, ED Crawford, J
Weetlaufer, ME Miller, A Bartolucci, L Schacter, LH
Einhorn. JCO 9(7):1163-1172, 1991.
GU
01/15/88
09/15/89
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*7916
(559)
*8789
(504)
8926
(415)
Treatment of advanced transitional cell carcinoma (TCC)
of the bladder with constant infusion Gallium Nitrate.
PA Seligman, ED Crawford. ASCO 10:168 (#534), 1991.
A randomized trial of etoposide + carboplatin
(EC) vs. etoposide + cisplatin (EP) in patients (PTS)
with metastatic germ cell tumors (GCT). DF Bajorin,
MF Sarosdy, GJ Bosi, S Welsen, G Heller.
ASCO 10:168 (535), 1991.
Efficacy of low dose continuous infusion 5-fluorouracil
(LDCI-5FU) in recurrent/metastatic (r/m) renal cell
carcinoma (RCC). A Southwest Oncology Group study.
JA Kish, JR Neefe, R Flanigan. AACR 32:186 (#1107),
1991.
GU
07/20/79
01/19/84
GU
08/15/88
12/15/90
GU
10/01/89
02/15/91
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8216/38
Fatal sepsis following intravesical bacillus calmetteguerin administrations for bladder cancer. WH Rawls,
DL Lamm, BA Lowe, ED Crawford, MF Sarosdy, JE
Montie, HB Grossman, PT Scardino. Urology 144:13281330, 1990.
GU
12/01/82
02/15/90
8219
(305)
Combined versus sequential chemo-endocrine therapy
in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. CK Osborne, B
Blumenstein, ED Crawford, CA Coltman, Jr, AY Smith, BW
Lambuth, RA Chapman. JCO 8(10):1675-1682, 1990.
Combined androgen blockade: Leuprolide and
flutamide versus leuprolide and placebo. ED
Crawford, P Goodman, B Blumenstein.
Seminars in Urology 8(3):154-158, 1990.
GU
08/11/84
10/01/86
GU
03/18/85
07/01/87
8504
(329)
Evaluation of menogaril in renal cell carcinoma. A
Southwest Oncology Group phase II study.
RL Stephens, P Goodman, ED Crawford, CF Spicer,
BA Lowe, FR Ahmann, R Chapman, RB Natale.
IND 8:S69-S71, 1990.
GU
09/27/85
01/15/87
8519
(331)
Methylglyoxal bis-guanylhydrazone in advanced
bladder cancer. DD Von Hoff, BA Blumenstein, TW
Pollock, ED Crawford, JK Weick, JT Guy, M
Eisenberger, WS Fletcher, RB Natale. EJC
26(7):848-849, 1990.
GU
01/86
05/15/89
8617
(341)
Phase II trial of high dose intermittent interleukin-2
in metastatic renal cell carcinoma: A Southwest
Oncology Group study. RM Bukowski, P Goodman,
ED Crawford, JS Sergi, BG Redman, RP Whitehead.
JNCI 82(2):143-146, 1990.
GU
03/15/87
08/15/88
8707
(343)
Phase II study of continuous infusion recombinant
gamma interferon in renal carcinoma: A Southwest
Oncology Group study. JP Kuebler, PJ Goodman,
TD Brown, ED Crawford, CL Reitz, WA Knight, III,
JA Kish. IND 8:307-309, 1990.
GU
06/01/87
01/01/88
None
Editorial on the importance of clinical trials. ED
Crawford. Journal of Urology 143(4):787, 1990.
GU
None
Quality of life assessment in Southwest Oncology
Group trials. CM Moinpour, K Hayden, IM Thompson,
P Feigl, B Metch. Oncology 4(5):79-89, 1990.
8494
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
8216/38
(353)
Effect of colony-forming unit dose of connaught
BCG on outcome to immunotherapy in superficial
bladder cancer: A Southwest Oncology Group study.
B Blumenstein, D Lamm, MAS Jewett, G Humphries,
L Boux, J Montie, P Scardino, H Grossman, ED
Crawford, JA Smith, T Stanisic. Journal of Urology
143(4):340A, (#608), 1990.
GU
12/01/82
12/20/85
*8325
(357)
Cisplatin (CDDP) and mitotane in metastatic adrenal
carcinoma: A Southwest Oncology Group study.
RM Bukowski, J Montie, ED Crawford, M Wolf.
ASCO 9:136 (#527), 1990.
GU
01/19/84
07/01/89
*8494
(361)
Evaluation of "complete androgen blockade" (CAB) with
flutamide (F) added to leuprolide (L) after progression
on leuprolide (L) alone: Results of INT-0036 study in
stage D2 cancer of the prostate (CP). D McLeod,
B Blumenstein, M Eisenberger, ED Crawford, D Spicer,
J Spaulding, A Dorr, R Benson. ASCO 9:136 (#526),
1990.
GU
03/18/85
07/01/87
*8594
(363)
Advanced bladder cancer: A prospective intergroup
trial comparing single agent cisplatin (CDDP) vs. M-VAC
combination therapy (INT-0078). PJ Loehrer, P Elson,
JP Kuebler, ED Crawford, I Tannock, D Raghavan,
R Stuart-Harris, D Trump, LH Einhorn. ASCO 9:132 (#511),
1990.
*8788
(373)
Phase III study of cisplatin dose intensity in advanced
germ cell tumors (GCT): A Southeastern and Southwest
Oncology Group protocol. L Einhorn, S Williams, P Loehrer,
ED Crawford, J Wettlaufer, A Bartolucci, L Schacter.
ASCO 9:132 (#510), 1990.
GU
Multiple
Studies
(379)
Evaluation of chemotherapy (CT) in endocrine resistant
prostate cancer (ERPC) patients (PTS) with measurable
(MD) versus bone disease only (BDO): The Southwest
Oncology Experience. M Eisenberger, B Blumenstein,
P Scardino, ED Crawford. ASCO 9:153 (#596), 1990.
GU
GU
04/15/86
01/15/88
05/15/89
09/15/89
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8026
Cis-diamminedichloroplatinum in the treatment of
advanced epidermoid carcinoma of the penis: A
Southwest Oncology Group study. RG Gagliano,
BA Blumenstein, ED Crawford, RL Stephens,
CA Coltman, Jr, JJ Costanzi. J Urol 141:66-67,
1989.
GU
09/19/80
08/01/86
8494
A controlled trial of leuprolide with and without
flutamide in prostatic carcinoma. ED Crawford,
MA Eisenberger, DG McLeod, JT Spaulding,
R Benson, FA Dorr, BA Blumenstein, MA Davis,
PJ Goodman. N Engl J Med 321:419-424, 1989.
GU
03/18/85
07/01/87
ABSTRACTS PUBLISHED/PRESENTED
8110
A randomized trial of cisplatin (P), vinblastine (VLB)
plus either bleomycin (PVB), or VP-16 (VPV) in
patients with advanced testicular cancer.
MK Samson, ED Crawford, S Altman, R Natale,
NT Shah, B Blumenstein. ASCO 8:134 (#522),
1989.
GU
04/26/82
08/01/86
*8216/38
BCG versus adriamycin intravesical therapy for
in situ and papillary transitional cell carcinoma of
the urinary bladder: A Southwest Oncology Group
study. DL Lamm, J Crissman, ED Crawford,
B Blumenstein, JE Montie, PT Scardino,
HB Grossman, T Stanisic, JA Smith, M Sarosdy.
ASCO 8:130 (#504), 1989.
GU
12/01/82
12/20/85
*8494
Significance of pre-treatment stratification by
extent of disease (ED) in stage D2 prostate
cancer (PC) patients treated with leuprolide +
flutamide (LF) or leuprolide + placebo (LP).
M Eisenberger, ED Crawford, B Blumenstein,
R Benson, D McLeod, A Dorr, J Spaulding.
ASCO 8:132 (#515), 1989.
GU
03/18/85
07/01/87
8617
Phase II evaluation of recombinant interleukin-2
(rIL-2) in metastatic renal cell carcinoma (RCC):
SWOG-8617. RM Bukowski, P Goodman,
ED Crawford, JS Sergi, L Baker, J Neidhart.
ASCO 8:143 (#556), 1989.
GU
03/15/87
08/15/88
8707
Continuous infusion recombinant gamma interferon
(CIr-GIFN) for renal cell carcinoma (RCC). J Kuebler,
T Brown, P Goodman, D Crawford, C Reitz, W Knight,
J Kish. ASCO 8:140 (#544), 1989.
GU
06/01/87
01/01/88
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
8716
A phase II trial of amonafide in advanced renal cell
carcinoma. CS Higano, J Craig, P Goodman,
B Blumenstein, J Wettlaufer, ED Crawford.
ASCO 8:147 (#574), 1989.
GU
11/01/87
11/15/88
8722
Phase II trial of amonafide in advanced prostate
cancer: A Southwest Oncology Group study.
J Craig, E Crawford. ASCO 8:147 (#573), 1989.
GU
11/01/87
04/01/89
8728
Phase II trial of didemnin B (Did-B) in advanced
adenocarcinoma of the kidney. A Southwest
Oncology Group study. S Taylor, B Pistone,
RL Stephens, ED Crawford. ASCO 8:145
(#564), 1989.
GU
01/01/88
02/01/89
Charles A. Coltman, Jr., M.D.
198-24-5536
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988
_________________________________________________________________________________________________________
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7990
The clinical significance of unconventional
orchiectomy approaches in testicular cancer:
A report from the testicular cancer intergroup
study. JK Giguere, DM Stablein, JT Spaulding,
DG McLeod, DF Paulson, RB Weiss. J Urol
139:1225-1228, 1988.
GU
06/22/79
03/22/85
7990
Toxicity comparison between two chemotherapy
regimens as adjuvant or salvage treatment in
nonseminomatous testicular cancer. RB Weiss,
DM Stablein, FM Muggia, LH Einhorn, RB Golbey,
WD DeWys. Cancer 62(1):18-23, 1988.
GU
06/22/79
03/22/85
8602
A phase II clinical trial of interleukin-2 and lymphokine
activated killer cells in metastatic renal cancer.
RI Fisher, CA Coltman, Jr, JH Doroshow, AA Rayner,
MJ Hawkins, JW Mier, P Wiernik. Annals Internal
Medicine 108:518-523, 1988.
GU
04/07/86
ABSTRACTS PUBLISHED/PRESENTED
8231
Phase II trial of alternating combination chemotherapy
in patients with extragonadal germ cell tumors: A
Southwest Oncology Group study (SWOG 8231).
RM Bukowski, J Montie, D Crawford. ASCO 7:133
(#516), 1988.
GU
04/25/83
10/15/86
*8494
Treatment of newly diagnosed stage D2 prostate
cancer with leuprolide and flutamide or leuprolide
alone, phase III, Intergroup study 0036. E Crawford,
D McLeod, A Dorr, J Spaulding, R Benson, M
Eisenberger, B Blumenstein. ASCO 7:119 (#460),
1988.
GU
03/18/88
07/01/87
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987
________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7990
Immediate adjuvant chemotherapy versus observation
with treatment at relapse in pathological stage II
testicular cancer. SD Williams, DM Stablein, LH Einhorn,
FM Muggia, RB Weiss, JP Donohue, DF Paulson,
KW Brunner, EM Jacobs, JT Spaulding, W DeWys,
ED Crawford. NEJM 317:1433-1438, 1987.
GU
06/22/79
03/22/85
7990
Early stage testis cancer: The testicular cancer
intergroup studies. Adjuvant chemotherapy of
testicular cancer. SD Williams, D Stablein, F Muggia,
LH Einhorn, R Hahn, JP Donohue, K Brunner,
W DeWys, D Crawford, S Spaulding, RB Weiss,
R Golbey, EM Jacobs. In Adjuvant Therapy of
Cancer V. Sydney E. Salmon (Ed). New York, Grune &
Stratton, pp. 587-592, 1987.
GU
06/22/79
03/22/85
8101
Teniposide in metastatic renal and bladder cancer: A
Southwest Oncology Group study. N Oishi, J Berenberg,
BA Blumenstein, K Johnson, SE Rivkin, RM Bukowski,
RM O'Bryan, RL Stephens, J Quagliana, JH Saiers,
ED Crawford. Cancer Treat Rep 71(12):1307-1308, 1987.
GU
07/31/81
01/11/85
8217
Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: A Southwest Oncology Group
study. JH Saiers, B Blumenstein, M Slavik, JJ Costanzi,
ED Crawford. Cancer Treat Rep 71(12):1305-1306, 1987.
GU
08/11/82
03/22/85
8221
Preoperative radiation therapy in the treatment of
bladder cancer. ED Crawford, S Das, JA Smith, Jr.
Urol Clinics of North Am 14(4):781-787, 1987.
GU
10/29/82
11/15/89
8316
Evaluation of fludarabine phosphate in renal cell
carcinoma: A Southwest Oncology Group study.
L Balducci, B Blumenstein, DD Von Hoff, M Davis,
HE Hynes, RM Bukowski, ED Crawford. Cancer
Treat Rep 71(5):543-544, 1987.
GU
04/20/84
03/22/85
________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
8110
A randomized clinical trial comparing cisplatin, vinblastine
plus either bleomycin (PVB) or VP-16 (VPV) and surgical
resection of residual disease in advanced testicular cancer:
A Southwest Oncology Group study. ED Crawford, MK
Samson, R Natale, NT Shaw, B Blumenstein, MA Davis.
Journal of Urology 137(4):212A (#436), 1987.
GU
04/26/82
08/01/86
8494
A comparison of leuprolide (L) with flutamide (F) and
leuprolide in previously untreated patients with clinical
stage D2 cancer of the prostate, phase III, Intergroup
study-0036. ED Crawford, D McLeod, A Dorr, J Spaulding,
R Benson, M Eisenberger, B Blumenstein. Presented at
the 66th Annual Meeting of the South Central Section of
the Amercan Urologic Association, Inc., London, England,
October 25-28, 1987.
GU
03/18/85
07/01/87
Charles A. Coltman, Jr., M.D.
198-24-5536
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7990
Resectable stage II testicular carcinoma: A randomized
comparison of post-lymphadenectomy chemotherapy
and initial observation - A Cooperative Intergroup study.
JT Spaulding, DM Stablein, LH Einhorn, JP Donohue,
FM Muggia, K Cummings, ED Crawford, R Weiss,
DF Paulson, EM Jacobs. Am J Clin Oncol 9:103, 1986.
GU
06/22/79
03/22/85
8207
High dose AZQ in renal cancer. A Southwest Oncology
Group phase II study. RL Stephens, R Kirby,
ED Crawford, R Bukowski, SE Rivkin, RM O'Bryan.
Invest New Drugs 4:57-59, 1986.
GU
07/09/82
03/16/84
8216/38
(1299)
A trial of bacillus calmette-guerin versus adriamycin
in superficial bladder cancer: A South-West
Oncology Group study. K Mori, DL Lamm, ED
Crawford. Urology Internationalis 41(4):254-259, 1986.
GU
ABSTRACTS PUBLISHED/PRESENTED
7990
Resected stage II testicular cancer: immediate
adjuvant chemotherapy versus observation.
S Williams, F Muggia, L Einhorn, R Hahn, J Donohue,
K Brunner, D Stablein, W DeWys, D Crawford,
J Spaulding. ASCO 5:90 (#380), 1986.
GU
06/22/79
03/22/85
7990
Toxicity of chemotherapy as adjuvant or salvage
treatment in early stage nonseminomatous testicular
cancer (NSTC). RB Weiss, DM Stablein, FM Muggia,
LH Einhorn, RL Stephens, JT Spaulding, WD DeWys.
ASCO 5:99 (#384), 1986.
GU
06/22/79
03/22/85
8110
A randomized comparison of cisplatin, vinblastine
(VLB) plus either bleomycin (PVB) or VP-16 (VPV)
in patients with advanced testicular cancer.
MK Samson, ED Crawford, R Natale, B Bouroncle,
S Altman. ASCO 5:96 (#373), 1986.
GU
05/11/82
08/01/86
8217
Spirogermanium in the treatment of stage D2
adenocarcinoma of the prostate: A Southwest
Oncology Group study. JH Saiers, M Slavik,
J Costanzi, ED Crawford. ASCO 5:111
(#433), 1986.
GU
08/11/82
03/22/85
Charles A. Coltman, Jr., M.D.
198-24-5536
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
*8308
Combination cisplatin and dichloromethotrexate in
advanced bladder cancer: A Southwest Oncology
Group (SWOG) study. RB Natale, HB Grossman,
ED Crawford, JR Borst, W Tranum, BA Blumenstein.
ASCO 5:104 (#402), 1986.
GU
10/18/83
03/20/86
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7922
Phase II trial of cyclophosphamide, doxorubicin,
and cisplatin (CAP) versus amsacrine in patients
with transitional cell carcinoma of the urinary bladder:
A Southwest Oncology Group study. M Al-Sarraf,
J Frank, JA Smith Jr., RM O'Bryan, JJ Costanzi,
RL Stephens, J Caraveo, ED Crawford. Cancer
Treat Rep 69:189-194, 1985.
GU
08/08/79
09/10/82
7945
Phase II trial of diaziquone in advanced large bowel
carcinoma in previously treated and untreated
patients: A Southwest Oncology Group study.
R Shildt, RL Stephens, VP Subramanian, LH Baker,
WS Fletcher, RM O'Bryan, JD McCracken. Cancer
Treat Rep 69:709-710, 1985.
GU
06/04/81
05/05/82
7956
Infarction - nephrectomy for metastatic renal
carcinoma. A Southwest Oncology Group study.
JE Gottesman, ED Crawford, HB Grossman,
P Scardino, JD McCracken. Urology 25(3):
248-50, 1985.
GU
02/09/80
01/19/84
8104
Treatment of stage cII (N4) and cIII seminoma with
chemotherapy followed by irradiation therapy: A
Southwest Oncology Group study. ED Crawford,
R Stephens, N Oishi, K Khan, LM Pass. J Urol 133:
246A, 1985.
GU
12/21/81
08/01/86
ABSTRACTS PUBLISHED/PRESENTED
8026
Cis-platinum in advanced squamous cell penile
carcinoma: A Southwest Oncology Group study.
R Gagliano, ED Crawford. ASCO, #C-375, 1985.
GU
09/15/80
08/01/86
8104
Treatment of stages cII (N4) and cIII seminoma with
chemotherapy followed by irradiation therapy: A
Southwest Oncology Group study. ED Crawford,
R Stephens, N Oishi, K Khan, LM Pass. J Urol 133:
246A, 1985.
GU
12/21/81
01/19/84
8216/38
BCG versus adriamycin in bladder cancer: A
Southwest Oncology Group study. DL Lamm,
ED Crawford. ASCO, #C-424, 1985.
GU
12/01/82
12/20/85
8216/38
BCG versus adriamycin in the treatment of transitional
cell carcinoma in-situ: A Southwest Oncology Group
study. Proc AUA 133:184A (#283), 1985.
GU
12/01/82
12/20/85
8216/38
Intravesical adriamycin for recurrent superficial
bladder cancer: A Southwest Oncology Group study.
ED Crawford, DL Lamm, JE Montie, PT Scardino,
HB Grossman, T Stanisic, JA Smith, JW Sullivan.
Proc AUA 133:213A (#397), 1985.
GU
12/01/82
12/20/85
8216/38
BCG versus adriamycin in bladder cancer: A
Southwest Oncology Group study. DL Lamm,
ED Crawford. Inter-American Society for
Chemotherapy, p. 49, #E7, 1985.
GU
12/01/82
12/20/85
8231
Phase II trial of combination chemotherapy in
patients with extragonadal germ cell tumors: A
Southwest Oncology Group study. RM Bukowski,
J Montie. AACR, #658, 1985.
GU
09/29/82
10/15/86
8302
Treatment of Stage DII adenocarcinoma of the
prostate with doxorubicin, mitomycin-C and 5fluorouracil (DMF): A Southwest Oncology Group
study. JH Saiers, BL Tranum, R Stephens, ED
Crawford. ASCO, #C-423, 1985.
GU
07/26/83
08/17/84
8316
Evaluation of fludarabine phosphate (NSC 312887)
in renal cell carcinoma: A Phase II study. L Balducci,
MA Davis, ED Crawford, DD Von Hoff, J Gordon, TN
Kim, A Bagley, S Wright, G Kajikawa, RM Bukowski,
JF Boyd, DK Cash, FH Stutz, GT Budd, SR Dakhil,
HS Eyre, BW Dana, WS Fletcher, HE Hynes. ASCO,
#C-429, 1985.
GU
04/20/84
03/22/85
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7630
Adriamycin and cyclophosphamide versus hydroxyurea in
advanced prostatic cancer. A randomized Southwest
Oncology Group study. RL Stephens, C Vaughn, M Lane,
J Costanzi, R O'Bryan, SP Balcerzak, H Levin, J Frank,
CA Coltman Jr. Cancer 53:406-410, 1984.
GU
7817
Dose-response and dose-survival advantage for high versus
low-dose Cisplatin combined with Vinblastine and Bleomycin
in disseminated testicular cancer. A Southwest Oncology
Group study. MK Samson, SE Rivkin, SE Jones, JJ Costanzi,
AF LoBuglio, RL Stephens, EA Gehan, GD Cummings. Cancer
53:1029-1035, 1984.
GU
7817
The Southwest Oncology Group study for advanced testicular
cancer. ED Crawford. Seminars in Urology 2(4), 1984.
GU
7904
A randomized trial of Hexamethylmelamine versus 5-FU,
doxorubicin and cyclophosphamide (FAC) in advanced
transitional cell bladder carcinoma: A Southwest Oncology
Group study. RG Gagliano, RL Stephens, JJ Costanzi,
N Oishi, WJ Stuckey, PN Grozea, J Frank, ED Crawford.
Cancer Treat Rep 68:1025-1026, 1984.
GU
8011
Phase II clinical trial of mitoxantrone in patients with
advanced renal cell carcinoma: A Southwest Oncology
Group study. SA Taylor, DD Von Hoff, LH Baker,
SP Balcerzak. Cancer Treat Rep 68:919-920, 1984.
GU
8268
Interferon-α therapy of renal cancer. JA Neidhart, MM Gagen,
D Young, R Tuttle, TJ Melink, A Ziccarrelli, D Kisner. Cancer
Res 44:4140-4143, 1984.
GU
Multiple
Studies
Southwest Oncology Group experience with randomized
protocols for bladder cancer. JA Smith Jr, ED Crawford.
In: Controlled Clinical Trials in Urologic Oncology . L Denis,
GP Murphy, GR Prout Jr, F Schroder, eds. New York:
Raven Press, 249-254, 1984.
GU
ABSTRACTS PUBLISHED/PRESENTED
7916
Treatment of metastatic bladder cancer with gallium nitrate.
ED Crawford, JH Saiers, LH Baker. 13th International
Congress of Chemotherapy SE 12(1):7A, 1984.
GU
7956
Infarction-nephrectomy for metastatic renal carcinoma. A
Southwest Oncology Group study. JE Gottesman,
ED Crawford, HB Grossman, PT Scardino. Abstracts of the
GU
8101
VM-26 in advaced renal cell carcinoma - A Southwest
Oncology Group study. N Oishi, M Inamasu, D Wachi,
R Bukowski, S Rivkin, J Frank, C Coltman, D Crawford.
ASCO, #C-598, 1984.
*8110
Surgical resection of residual disease in advanced testicular
GU
cancer. ED Crawford, MK Sampson, R Klugo. Presented at
the 48th Annual Meeting of the American Urological Association
Inc. , April 1-4, 1984.
*8268
A Phase II trial of lymphoblastoid interferon (Wellferon™) in
metastatic renal adenocarcinoma. A Southwest Oncology
Group study. D Kisner, T Melink, A Ziccarrelli, M Gagen,
R Tuttle, J Neidhart. 4th NCI-EORTC Symposium on New
Drugs in Cancer Therapy (Brussels, 1984). DD Von Hoff, ed.
Investigational New Drugs 2:107, 1984.
GU
*8268
Therapy of renal cancer with low (LD), intermediate (ID), and
high (HD) dose regimens of human lymphoblastoid interferon
(HBLI; Wellferon*). J Neidhart, M Gagen, D Kisner, R Tuttle,
J Whisnant. ASCO, #C-232, 1984.
GU
* Abstracts presented
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7525
The Southwest Oncology Group experience. Adjuvant therapy
for stage IB and II non-seminomatous testicular cancer.
RL Stephens, JR Eltringham, CA Coltman Jr, J Neidhart,
J Mullins, J Frank. Int J Rad Onc Bio Phys 9:1885-1890, 1983.
GU
7624
Adriamycin versus adriamycin plus cis-diamminedichloroGU
platinum (DDP) in advanced transitional cell bladder
carcinoma. A Southwest Oncology Group study. R Gagliano,
H Levin, MN El-Bolkainy, HE Wilson, RL Stephens, WS Fletcher,
SE Rivkin, RM O'Bryan, CA Coltman Jr, JH Saiki, WJ Stuckey,
L Balducci, JD Bonnet, DO Dixon. Am J Clin Oncol (CCT) 6(2):
215-218, 1983.
7959
Mitoguazone in advanced renal carcinoma. A Phase II trial of
GU
the Southwest Oncology Group. WA Knight III, A Drelichman,
C Fabian, RM Bukowski. Cancer Treat Rep 67:1139-1140, 1983.
8010
Mitoxantrone: Modest activity in a Phase II trial in advanced
prostate cancer. CK Osborne, A Drelichman, DD Von Hoff,
ED Crawford. Cancer Treat Rep 67:1133-1135, 1983.
GU
ABSTRACTS PUBLISHED/PRESENTED
*7302/7434/
7801/7940
7904
Southwest Oncology Group experience with 5-fluorouracil in
carcinoma of the colon. JD McCracken, TT Chen,
LP Leichman, VK Vaitkevicius. 13th International Congress
of Chemotherapy (Vienna, September 2, 1983), Part 259,
SE 12.1, 20-8, 1983.
Hexamethylmelamine (HEX) vs. Flourouracil, Adriamycin and
Cytoxan (FAC) in advanced bladder cancer - A SWOG study.
ED Crawford, R Gagliano, J Frank. ASCO, #C-518, 1983.
GU
GU
7922
Combination of Cytoxan, Adriamycin and Cis-platinum (CAP)
vs. Phase II agent m-AMSA in patients with advanced and
metastatic bladder cancer--A Southwest Oncology Group
study. M Al-Sarraf. AACR, #558, 1983.
GU
*8110
The role of surgical resection in the management of advanced
testicular cancer: A Southwest Oncology Group study.
ED Crawford, MK Sampson, R Klugo. Abstracts of the
American Urological Association , p. 99, #134, 1983.
GU
* Abstracts presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7520
Phase II trial of Dianhydrogalactitol (NSC-132313) in
advanced renal carcinoma. A Southwest Oncology Group
study. V Ratanatharathorn, LH Baker, L Balducci, RW Talley,
B Hoogstraten. Cancer Treat Rep 66:1231-1232, 1982.
GU
7805
Yoshi 864 plus Medroxyprogesterone Acetate (MPA) in
adenocarcinoma of the kidney: A Southwest Oncology
Group study. SJ Altman, RL Stephens, JD Bonnet. Cancer
Treat Rep 66:1781-1782, 1982.
GU
ABSTRACTS PUBLISHED/PRESENTED
7922
Combination of Cyclophosphamide, Adriamycin, and CisPlatinum (CAP) versus m-AMSA in patients with advanced
transitional bladder cancer. M Al-Sarraf. ASCO, #C-406,
1982.
GU
7956
Infarction-nephrectomy for metastatic hypernephroma: A
Southwest Oncology Group study. JE Gottesman,
D Crawford, M Grossman, P Scardino. 13th International
Cancer Congress, 393, 1982.
GU
8010
A Phase II clinical investigation of dihydroxyanthracenedione
(DHAD) in patients with advanced prostatic cancer.
A Drelichman, CK Osborne, DD Von Hoff. ASCO, #C-465,
1982.
GU
8011
Phase II trial of dihydroxyanthracenedione (DHAD) in
advanced renal cell carcinoma: A SWOG study. SA Taylor,
DD Von Hoff. ASCO, #C-457, 1982.
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7634
Evaluation of beta-2'-deoxythioguanosine combined with
methyl-CCNU or mitomycin in advanced colorectal cancer: A
Southwest Oncology Group study. RG Gagliano,
FJ Panettiere, CD Haas, L Baker, J Hewlett, WJ Stuckey,
RM O'Bryan, R Bottomley, LK Heilbrun. Cancer Clin Trials
4:401-405, 1981.
GU
7716
Study of Tamoxifen in renal cell carcinoma and the influence
of certain prognostic factors: A Southwest Oncology Group
study. M Al-Sarraf, H Eyre, J Bonnet, J Saiki, R Gagliano,
R Pugh, D Lehane, DO Dixon, R Bottomley. Cancer Treat Rep
65:447-451, 1981.
GU
ABSTRACTS PUBLISHED/PRESENTED
?
Hormonal priming and chemotherapy for advanced prostate
cancer: a pilot study. CK Osborne, DL Lamm, HM Radwin.
AACR 22:461, 1981.
GU
7817
Positive dose-response of high (H) versus low (L) dose cisplatinum (DDP), vinblastine (VLB) and bleomycin (Bleo) in
disseminated germ cell neoplasms of the testis. MK Samson,
RL Stephens, RC Klugo. ASCO, #C-538, 1981.
GU
7959
A Phase II trial of Methyl-Glyoxal Bisguanylhydrazone (MGBG,
Methyl-GAG) in renal carcinoma. A Southwest Oncology
Group study. SK Callahan, WA Knight III. AACR, #649, 1981.
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7610
Vinblastine (VLB), Bleomycin (BLEO), CisDiamminedichloroplatinum (DDP) in disseminated
extragonadal germ cell tumors: A Southwest
Oncology Group study. L Feun, M Samson, R
Stephens. Cancer 45:2543-2549, 1980.
GU
7610
Vinblastine, Bleomycin and Cis-Diamminedichloroplatinum in disseminated testicular cancer:
Response to treatment and prognostic correlations:
A Southwest Oncology Group study. MK Samson,
R Fisher, RL Stephens, S Rivkin, M Opipari, T
Maloney, CW Groppe. European Journal of Cancer
16:1359-1366, 1980.
GU
7610
Probable cure of metastatic testicular tumors treated
with sequential therapy. JA Neidhart, R Memo, EN Metz,
H Wise. Cancer Treat Rep 64(4-5):553-558, 1980.
GU
7803
Phase II trial of Baker's Antifol in metastatic renal
cell carcinoma: A Southwest Oncology Group study.
RM Bukowski, A LoBuglio, JD McCracken, R Pugh.
Cancer Treat Rep 64(12):1387-1388, 1980.
GU
ABSTRACTS PUBLISHED/PRESENTED
7624
Adriamycin versus Adriamycin plus Cis-Platinum
in transitional cell bladder carcinoma. A Southwest
Oncology Group study. R Gagliano. ASCO, #C-110,
1980.
GU
7860
Methyl-Glyoxal Bis-Guanylhydrazone (Methyl GAG,
MGBG) in advanced renal carcinoma. WA Knight III,
RB Livingston, CJ Fabian, JJ Costanzi. ASCO, #C-190,
1980.
GU
7860
Chemotherapy of advanced renal adenocarcinoma
with methylglyoxal-bis-guanylhydrazone (methylGAG). RF Todd, MB Garnick, GP Canellos.
AACR, 21:340, 1980.
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7610
Vinblastine, bleomycin, and cis-dichlorodiammineplatinum (II) in disseminated testicular cancer:
Preliminary report of a Southwest Oncology Group
study. MK Samson, RL Stephens, S Rivkin, M
Opipari, T Maloney, CW Groppe, R Fisher. Cancer
Treat Rep 63:1663-1667, 1979.
GU
ABSTRACTS PUBLISHED/PRESENTED
7610
Vinblastine, Bleomycin and Cis-Platinum in disseminated estragonadal germ cell tumors. L Feun,
M Samson. ASCO, #C-325, 1979.
GU
7716
The clinical trial of Tamoxifen in patients with
advanced renal cell cancer. M Al-Sarraf. ASCO,
#C-360, 1979.
GU
1
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7303
Chemotherapy of disseminated germinal tumors of the
testis - comparison of vinblastine and bleomycin with
vincristine, bleomycin and actinomycin D. SC Spigel,
RL Stephens, CD Haas, SE Jones, D Lehane, TE Moon,
CA Coltman, Jr. Cancer Treat Rep 62(1):129-130, 1978.
GU
ABSTRACTS PUBLISHED/PRESENTED
7610
Vinblastine (VLB), bleomycin (Bleo) and cisdiamminedichloroplatinum II (DDP) in disseminated
testicular cancer. M Samson, R Stephens. AACR
19:12 (#47), 1978.
1
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
7438
Phase II evaluation of single high-dose cis-diamminedichloroplatinum (II) (NSC-119875, CACP) in gynecologic
*GYN) and genitourinary (GU) neoplasia. AH Rossof, RW
Talley and RL Stephens. AACR, #388, 1977.
1
GYN
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
226
Porfiromycin (NSC 56410) in the management of
epidermoid and transitional cell cancer: A Phase II study.
FJ Panettiere, RW Talley, J Torres, M Lane. Cancer Treat
Rep 60(7):907-911, 1976.
1
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1974
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
7303
Combination chemotherapy of testicular carcinoma. SC
Spigel and CA Coltman, Jr. ASCO, 1974.
1
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1973
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
7303
Combination chemotherapy of testicular carcinoma.
SC Spigel, CA Coltman, Jr. ASCO, 1973.
1
GU
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1970
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
?
Vinblastine in the management of testicular cancer. ML
Samuels, CD Howe. Cancer 25:1009-1017, 1970.
GU
?
Vinblastine sulfate in the treatment of germinal tumors
of the testes. ML Samuels, CD Howe. Xth International
Cancer Congress Abstracts, Houston, TX, May 1970.
Medial Arts Publishing Co.:458, 1970.
GU
1
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
?
Phase II studies of hydroxyurea (NSC-32065) in adults:
Urologic and gynecologic neoplasms. CD Howe, ML
Samuels. Cancer Chemotherapy Reports 40:47-48, 1964.
1
GU
GYN